



2016 Hospital Reporting Manual

Sixth Edition

Arkansas Central Cancer Registry

**4815 West Markham Street
Little Rock, AR 72205**

<http://www.healthy.arkansas.gov/programsServices/healthStatistics/CancerRegistry/Pages/default.aspx>

**1-800-462-0599
501-661-2952
Fax (501) 661-2891**



TABLE OF CONTENTS

Preface	4
Introduction: Arkansas Cancer Reporting Requirements	6
Chapter 1 – General Instructions	9
Basic Reporting Rules	9
Changing Information	9
Follow Up Information	9
Non-Reportable File	9
Data Transmission	9
Chapter 2 – Determining Reportability	12
Casefinding	12
Ambiguous Terminology	14
Chapter 3 – Determining Primary Tumors	16
Multiple Primaries for Solid Tumors	16
Multiple Primary Rules for Hematopoietic Cases	16
Chapter 4 – First Course of Therapy	18
Definitions	18
All Malignancies except Leukemia	18
Leukemias	18
Time Periods for First Course of Treatment	18
RX Summ – Treatment Status	19
Surgical Diagnostic and Staging Procedures	20
Palliative Procedure	20
Chapter 5 – Initial Abstract	21
Patient Identification Information	21
Reporting Hospital/Facility Number	21
Accession Number/Sequence Number	21
Sequence Number	21
Patient Name	24
Patient Address	25
Birth Date	27
Social Security Number	28
Birth Place – State	29
Alcohol History	29
Tobacco History	30
Family History	30
Race (1-5)	30
Spanish/Hispanic Origin	31
Sex	32
Occupation – Text	32
Industry – Text	32
Primary Payer at Diagnosis	33
Date of First Contact	34
Class of Case	34
Type of Reporting Source	37
NPI – Primary Surgeon	37
NPI – Attending Physician	38
NPI – Following Physician	38
Chapter 6 – Cancer Identification	39
Primary Site	39
Histologic Type	40
Behavior Code	41
Grade or Differentiation	42
Date of Diagnosis	47

Diagnosis Confirmation	48
Laterality	51
Chapter 7 – Staging Schemes	54
SEER Summary Stage	54
AJCC Stage	54
Collaborative Stage	54
Regional Node Positive	55
Regional Node Examined	55
Surgical Diagnostic and Staging Procedure	55
Chapter 8 – Tumor Directed Treatment	58
Date of First Course Treatment	58
RX Summ – TX Status	58
Date First Surgical Procedure	59
Date Most Definitive Surgery	60
Surgical Procedure Primary Site	60
Reason No Primary Surgery	61
Surgical Margins Primary Site	62
Scope Regional Lymph Node Surgery	63
Surgical Procedure/Other Site	64
Date Radiation Started	65
Regional Treatment Modality	65
Regional Dose	66
Boost Treatment Modality	66
Date Radiation Ended	66
Radiation/Surgery Sequence	66
Date Chemotherapy Started	67
Hormone Therapy	68
Immunotherapy	69
Hematologic Transplant/Endocrine Procedure	69
Other Treatment	70
Palliative Procedure	72
Recurrence	73
Chapter 9 – Outcome Information	74
Date Last Contact or Death	74
Vital Status	74
Cancer Status	74
Underlying Cause of Death	75
ICD Revision Number	75
Chapter 10 – Text Fields	76
Appendix A – ACCR Staff Contact List	77
Appendix B – State Law	79
Appendix C – Cancer Registry Amendment Act	86
Appendix D – HIPAA Act	91
Appendix E – Reportable List	92
Appendix F – Medical Abbreviation	94
Appendix G – Official United States Postal Service Abbreviations	97
Appendix H – Surgery Cancer Treatment	99
Appendix I – Glossary Treatment Terms	105
Appendix J – Abstracting Tips	112
Appendix K – Geocodes	114
Appendix L – Effective Cancer Registry Dates	136
Appendix M – Health Care Facility Contact List	137

PREFACE

ABOUT THIS MANUAL

Public Law 102-515 and the Arkansas Central Cancer Registry

The Arkansas Central Cancer Registry (ACCR) Hospital Reporting Manual has been created to assist hospital registries in reporting cancer cases to the central cancer registry. This is the fifth edition (2013) of this manual and it is being implemented to meet the requirements from the National Program of Cancer Registries (NPCR), the North American Association for Central Cancer Registries (NAACCR) and the Commission on Cancer (CoC) Facility Oncology Required Data Standards (FORDS). There are also clarifications and rules that are in place, in order to accurately complete abstraction of cancer cases. Implementation of this manual is to begin with cancer cases diagnosed as of January 1, 2012.

The Arkansas General Assembly originally established the Arkansas Central Cancer Registry (ACCR) in 1938. The registry only collected minimal data and was only for indigent patients who were referred to participating tumor clinics throughout the state of Arkansas. No funds were available from the state until 1945. By 1970, the data collected was computerized, but due to a state-funding crisis in 1979, The Arkansas Central Cancer Registry was eliminated.

In 1989, Arkansas again authorized a state cancer registry to be located at the Arkansas Department of Health, although funding was not available to staff the registry or collect the data. In 1992, The United States Congress passed the “Cancer Registries Amendment Act” (Public Law 102-515), which provided federal funding for state cancer registries. The law was carried out through efforts by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. Funding for a cancer program in Arkansas began in 1994, when the first federal funds were awarded through the National Program for Cancer Registries (NPCR).

NPCR requires central registries to:

- Collect incidence data on all patients diagnosed and/or receiving first course of treatment in the registry’s state, regardless of residency.
- Have legislation mandating the reporting of cancer cases by all facilities diagnosing and/or treating cancer
- Provide training for central registry staff, hospital registry and non-hospital reporting facility staff
- Collect information on cancer cases in a standard data format
- Produce pre-calculated data tables in an electronic data file or report, within 12 months of the end of the diagnostic year, 90% complete
- Produce pre-calculated data tables in an electronic data file or a report, within 24 months of the end of the diagnostic year, 95% complete

- Conduct case finding and re-abstracting audits to determine the completeness and quality of all cancer cases being submitted to the registry.

In 1994, the Arkansas Board of Health mandated cancer as a reportable disease in the State of Arkansas. The reference date for the Arkansas Central Cancer Registry is January 1, 1996. This is the first time since 1979 that cancer data was collected in Arkansas.

The ACCR:

- 1) Collects data that are compliant with required NPCR data elements;
- 2) Meets standard requirements designated by NPCR and NAACCR for incidence reporting;
- 3) Assists in determining data quality; and
- 4) Provide useful information, feedback and assistance to submitting facilities.

Data is submitted annually to NPCR and to NAACCR for registry certification and publication in Cancer in North America (CINA). Registries that submit data that meets established criteria of timeliness, accuracy and completeness are recognized annually as Silver or Gold Certified registries.

Without this data, our research and analytical studies cannot be accurate. The ACCR staff is available to assist with any questions and/or provide in-services to better prepare you for the process. (Refer to Appendix A to review registry personnel.)

ACCR Mission Statement

The mission of the Arkansas Central Cancer Registry is to serve the public by collecting, analyzing, researching and disseminating cancer data to help describe the burden of cancer, so evidence-based prevention and control programs can be implemented to reduce cancer incidence and mortality in Arkansas.

Changes for 2015

Explanations added to the ACCR Hospital Reporting Manual entries for 2015, are show in blue font for your convenience.

- Clarifications were added per updates to the FORDS manual and NPCR requirements
- Carcinoid tumors of the appendix (C18.1) are now coded 8240/3 and are reportable
- Code 999 is used for non-US residents when reporting county at diagnosis
- There are two new codes to specify natal sex of transsexual persons
- Classes of Case requiring the fields institution Referred To/From are clarified
- FORDS clarified the definition of staff physician
- SEER Summary Staging 2000 is required of all facilities
- AJCC TNM staging is required of all facilities
- Date of Most Definitive Surgery or the associated Date Flag are now required
- Several Date Flag coding instructions were clarified
- To align with FORDS 2015, wording was added to *Surgical, Diagnostic and Staging Procedure*, *Surgical Procedure of the Primary Site* and *Date of First Surgical Procedure* sections regarding changes in the coding of needle biopsies
- Diagnostic confirmation code instructions were updated to agree with Hematopoietic Manual

INTRODUCTION

ARKANSAS CANCER REPORTING REQUIREMENTS

Arkansas State reporting laws, NPCR standards, data quality and projected needs of the citizens of this state govern reporting requirements. This manual is for the intended use of hospital registries. The statutes also include facilities that provide diagnostic or therapeutic services, screening, patients diagnosed and/or treated as hospital in-patients, outpatients and in non-hospital facilities (e.g., pathology laboratories, ambulatory surgery centers, physician offices, freestanding treatment centers and long term care facilities) in an effort to become a true population-based central registry.

Hospitals are required to report all malignant, specific in-situ cancers and reportable benign brain and central nervous system tumors to the Arkansas Department of Health/Arkansas Central Cancer Registry. ACCR generally follows the rules of the following standard setters: Commission on Cancer, Facility Oncology Registry Data Standards (FORDS), and Surveillance Epidemiology and End Results (SEER) program of the National Cancer Institute. Data requirements are based on fields required by the National Program of Cancer Registries (NPCR) and the North American Association for Central Cancer Registries (NAACCR) recommendations for central cancer registries collecting incidence data, and some Arkansas specific fields.

ROLE OF HOSPITALS

The hospital cancer registry is the primary source for obtaining epidemiological information. A registry is responsible for providing a listing of cancer patients and pertinent information regarding their disease. A registry may be small or large, and the extent of submission of information is varied, depending on hospital size and the reporting methods for each facility. Some hospitals have had their own registries for years in accordance with American College of Surgeons-Commission on Cancer (ACoS-CoC) requirements; while others have limited registries and in some cases, collection of cancer cases is provided by central registry staff.

ROLE OF ARKANSAS CENTRAL CANCER REGISTRY

The role of the Arkansas Central Cancer Registry (ACCR) is to gather information from hospitals and other sources to monitor the incidence of cancer in the state, to develop and evaluate cancer prevention and control through epidemiological research. The data is received in abstract form, electronically from hospitals that have on-site or contract registrars. ACCR regional abstractors or hospitals that serve as regional registries will obtain data from facilities

that do not have registrars or where there is an annual caseload of 50 cases or less. The information is valuable in determining risk factors, environmental impacts, ethnic and social variations as well as effectiveness of state cancer control programs.

CONFIDENTIALITY

According to State Cancer Law (20-15-202) “Information accumulated and maintained in the Cancer Registry of Arkansas shall not be divulged except as statistical information which does not identify individuals and for purposes of such research as approved by the Arkansas State Board of Health”. The rules and regulations also state “ All information reported to the Department of Health shall be confidential and shall not be disclosed under any circumstances except (1) to other state cancer registries with which the Department of Health has agreements that insure confidentiality; (2) to other state health officials who are obligated to keep such information confidential; and (3) to approved cancer research centers under specific conditions where names and identities of the individuals are appropriately protected, and when such research is conducted for the purpose of cancer prevention, control and treatment.

ACCR staff is required to sign confidentiality agreements and follow confidentiality procedures as stated in the Arkansas Central Cancer Registry Policy and Procedure Manual. This also includes secure electronic access, fire resistant, locked file cabinets for confidential data, procedures for handling requests for data and policies for handling breaches of confidentiality.

NOTE: The Health Insurance Portability and Accountability Act (HIPAA) allows for the reporting of identifiable cancer data to public health entities. Because ACCR falls under the definition of a public health authority, HIPAA allows your facility to continue reporting cancer incidence data in compliance with the current state statutes (20.15.201 – 20.15.205). Written informed consent from each cancer patient reported to public health entities is not required under HIPAA nor is a Business Associate Agreement required; rather, hospitals must simply document that reporting has occurred.

AUDITS

ACCR Quality Assurance Coordinator and/or Cancer Information Management Specialists (CIMS) conduct annual casefinding and quality assurance (re-abstracting) audits as required by NPCR. The purpose of these audits is to ensure that all reportable cases are being identified and reported to the Central Registry and that all information submitted to the registry is of good quality and accurately coded.

The audits are scheduled in advance to ensure the facilities adequate preparation time for the impending audit. After completion of audits, a report is provided to the facility cancer registry director and/or administrator, which summarize the percentage of case ascertainment or completeness and any suggestions that would help to improve the reporting process.

Casefinding audits are performed on inpatient and outpatient disease indices, pathology reports and other pertinent case finding documents such as: clinic sign-in logs, and surgery logs. These documents are reviewed and all reportable codes are compared to the facility information housed in the ACCR database. All cases that are not identified in the database will have to be reconciled by the registrar at the audited facility. The registrar will have a minimum of 30 days to complete the reconciliation process and return an updated list to ACCR with reasons why the identified cases were not abstracted or if the cases are reportable and were missed during the original abstracting period.

Cases that are reportable but were missed must be abstracted into their database and submitted to ACCR. All cases diagnosed before January 1, 1996 or cases not diagnosed or treated at the reporting facility are removed from the reconciliation log and a percentage is calculated at that time. A report is sent to the cancer registry supervisor and the administrator of the facility that summarizes the percentage of case ascertainment and provides suggestions to help improve the case ascertainment process.

Quality assurance or re-abstracting audits consists of an ACCR Quality Assurance Coordinator and/or CIMS re-abstracting specific fields selected by ACCR and are compared with the original data that has been submitted. Any discrepancies are documented and sent to the audited facility in a summary report. Exceptions are taken into consideration, (i.e. if a case has been merged/consolidated in the ACCR database and the audited facility did not have this information, which could indicate that the other procedures were done elsewhere and not available to the audited facility at the time the case was abstracted).

Chapter 1

GENERAL INSTRUCTIONS

Basic Reporting Rules for State Reporting

Important Items for Reporting:

- Hospital based registries are *required* by Arkansas statute (20.15.201-20.15.205) to abstract inpatient and outpatient cancer cases. Outpatient treatment is increasing and it is important to also collect cases from these facilities, to ensure completeness of data collection.
- All reportable cancer cases diagnosed and/or treated in your facility after January 1, 1996, must be abstracted and reported to ACCR.
- All required data items should be *collected and reported* to ACCR. The list is based on the rules and regulations stated in the Arkansas statute, NPCR and NAACCR and CoC.
- Electronic reporting is required for all facilities with an annual caseload greater than 5 cases. ACCR no longer accepts paper abstracts. ACCR will provide free software (Web Plus) to small non-hospital facilities with an annual caseload of 5-50 and Abstract Plus to small hospitals with an annual caseload of 50 or less. Please contact us at 501-661-2463 to inquire about Abstract Plus.
- Solid tumors diagnosed on or after January 1, 2007 MUST be abstracted according to reportability and coding instructions set forth in *The Multiple Primary and Histology Coding Rules Manual* which can be downloaded from <http://seer.cancer.gov/tools/mphrules/download.html>
- The ICD-O-3 coding scheme *must be used* for site and histology for cases diagnosed on or after January 1, 2001. The ICD-O-2 coding scheme must be used for cases diagnosed prior to January 1, 2001.

Note: Hematopoietic malignancies are coded according to the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic Database* for cases diagnosed on or after January 1, 2010. **For cases diagnosed on or after January 1, 2015 use version 3.1.0 which can be downloaded at <https://seer.cancer.gov/tools/heme/download>.**

Please stay abreast of revisions to manuals by periodic check of websites specific to provider of manual.

- Completed cases should be submitted to ACCR within six (6) months after date of initial diagnosis.
- All pathology reports that are read by hospital pathology laboratories, but are not the responsibility of the hospital registry to abstract, should be forwarded to ACCR for further investigation. ACCR will be responsible for contacting the physicians on the pathology reports to obtain the information needed to include the case into the registry database.
- Occasionally hospitals require special data reports from the central registry. Requests for studies, reports or information should be submitted on a data request form. To access this

online data request form at the following website:

<http://www.healthy.arkansas.gov/programsServices/healthStatistics/CancerRegistry/Pages/default.aspx> or by phone at 1-800-462-0599 or 501-280-4830.

- It is important that all reporting facilities submit data in a timely manner, to ensure the availability of data during the merging and de-duplication process. The requirements for data submissions are monthly reporting of cases.
- All facilities submitting data electronically are required to perform EDITS on these cases to detect any errors that may exist. Upon arrival to ACCR, all files will undergo additional edit checks. If the file contains an unacceptable number of errors, it will be returned to the facility. A summary report of the errors is automatically sent to the facility with the rejected file. The facility will be given a maximum of 14 days to correct all errors and return the data file.

Changing Information

It is possible that after a case has been submitted to the ACCR, additional information added to the patient's chart would change specific data items. It is permissible to change any data item, including the primary site and histology. For changes made on five (5) or less cases please call ACCR and report changes. For changes to more than five (5) cases, make corrections to cases and resubmit via WebPlus, case can be included with next submission. If path report is amended, the amended report can be faxed to ACCR and changes will be made.

Follow Up Information

Additional follow-up information is not required by ACCR on any case.

Non-Reportable File

All hospitals are required to submit non-reportable cases to ACCR twice a year, January and October. These cases are to be documented and submitted electronically on an Excel spreadsheet. The following information should be included: Facility Name and Number, months/year being submitted, Patient Name (last and first), Social Security Number, Cancer Diagnosis (ICD-9/ICD-10 code), Cancer Site (ICD-O-3 code), Date of Birth, and Date of Diagnosis.

Data Transmissions

Security of Data Transmissions – Electronic data are to be transmitted using the Web Plus upload. Instructions for the use of Web Plus can be found on the ACCR website. If your facility has other methods of data transmission, please contact the ACCR staff. **The ACCR requires that all data be submitted via a secure electronic method. Diskettes and CDs are no longer accepted.**

Protected Health Information (PHI) and other confidential data **MUST NOT** be included in e-mails to ACCR. Do not include information either in the text of the e-mail or as an attachment. If this happens, ACCR staff will alert the registrar, so that the information can be deleted from all e-mail.

Confidential information on individual cases may be uploaded using Web Plus non-NAACCR layout function, or it may be transmitted via fax. The ACCR fax machine is in a locked office, accessible only to ACCR personnel. The office is secure 24 hours a day.

Chapter 2

DETERMINING REPORTABILITY

Casefinding Techniques

Reportable Cases can be identified via many sources. The hospital pathology laboratory can provide cases diagnosed by histology, cytology, hematology, bone marrow or autopsy. Other sources are clinic admission logs, daily discharges, disease indices, inpatient and outpatient surgery logs, radiotherapy consults, treatment reports and logs, oncology clinic treatment reports and logs. *Never rely solely on the pathology department to provide reportable cases.* Doing so could exclude cases for which the hospital has no diagnostic tissue reports. Cases diagnosed elsewhere but treated at your facility and those diagnosed radiographically or clinically only without tissue confirmation would be missed during casefinding unless additional resources are employed. It is essential to include review of the Medical Record Disease Index (usually provided by Health Information Management) and other tracking tools such as medical and radiation oncology clinic logs to ensure that all reportable cases are identified. You should form an alliance with staff from the aforementioned departments to establish and develop a systemic method to routinely receive necessary information from them.

Reportable List for Casefinding

A link to the SEER table listing reportable diagnosis for casefinding is posted on the ACCR website: <http://www.healthy.arkansas.gov/programsServices/healthStatistics/CancerRegistry/Pages/Registrars.aspx>

The current reportable list is also included in this manual, Appendix E.

Diagnoses are listed by ICD-9-CM and ICD-10-CM codes which can be used by facilities to identify which cases to include on their MRDI casefinding lists. The list is updated annually to ensure that any new applicable codes are added.

Cases That Must Be Reported

- Refer to the “ACCR Reportable List for Casefinding” noted above when conducting casefinding activities. Depending on how casefinding is conducted, not all codes will be used by all facilities.
- Malignancies with a behavior code (fifth digit of the morphology code) of 2 or 3 in ICD-0-3 (cases diagnosed on or after January 1, 2001) or the Hematopoietic Database Appendix D, except as otherwise noted in this manual
- Beginning with cases diagnosed on or after January 1, 2004, non-malignant primary intracranial and central nervous system tumors are required to be reported. See below for applicable site codes

Topography Codes for Intracranial and Central Nervous System Tumors

Codes	Description
C70.0-C70.9	Meninges
C71.0-C71.9	Brain
C72.0-C71.1	Spinal cord
C72.3-C72.5	Cranial nerves
C72.8-C72.9	Overlapping brain and CNS; CNS, nos
C75.1	Pituitary gland
C75.2	Craniopharyngeal duct
C75.3	Pineal gland

- Beginning with cases diagnosed **on or after January 1, 2002**, the following squamous intraepithelial neoplasia, grade III (8077/2) are reportable (NPCR requirement)
 - AIN III (C21.1)
 - VIN III (C51.*)
 - VAIN III (C52.*)
- **Analytic cases-** Patients whose initial diagnosis was made at your facility and/or any part of the first course of treatment was delivered or prescribed at your facility (Class of Case: 00, 10, 11, 12, 13, 14, 20, 21, 22)
- Patients diagnosed at a staff physician's office and receiving any or their entire first course of treatment in your facility **or a decision is made not to treat at facility??** (Class of Case 12)
- **Nonanalytic cases-** Patients diagnosed elsewhere who had all first course treatment elsewhere who were seen at your facility for diagnosis of recurrent disease or for treatment of relapsed, persistent or progressive disease; cases diagnosed prior to the facility's Reference Date and diagnosis or treatment was given by the reporting facility; diagnosis was established by autopsy at reporting facility and was unsuspected prior to death. These cases are not required to be reported to ACCR.
- Malignant tumors of the skin such as adnexal carcinoma/adenocarcinoma (8390/3-8420/3), lymphoma, melanoma, sarcoma, and Merkel cell carcinoma **must be reported**. Any carcinoma arising in a hemorrhoid is reportable, since hemorrhoids arise in mucosa, not in the skin.
- Gastrointestinal stromal tumors (GIST) and thymomas are frequently non-malignant. However, they must be abstracted and assigned a behavior code 3 if they are noted to have multiple foci, metastasis or positive lymph nodes or if the pathologist designates that they are malignant.
- **Carcinoid tumors of the appendix (C18.1) must be coded 8240/3 effective in 2015**

Cases Not Required To Be Reported

- Skin cancers (C44.*) with histology codes 8000-8110 as of January 1, 2001
- Patients who have a history of cancer but diagnosis or treatment were not performed at your facility (Class of Case 33)
- Patients who receive transient care to avoid interruption of therapy started elsewhere (Class of Case 31)
- Patients seen only in consultation to confirm a diagnosis (Class of Case 30)
- Pathology cases that are consultative readings of slides submitted from outside facilities (Class of Case 43)
- Patients with adenocarcinoma in situ and carcinoma in situ of the cervix, cervical intraepithelial neoplasia (CIN) or prostatic intraepithelial neoplasia (PIN)
- Patients with a pre-cancerous condition or benign tumor (other than CNS sites stated above)
- Patients admitted to a hospice unit or home health care services

Note: Your cancer committee may decide to require additional benign or borderline cases. Please do not submit these reportable-by-agreement cases to ACCR.

Ambiguous Terms at Diagnosis

Reportable cases are usually based on unequivocal statements made by recognized medical practitioners that the patient has a reportable diagnosis. However, physicians sometimes use vague or ambiguous terms to describe a tumor when its behavior is uncertain. In instances where pathology or cytology findings cannot definitively confirm a cancer diagnosis or when imaging studies show inconclusive results, physicians often state the diagnosis in ambiguous terms. Reportability of such a diagnosis depends on the verbiage used. **For a cancer case to be reportable, the ambiguous term must always include a reference to the reportable diagnosis being described, e.g. favors carcinoma or suspicious for malignancy.** When the diagnosis is stated in only ambiguous terms, use the following guidelines to determine whether a particular case should be reported. Note: Synonyms of these terms do not constitute diagnosis.

Ambiguous terms that constitute a diagnosis

Apparent(ly)
Presumed
Comparable with
Favors

Most likely
Compatible with
Suspect(ed)
Typical of

Appears
Probable
Suspicious (for)
Malignant appearing

Consistent with **tumor** (delete)* (beginning with 2004 diagnosis and only for C70.0-C72.9, C75.1-C75.3)

Neoplasm* or Tumor (beginning with 2004 diagnosis and only for C70.0-C72.9, C75.1-C75.3)

*additional terms for nonmalignant primary intracranial and central nervous system tumors only

Exception: If cytology is reported only using an ambiguous term (such as suspicious), do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician's clinical impression of cancer supports the cytology findings.

Example: Discharge summary and X-ray results report "CT of the chest *compatible with* carcinoma of left lung." Although there may be no further work-up or treatment, the case is radiographically diagnosed and **is reportable**.

Example: The only documentation says "likely" carcinoma. Because it does not say "most likely" it **is not reportable**.

Terms that DO NOT constitute a diagnosis**

Cannot be ruled out	Questionable	Equivocal
Rule out	Possible	Suggests
Potentially malignant	Worrisome	

**unless supplemented by additional information

Example: Barium Enema reveals a sigmoid mass *suspicious* for neoplasm. Colonoscopy reveals a sigmoid mass, "*possible* malignant neoplasm." The patient is referred for biopsy and colon resection at another facility revealing carcinoma. The case is **NOT reportable** for your facility because mass and neoplasm are not associated with a reportable malignant term, whereas if it had been stated "suspicious sigmoid mass, *probable* malignant neoplasm," it would be reportable.

Chapter 3

DETERMINING PRIMARY TUMORS

When potential cases are identified through the casefinding process, it is important to determine whether they represent new reportable primaries, or whether they are actually pointing to cases previously accessioned into the cancer registry database. The *Multiple Primaries and Histology Coding Manual* contains all rules for determining multiple primaries for solid tumors. These rules **MUST** be applied to all cases (except hematopoietic primaries) diagnosed on or after January 1, 2007. For determining multiple primaries of hematopoietic origin diagnosed on or after January 1, 2010, refer to the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic Database which can be found at <https://seer.cancer.gov/tools/heme/download>.

Multiple Primaries for Solid Tumors

Multiple primaries for solid tumors are determined according to the rules detailed in the *Multiple Primaries and Histology Coding Manual* (MP/H) for cases diagnosed **January 1, 2007** and after. The MP/H contains site-specific rules to apply in specific sequence for deciding whether multiple reportable primaries are present. Site-specific rules are subdivided into modules according to whether the case involves single or multiple tumors, or it is unknown whether multiple tumors are present in the primary site. The site-specific coding rules are presented in three different formats geared to suit the preferences of individual users: Flow chart, Matrix and Text list. **It is essential** to read the general instructions and the site-specific equivalent terms and definitions on pages 5-31 of the MP/H Manual before using the site-specific coding rules. Further instructions for using the Multiple Primary Rules are listed below.

Multiple Primary Rules for Hematopoietic Cases

Beginning with cases diagnosed January 1, 2010, multiple primaries for hematopoietic cases are determined according to rules set forth in the *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* and the Hematopoietic Database which can be found at <https://seer.cancer.gov/tools/heme/download>. Training modules are also available at this site and are highly recommended. The rules manual is navigated in a 5 step process:

1. Search the database for a provisional site and histology code
2. Use the Case Reportability Instructions to determine if the case is reportable
3. If so, go to the Multiple Primary Rules
4. Go to the Primary Site & Histology Rules (for every primary). Consult the database only when the rules specify to do so
5. Use the Grade of Tumor Rules

For hematopoietic cases diagnosed prior to 2010, use the tables in Appendix A of *FORDS* to decide whether differing hematopoietic histologies represent one or more primaries. Primary site and timing are not applicable for determining whether these malignancies represent one or more primaries.

Chapter 4

FIRST COURSE OF THERAPY

Definitions

Treatment or therapy for cancer is meant to modify, control, remove, or destroy cancer tissue (cancer-directed treatment). Therapy can be used to treat cancer tissue in primary or metastatic site(s), regardless of the patient's response to that treatment. The first course of therapy should include all cancer-directed treatments indicated in the initial treatment plan and delivered to the patient after initial diagnosis of cancer. Multiple modalities of treatment may be included and therapy of cancer-directed therapies proposed to eliminate or control the patient's disease. Treatment intentions may be found in discharge summaries, consultations, and outpatient records. All cancer-directed therapies (surgery, radiation, chemotherapy, hormone therapy, immunotherapy, or other therapy) documented in the physician's treatment plan and administered are included in the first course of therapy.

All Malignancies except Leukemia

The **first course of treatment** includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Treatment given specifically for tumor progression or recurrence, and treatment started when there is failure of the initial course of therapy are considered subsequent treatment.

Leukemia

The **first course of treatment** includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

Time Periods for First Course of Treatment (FCT)

The **Date of First Course of Treatment** is earliest of *Date of First Surgical Procedure*, *Date Radiation Started*, *Date Systemic Therapy Started*, *Date Other Treatment Started* or the date the decision for no treatment was documented.

- No Treatment: is considered a treatment option and may represent the first course of therapy. Reason for no treatment should be entered in the appropriate treatment field.

- If there is no documented treatment plan and no other treatment guidelines are established, evaluate the therapy and the time it began in relation to the diagnosis date. If the therapy is a part of an established protocol or within accepted guidelines for the disease, consider it the first course of therapy.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle “initial treatment must begin within one year of the date of initial diagnosis”
- If FCT systemic treatment regimen is changed due to and adverse reaction, follow these guidelines:
 - If the new chemotherapy drug(s) is in the same subcategory as the initial therapy (i.e. antimetabolite, alkylating agent, etc.) it is considered continuation of the first course of treatment. Some drugs overlap categories (alkaloid-antimetabolite) and are considered in the same category if either term matches the original subcategory.
 - If the drug(s) is not in the same group it is no longer the first course of therapy
 - If the patient fails to respond to treatment and the regimen is changed, it is no longer first course of treatment. Lists of drugs and their classification(s) are available at <http://www.seer.cancer.gov/tools/seerrx/>

Example: Patient A is started on a planned course of Tamoxifen (anti-estrogen). It is effective, but she does not tolerate the drug side effects and is changed to Arimidex (aromatase inhibitor). This starts a new course of therapy because the two hormone drugs are not in the same subcategory.

Example: Patient B is started on Aromasin (aromatase inhibitor). It is effective but she is changed to Arimidex (aromatase inhibitor) for insurance reasons. That is still first course of therapy because both hormone drugs are in the same subcategory.

Example: Physician plans a combination regimen of chemotherapy. Velban (plant alkaloid) is one of the drugs, after several cycles, it is replaced with Oncovin (Plant alkaloid-antimetabolite) due to adverse reaction. This is still first course of therapy because both are in the same subcategory- alkaloid.

Example: Physician plans a regimen of Adriamycin (antitumor antibiotic)/Cytosan (alkylating agent). The patient does not respond so the treatment is changed to Methotrexate (antimetabolite)/5FU (antimetabolite). Because the initial treatment failed, the new chemotherapy regimen is coded as subsequent treatment.

Rx Summ – Treatment Status

Per FORDS, this date item summarizes whether the patient received any treatment or if the tumor was under active surveillance. The item was added to document active

surveillance (watchful waiting) and to eliminate searching each treatment modality to determine whether treatment was given. It is used in conjunction with *Date of First Course of Treatment* to document whether treatment was or was not given, it is unknown if treatment was given, or treatment was given on an unknown date.

Surgical Diagnostic and Staging Procedures (Non-Cancer Directed Surgery)

Surgical diagnostic and staging procedures such as biopsies, thoracentesis, and bypasses do not modify or destroy cancer cells. Surgical procedures that aspirate, biopsy or remove lymph nodes to diagnose and/or stage disease are to be entered in *Scope of Regional Lymph Node Surgery* not in this field.

Palliative Procedure

Procedures performed to palliate or alleviate symptoms may include surgery, radiation, systemic therapy and/or other pain management therapy. This data element allows the tracking of procedures that are considered palliative rather than therapeutic, diagnostic or used for staging. Examples of palliative procedures include: bypass/stent for pancreatic carcinoma; radiation for bone metastasis; palliative chemo for advanced lung cancer. Palliative treatments are to be coded in palliative procedure **and** First Course of Therapy. When palliative treatment is given as first course of therapy, the case is considered analytic. When palliative procedures do not remove, modify or destroy tissue (bypass stents, persistent pain management), the procedure is not treatment and is coded only if the case is otherwise reportable.

Note: Palliative radiation would be coded as '2' in Palliative Procedure field. The Appropriate code would also be entered in the Radiation field.

Chapter 5

INITIAL ABSTRACT

Identification Information

In the chapters that follow, this manual lists both standard field names and Abstract Plus software field names where there are differences. Please be aware that a given standard setter or software may display field names slightly differently.

Reporting Hospital/Facility Number (Reporting Facility)

The number entered in this data field is used by the central registry to identify the facility reporting the case(s). The 10-digit institution number assigned by the Cancer Department of the American College of Surgeons (ACoS) must be right justified and preceded by zeros if less than 10 characters. For facilities with a 7-digit number (6-digit number preceded by a constant 6), this number would be right justified and preceded by 3 zeros. Some software can be programmed to autocode this field.

NPI – Reporting Facility

Enter the NPI number assigned to the facility identified above. The software vendor may have set this to code automatically.

Accession Number + Sequence Number

The **accession number** is assigned by the reporting facility and provides a unique identifier for the patient consisting of the year in which the patient was first seen at the reporting facility and the consecutive order in which the tumor was abstracted. This data item protects patient identity and allows cases to be identified on a local, state, and national level.

Instructions for Coding:

- The first four digits specify the **year** in which the patient was first diagnosed or treated for cancer at the reporting hospital. The next five digits designate the **numerical order** in which the patient was entered into the registry database.
- The reporting facility assigns **only one** accession number to each patient for life, even if additional primary cancers are diagnosed. Additional primary cancers are represented by the “**sequence number**” component of the accession number. The sequence number represents the number of primary cancers a patient may have during his lifetime. ‘00’ indicates the first and only primary cancer, ‘01’ would indicate the first of more than one

primary cancers, '02' indicates the second of two or more primary cancers, '03' denotes the third of three or more cancers, etc.

- A patient's accession number is not reassigned after a case is voided.
- A patient retains the original accession number even when the registry reference year changes. If a new primary is then discovered, the sequence number is updated accordingly.

Sequence Number(s)

This data item indicates the sequence of all reportable neoplasms over the lifetime of the patient. It is used to distinguish among cases having the same accession numbers, to select patients with only one primary tumor for certain follow-up studies, and to analyze factors involved in the development of multiple tumors. (See Coding Instructions/Patient Identification, Section 2 of the FORDS Manual).

The sequence (first, second, third, etc. primary) for the particular primary cancer being reported is represented by a **two-digit number**.

Instructions for Coding:

The decision regarding which sequence number to assign a neoplasm depends upon its behavior code at the time of diagnosis. Codes 00-59 and 99 indicate the sequence of neoplasms of in situ or malignant behavior (2 or 3). Codes 60-88 indicate the sequence of non-malignant tumors. Neoplasms which are reportable by agreement, either by ACCR or your facility's cancer committee, follow these same guidelines.

- Codes 00-59 and 99 indicate reportable neoplasms of malignant or in situ behavior (behavior equals 2 or 3).
- Codes 60-88 indicate neoplasms of non-malignant behavior (behavior equals 0 or 1)
- Code 00 only if the patient has a single malignant primary. If the patient develops a subsequent reportable primary tumor, change the code for the first tumor from "00" to "01", and number subsequent tumors sequentially.
- Code 60 only if the patient has a single non-malignant primary. If the patient develops a subsequent non-malignant primary, change the code for the first tumor from 60 to 61, and assign codes to subsequent non-malignant primaries sequentially.
- If two or more reportable neoplasms, **malignant or in situ** are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- If two or more **non-malignant** neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident, the decision is arbitrary.
- Any tumor in the patient's past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors, regardless of where it was diagnosed. If the prior tumor

had a behavior code of 2 (in situ) or 3 (malignant), and the current tumor is also behavior code 2 or 3, assign a sequence code 02-59 range. An intracranial or central nervous system tumor (diagnosed 1/1/2004 or later) with a behavior code of 0 (benign) or 1 (borderline) is assigned a sequence code in the range of 60-88. However, do not reassign sequence numbers if one of those tumors becomes non-reportable later.

- Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that would affect the sequence.
- Do not include past non-reportable skin cancers in sequencing. If the patient had a previous non-reportable skin cancer, please document that in a text field.

Malignant or in situ

Code	Definition
00	One malignant or in situ primary only in the patient's lifetime
01	First of two or more independent malignant or in situ primaries
02	Second of two or more independent malignant or in situ primaries
...	Actual sequence of this malignant or in situ primary
59	Fifty-nine or more independent malignant or in situ primaries
99	Unknown number of malignant or in situ primaries

Non-Malignant Primaries

Code	Definition
60	Only one non-malignant primary in a patient's lifetime
61	First of two or more independent non-malignant primaries
62	Second of two or more independent non-malignant primaries
...	Actual sequence of this non-malignant primary
87	Eighty-seven or more independent non-malignant primaries
88	Unspecified number of independent non-malignant primaries

Examples:

Code	Reason
00	A patient with no history of previous cancer is diagnosed with in situ breast carcinoma June 13, 2010
01	The above patient (diagnosed with in situ breast carcinoma on June 13, 2010) is diagnosed with a subsequent skin melanoma on August 30, 2012 the sequence is changed from 00 to 01.
02	The sequence number assigned to a skin melanoma diagnosed on August 30, 2012, following the diagnosis of a breast carcinoma on June 13, 2010.
04	A nursing home patient is admitted to a hospital for first course surgery for a colon adenocarcinoma. The patient has had three previous primary cancers that are reportable, but was not seen at this facility. No sequence numbers 01, 02, or

	03 are entered for this patient.
60	The sequence number assigned to a benign brain tumor diagnosed on November 1, 2005, following a breast carcinoma diagnosed on June 13, 2003 and a skin melanoma diagnosed on August 30, 2003.
63	Myeloproliferative disease (9975/1) is diagnosed by the facility in 2003 and accessioned as sequence 60. A benign brain tumor was diagnosed and treated elsewhere in 2002; patient comes to the facility with a second independent benign brain tumor in 2004. Unaccessioned earlier brain tumor is counted as Sequence 61, myeloproliferative disease is resequenced to 62, and second benign brain tumor is sequence 63

Name – Last

Record the patient's last name. Mixed-case, embedded spaces, hyphens, and apostrophes are allowed.

Name – First

Record the patient's first name. Mixed-case and embedded spaces are allowed. Special characters are not allowed.

Name – Middle

Record the patient's middle name. Middle initial may be used if full middle name is not available. Leave blank if no middle name/initial is given. Mixed-case and embedded spaces are allowed, special characters are not.

Name – Alias

Many patients use a name different from their given name. If the patient uses an alias for the first name, record only the first name alias. If a patient uses an alias for the last name, record the last name alias. If a patient uses an alias for the first and last name, record both the last and first name aliases. Do not use commas.

Name – Maiden

Record the maiden name of married female patients. If the patient has no maiden name or the information is not available, leave blank.

PATIENT ADDRESS AND RESIDENCY RULES

The address at diagnosis can provide information to identify possible cancer clusters for environmental and epidemiological studies and provide essential information for public health activities.

- The patient's address at diagnosis is the place of residence at the time of original diagnosis. It does not change if the patient moves. If the patient has multiple primary tumors, the address at diagnosis may be different for subsequent primaries.
- Normally a residence is the home named by the patient. Legal status and citizenship are not factors in residency decisions. Rules of residency are identical to or comparable with the rules of the Census Bureau's definition, "the place where he or she lives and sleeps most of the time or the place the person considers being his or her usual home." Vital statistics rules may differ from Census rules. "Do not record the residence from the death certificate." Review each case carefully.
- Record the patient's number and street address at the time the cancer was diagnosed or treated. Mixed case and embedded spaces are allowed. Special characters are limited to periods, slashes, hyphens, and pound signs. Standard abbreviations may be used. If no street address is available, record "Unknown". **DO NOT LEAVE BLANK**
- It may be necessary to use "Unknown" if the correct address at diagnosis is not known.
- **Do not update this item if the patient's address changes.**

Rules for Persons with Ambiguous Residences

- Persons with more than one Residence (summer and winter homes): Use the address the patient specifies if a usual residence is not apparent.
- Persons with no usual residence (transients, homeless): Use the address of the place the patient was staying when the cancer was diagnosed. This could be a shelter or a diagnosing facility.
- Persons away at school: College students are residents of the school area. Boarding school students below the college level are residents of their parents' homes.
- Persons away in Institutions: The Census Bureau states, "Persons under formally authorized, supervised care or custody," are residents of the institution. This includes the following:
 - Incarcerated persons
 - Persons in nursing, convalescent, and rest homes
 - Persons in homes, schools, hospitals, or wards for the physically disabled, mentally disabled, or mentally ill.
 - Long-term residents of other hospitals, such as Veterans Affairs (VA) hospitals.
 - Persons in the Armed Forces and on Maritime Ships: Members of the armed forces are residents of the installation area. Use the stated address for military personnel and their families. Military personnel may use the installation address or the surrounding community's address.

Address at Diagnosis – Supplemental

Record any additional address at diagnosis information such as name of nursing home or apartment complex

Address at Diagnosis – City/Town

Record the city or town of the patient’s address at the time of cancer diagnosis. If the city is unknown record UNKNOWN. **DO NOT LEAVE BLANK.**

If the patient resides in a rural area, record the name of the city or town used in his or her mailing address.

Do not update this data item if the patient’s city/town or residence changes.

State at Diagnosis

Record the U.S. postal service two-letter state abbreviation for the state of residence at cancer diagnosis. Use the two-letter abbreviation for patients whose residence at diagnosis was a Canadian province:

Abbreviations for Canadian provinces/territories

Province/Territory	Code	Province/Territory	Code
Alberta	AB	Nunavut	NU
British Columbia	BC	Ontario	ON
Manitoba	MB	Prince Edward Island	PE
New Brunswick	NB	Quebec	PQ
Newfoundland and Labrador	NL	Saskatchewan	SK
Northwest Territories	NT	Yukon	YT
Nova Scotia	NS	Canada, unknown	CD

Use the following codes when the state or province is unknown or not applicable

- US = Resident of United States, NOS
- XX = Resident of country other than U.S. or Canada and the country is known
- YY = Resident of country other than U.S. or Canada and country is unknown
- ZZ = Resident of the U.S., NOS; Canada, NOS; residence unknown

Do not update this data item if the patient’s state or residence changes.

Postal Code at Diagnosis

For U.S. residents record the 5-digit zip code and the 4-digit extension (if known) for the patient's address at diagnosis. For Canadian residents, use the 6-character alphanumeric postal code. Record 88888 8888 if the patient is a resident of a country other than Canada, U.S., or U.S. possessions and the postal code is not known. Record 99999 9999 if the patient is a resident of Canada, U.S., or U.S. possessions but the postal code is unknown or residence is unknown. Consult the zip code list at: <http://pe.usps.gov/cptm/pubs/pub28/pub23.pdf> ~~delete or correct - link does not work~~

County at Diagnosis

Code the county of the patient's residence at the time of diagnosis. For U.S. residents, standard codes are those of the FIPS publication *Counties and Equivalent Entities of the United States, Its Possessions, and Associated Areas*. This publication can be accessed on the Internet at <http://www.epa.gov/>. (be more specific with site, difficult to locate publication) If the patient has multiple tumors, the county codes may be different for each tumor.

- Code 998 if known town, city, state, or country of residence but county code not known AND a residence outside of the state of Arkansas (must meet all criteria)
- Code 999 if county of residence at diagnosis is unknown or for non-US residents

Do not update this data item if the patient's county or residence changes.

Address Current

Patient Address Current – Number and Street

City/Town Current

State – Current

Postal Code – Current (Zip Code)

County – Current

These data items provide a current address, otherwise the rules for coding are as above. These fields should be

BIRTH DATE

- Identifies the date of birth of the patient as indicated in the patient record.
- For *in utero* diagnosis and treatment, record the actual date of birth. It will follow one or both dates for those events.

- Beginning in 2010, the way dates are transmitted has changed. In order that registry data can be interoperable with other data sources, dates are transmitted in a format widely acceptable outside of the registry setting.
 - The interoperable form of Date of Birth transmits in CCYYMMDD form where blank spaces are used unknown trailing portions of the date.
 - If the year of birth is unknown, calculate the year.

EXAMPLE: The history and physical states that the patient is 75 years old at the time he is admitted into your facility, January 15, 2002. The patient is calculated to have been born in 1927. CCYY = 1927, MM = blank, DD = blank

- If month is unknown, the is coded unknown (left blank)
- If the year cannot be determined, the day and month are both coded unknown (left blank)
- If the date of birth cannot be determined at all the entire field is left blank. Record the reason in *Date of Birth Flag*.

Please see FORDS 2015 Section Two: Coding Instructions – Patient Identification- Date of Birth- page 63 & 64

Date of Birth and Date of Birth Flag

This flag explains why there is no appropriate value in the corresponding date field, Date of Birth. As part of an initiative to standardize date fields, date flag fields were introduced to accommodate non-date information that had previously been transmitted in date fields.

Instructions for Coding:

- Leave this item blank if Date of Birth has a full or partial date recorded
- Code 12 if the Date of Birth cannot be determined at all
- Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software

Please see FORDS 2015 Section Two: Coding Instructions – Patient Identification- Date of Birth- page 63 & 64

SOCIAL SECURITY NUMBER

- Record the patient’s Social Security number, if known, record without dashes.
- Do not record the spouse’s number. Code Social Security numbers that end with “B” or “D” as 999999999, the patient receives benefits under the spouse’s number and this is the spouse’s SSN.
- Use 9s also if patient does not have a SSN or if SSN is not available.

BIRTH PLACE - STATE

This data item is used to evaluate medical care delivery to special populations and to identify populations at special risk for certain cancers. This item was first defined for use in 2013; cases diagnosed before that date should be converted automatically by the registry's software from the former *Place of Birth*.

Instructions for Coding:

- Use the most specific code
- This item corresponds to Birthplace-Country
- See FORDS-2015, Appendix E for a list of state codes and their respective country codes

Examples:

Code	Definition
IL	If the state in which the patient was born is Illinois, then use USPS code for the state of Illinois.
XX	Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>known</i>
YY	Born in a country other than the U.S. (including its territories, commonwealths, or possessions) or Canada and the country is <i>unknown</i> .
US	Born in the U.S. (including its territories, commonwealths, or possessions) and the state is <i>unknown</i>
CD	Born in Canada and the province is <i>unknown</i>
ZZ	Place of Birth is unknown, not mentioned in patient record

DO NOT LEAVE THIS FIELD BLANK

ALCOHOL HISTORY

Code the patient's current or past usage of alcoholic beverages, such as wine or beer, using the codes:

CODE	DEFINITION
0	No history of alcohol usage
1	Current use of alcohol (this includes social usage)
2	Past history of alcohol usage, no current usage
9	Unknown (if no information is available)

DO NOT LEAVE THIS FIELD BLANK

TOBACCO HISTORY

Code the patient's current or past usage of tobacco products, using the codes:

CODE	DEFINITION
0	Never smoked
1	Cigarette smoker, current
2	Cigar/pipe smoker, current
3	Snuff, chew, smokeless tobacco, current
4	Combination use, current (Smokes and chews or dips)
5	Previous tobacco use
9	Unknown (no information available)

E-cigarettes *do not* qualify as tobacco use.

DO NOT LEAVE THIS FIELD BLANK

FAMILY HISTORY

Record any first-degree family (parents, brothers, sisters, and children) history of any reportable cancer. Record in text any personal history of cancer for the patient that may be documented in the medical record.

1 – Yes

2 - No

DO NOT LEAVE THIS FIELD BLANK

RACE (1-5)

Race 1 identifies the primary race of the person and is the field used to compare with race data on cases diagnosed prior to January 1, 2000. This field allows calculation of race specific incidence rates. Record these multi-racial patients using the following table:

Code	Definition	Code	Definition
01	White	20	Micronesian, NOS
02	Afro/American	21	Chamorro
03	American Indian, Aleutian, Eskimo (includes South and Central American Indians)	22	Guamanian, NOS
04	Chinese	25	Polynesian, NOS
05	Japanese	26	Tahitian
06	Filipino	27	Samoan
07	Hawaiian	28	Tongan
08	Korean	30	Melanesian, NOS
10	Vietnamese	31	Fiji Islander

11	Laotian	32	New Guinean
12	Hmong	96	Other Asian-Asian, NOS, Oriental, NOS
13	Kampuchean (Cambodian)	97	Pacific Islander, NOS
14	Thai	98	Other
15	Asian Indian or Pakistani, NOS (formerly code 09)	99	Unknown
16	Asian Indian		
17	Pakistani		

- If only one race is reported for the person, use code ‘88’ for remaining race fields (Race 2-5)
- If Race 1 is ‘99’, Unknown, Race 2-5 must also be ‘99’
- This field is used to code the primary race of the person and is to be used in conjunction with “Spanish/Hispanic Origin”. Additional races reported by the person should be coded in Race 2-5.
- Mexican, Puerto Rican or Cuban origins are coded as white. .
- If a person is multiracial and one of the races is white, code the other race(s) first with white in the next race field.
- If a person is multiracial and one of the races is Hawaiian, code Hawaiian as Race 1 followed by the other race(s).
- A known race code (other than blank or 99) must not occur more than once. For example, do not code “Black” in Race 1 for one parent and “Black” in Race 2 for the other parent.
- If the case is diagnosed prior to 1/1/2000, Race 2-Race 5 must be blank, UNLESS the patient has more than one primary with at least one primary diagnosed 1/1/2000.
- If Race 2 is blank, Race 3 – Race 5 must also be blank.

SPANISH/HISPANIC ORIGIN

This code identifies whether or not the person should be classified as “Hispanic”

Code	Definition
0	Non-Spanish; Non-Hispanic
1	Mexican (includes Chicano)
2	Puerto Rican
3	Cuban
4	South or Central American (except Brazil)
5	Other specified Spanish/Hispanic origin (<i>includes</i> European; <i>excludes</i> Dominican Republic)
6	Spanish NOS; Hispanic NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category of 1-5)

7	Spanish surname only (The only evidence of the person's Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic)
8	Dominican Republic (for use with patients who were diagnosed with cancer on January 1, 2005 or later)
9	Unknown whether Spanish/Hispanic or not stated in patient record

SEX

Code the patient's sex. Use the following codes:

Code	Definition
1	Male
2	Female
3	Other (hermaphrodite)
4	Transsexual
5	Transsexual, natal male
6	Transsexual, natal female
9	Not stated in patient record, Unknown

OCCUPATION TEXT

This data item is applicable for patients 14 years or older at the time of diagnosis and is reported in text only.

- Record the patient's usual (longest held) occupation before the cancer diagnosis.
- If the patient had several jobs over a lifetime, record the occupation engaged in for the longest period of time, if known.
- If the patient is retired and the occupation is unknown, **DO NOT RECORD RETIRED**, record **UNKNOWN**.
- If the patient was a housewife/househusband and never worked outside of the home, record "homemaker", "housewife" or "househusband". (Industry: "own home")
- Record "unknown" if no information is available. **DO NOT LEAVE BLANK**.

INDUSTRY TEXT

This data item is applicable for patients 14 years or older at the time of cancer diagnosis and is reported in text only.

- Record the primary type of business activity performed by the company where the patient was employed for the most number of years.

- Distinguish whether the industry is involved in manufacturing, wholesale, retail or service, etc.
- If the primary activity is unknown, record the name of the company and city or town. The central registry may be able to determine the business activity performed.
- Record “unknown” if no information is available. **DO NOT LEAVE BLANK.**
- If the patient is retired and the type of industry is unknown, **DO NOT RECORD RETIRED**, record **UNKNOWN** in this field.

Primary Payer at Diagnosis

This identifies the patient’s primary payer/insurance carrier at the time of initial diagnosis and/or treatment.

Instructions for Coding:

- If the patient is diagnosed at the reporting facility, record the payer at the time of diagnosis
- If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known record the payer when the patient is initially admitted for treatment
- Record the type of insurance reported on the patient’s admission page
- Codes 21 and 65-68 are to be used for patients diagnosed on or after January 1, 2006
- If more than one payer or insurance carrier is listed on the patient’s admission page, record the first
- If the patient’s payer or insurance carrier changes, do not change the initially recorded code

Use the following codes:

01 – Not insured: Patient has no insurance and is declared a charity write-off

02 – Not insured, self-pay: Patient is responsible for charges

10 – Insurance, NOS: Type insurance unknown or other than the types listed in codes 20, 21, 30, 60-68

20 – Private Insurance, Managed Care, HMO or PPO

21 – Private insurance: Fee-for-Service

31 – Medicaid

35 – Medicaid administered through a Managed Care Plan

60 – Medicare without supplement, Medicare NOS

61 – Medicare with supplement, NOS

62 – Medicare administered through a Managed Care plan

63 – Medicare with private supplement

64 – Medicare with Medicaid eligibility

65 – TRICARE

66 – Military

67 – Veterans Affairs

68 – Indian/Public Health Service

99 – Insurance status unknown

DATE OF FIRST CONTACT

Record the date of the first inpatient or outpatient encounter at this facility for diagnosis of and/or first course treatment of a reportable tumor. This may be the date of an outpatient visit for a biopsy, x-ray, scan or laboratory test.

This data item can be used to measure the time between first contact and the date that the case was abstracted. It can also be used to measure the length of time between the first contact and treatment for quality of care reports.

Instructions for Coding:

- When a patient is diagnosed in a staff physician's office, the date of first contact is the date the patient was physically first seen at the reporting facility.
- If autopsy only or death certificate only case, then the date of death is the date of first contact.
- Record the date as complete as possible. Leave any unknown portions of the date blank.
- For analytic cases (Class of Case 00-22), the *Date of First Contact* is the date the patient became analytic. For non-analytic cases, it is the date the patient first qualified for the Class of Case that causes the case to be abstracted.

Class of Case

This data element is designed to separate the reporting registry's cancer cases into *analytic* and *nonanalytic* categories. The code structure for this item was revised in 2010. ACCR requires Class of Case 00, 10,11,12,13, 14, 20, 21, and 22.

Instructions for Coding:

- Code the *Class of Case* that most precisely describes the patient's relationship to the facility
- Code **00** applies only when it is known the patient went elsewhere for treatment. If it is not known that the patient actually went somewhere else, code *Class of Case* 10.
- It is possible that information for coding Class of Case will change during the patient's first course of care. If that occurs during the abstracting process, change the code

accordingly as new information becomes available in the patient record or from other facilities.

- Document *Institution Referred To* for patients coded 00, 13 to establish that the patient went elsewhere for treatment. Document *Institution Referred from* for patients coded 20-22 to establish that patient came from elsewhere.
- A staff physician (codes 10-12) is a physician who is not employed by the reporting facility, but has routine practice privileges there.
- Physicians who are not employed by the hospital but are under contract with it or have routine admitting privileges that are described in codes 10-12 as physicians with admitting privileges. Treatment provided in the office of a physician with admitting privileges is provided “elsewhere”. That is because care given in a physician’s office is not within the hospital’s realm of responsibility.
- If the hospital purchases a physician practice, it will be necessary to determine whether the practice is now legally considered part of the hospital (their activity is coded as the hospital) or not. If the practice is not legally part of the hospital, it will be necessary to determine whether the physician involved are staff physicians or not, as with any other physician.
- “In-transit” care is given to a patient who is temporarily away from the patient’s usual practitioner for continuity of care. They are Class of Case 31 (not reportable to ACCR). Monitoring of **oral** medication started elsewhere is also Class of Case 31 (no reportable to ACCR). If the patient begins first course of radiation or chemotherapy **infusion** elsewhere and continues at the reporting facility, the case is not in-transit, the case is analytic (Class of Case 20) and reportable to ACCR.

DEFINITIONS:

Analytic Classes of Case

Initial diagnosis at reporting facility or staff physician’s office

Code	ACCR Status	Definition
00	Reportable	Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
10	Reportable	Initial diagnosis at the reporting facility or in a staff physician’s office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
11	Reportable	Initial diagnosis in staff physician’s office AND part of first course treatment was done at the reporting facility
12	Reportable	Initial diagnosis in staff physician’s office AND all first course treatment or a decision not to treat was done at the reporting facility

13	Reportable	Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility
14	Reportable	Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility
<i>Initial diagnosis elsewhere</i>		
Code	ACCR Status	Definition
20	Reportable	Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
21	Reportable	Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility
22	Reportable	Initial diagnosis elsewhere AND all first course treatment was done at the reporting facility

Non-analytic Classes of Cases

Patient appears in person at reporting facility

Code	ACCR Status	Definition
30	Not Reportable	Initial diagnosis and all first course treatment elsewhere AND reporting facility
31	Not Reportable	Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care
32	Not Reportable	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence
33	Not Reportable	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only
35	Not Reportable	Case diagnosed before program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility
37	Not Reportable	Case diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility

38	Not Reportable	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death <i>Patient does not appear in person at reporting facility (could be reportable by agreement for your facility)</i>
Code	ACCR Status	Definition
40	Not Reportable	Diagnosis AND all first course treatment given at the same staff physician's office
41	Not Reportable	Diagnosis and all first course treatment given in two or more different staff physician offices
42	Not Reportable	Non-staff physician or other facility not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (ex: hospital abstracts cases from an independent radiation facility)
43	Not Reportable	Pathology or other lab specimens only
49	Not Reportable	Death certificate only
99	Not Reportable	Non-analytic case of unknown relationship to facility

Type of Reporting Source

Code the source of documents used to abstract the majority of information on the tumor being reported. This may not be the source of original case finding (for example, if a case is identified through a path lab report review and all source documents used to abstract the case are from the physician's office, code this item 4). This data item is used by the central cancer registry to assist in the measurement of case reporting from all facilities.

Code	Definition
1	Hospital inpatient, hospital outpatient, clinic
2	Radiation Treatment Centers or Medical Oncology Centers (hospital affiliated or Independent)
3	Laboratory only (hospital-affiliated or independent)
4	Physician office/private medical practitioners (LMD)
5	Nursing home, convalescent home, convalescent hospital, hospice
6	Autopsies only
7	Death certificate only
8	Other hospital outpatient units/surgery centers

NPI -PRIMARY SURGEON

This identifies the physician who performed the most definitive surgical procedure. Record the 10-digit NPI number for the physician who performed the most definitive surgical procedure.

- To determine the physician's NPI number, search <https://nppes.cms.hhs.gov/NPPES/NPIRegistryHome.do>
- NPI should be recorded as available for cases diagnosed during 2007, and is required to be recorded for all cases diagnosed January 1, 2008, and later.
- If the patient did not have surgery, NPI for the primary surgeon is unknown or not available. The physician who performed the surgical procedure was not a surgeon (general practitioner), leave code blank

NPI-ATTENDING PHYSICIAN (MANAGING PHYSICIAN)

The managing physician is the doctor responsible for the overall management and care of the patient during the diagnosis and treatment of the reported cancer.

Use the 10-digit NPI number for the managing physician.

NPI for the managing physician is unknown, leave field blank

NPI-FOLLOWING PHYSICIAN (FOLLOW-UP PHYSICIAN)

Record the NPI for the physician currently responsible for the patient's medical care. The following physician is the first contact for obtaining information on a patient's status and subsequent treatment.

Chapter 6

CANCER IDENTIFICATION

PRIMARY SITE

The primary site is defined as the organ or site in which the cancer originated or began. A metastatic site indicates that the primary (originating) tumor has spread from the original site to other areas in the body. Cancer registries code only the primary site in this field, using the appropriate ICD-O manual, to determine the correct site code. Indications of metastatic sites are used in the registry for identifying the extent of the patient's disease and for staging purposes. Coding the primary site properly is very important, as many other field codes stem from it.

Code the primary site in this field, using the ICD-0-2 (cases diagnosed prior to January 1, 2001) or ICD-0-3 (cases diagnosed on or after January 1, 2001) manual to determine the correct site code and follow the instructions for coding.

Use current *SEER Multiple Primary and Histology Coding Rules* to determine the number of reportable primaries for solid tumors. Beginning with 2010 cases follow the instructions in *Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual* for assigning site for lymphomas, leukemia and other hematopoietic neoplasms. This manual may be downloaded from the SEER website at <http://seer.cancer.gov/tools/heme/index.html>. To determine primary site codes for cases diagnosed prior to 2010, follow instructions for coding in ICD-O-3, pages 20-40 and SEER's *Abstracting and Coding Guide for Hematopoietic Diseases*.

It is important to identify the exact location of the primary (originating) tumor whenever possible, and to enter the most specific ICD-O topography code listed into Primary Site field. The most specific location of a tumor should be coded. The registrar should use all documents available in the medical record to determine the most specific site code, including the pathology reports, scans, X-rays, MRIs, etc. The following points are helpful to consider when coding this field:

- Enter the specific subsite whenever applicable
EXAMPLE: A patient is diagnosed by CT scan with *mass in head of pancreas consistent with carcinoma*, code to C25.0 instead of C25.9, pancreas NOS.
- When a primary site is overlapping into one or more sub-sites, code the **.8** (overlapping lesion code). Overlapping applies to sites that are contiguous (adjacent) to one another.
EXAMPLE: Patient is diagnosed with colon cancer. The surgeon states that intraluminal tumor involved the colon from the cecum to mid-ascending colon. Code C18.8 rather than coding the site to either cecum or ascending colon.
- When the primary tumor is multifocal throughout an organ or when there is no information identifying the subsite from which the primary tumor arose, use the subsite code .9 to indicate the site, NOS.
EXAMPLE: The pathology from a mastectomy specimen shows diffuse, multifocal ductal carcinoma throughout the breast. Code C50.9

- When multiple tumor arising in different subsite of the same anatomic site are reported as a single primary and point of origin cannot be determined, code the last digit of the primary site to .9.

EXAMPLE: Patient has an infiltrating duct cancer in the UOQ (C50.4) of the right breast, and another infiltrating duct cancer in the LIQ (C50.5) of the same breast. Code the primary site as C50.9.

- If the primary site is documented as an “unknown primary”, use code C80.9.
- Kaposi’s Sarcoma is coded to the site in which it originates. Code to skin, NOS (C44.9) if the disease arises simultaneously in the skin and another site, AND the primary site is not identified.

HISTOLOGIC TYPE

Histologic type refers to the *classification* of malignancy described in the pathology or cytology report. This describes the microscopic composition of cells and/or tissue for a specific primary site. The tumor type or histology is a basis for staging and determination of treatment options.

Record histology using the 4-digit morphology codes found in the appropriate references as shown in the following table. The first three digits of the histology code will indicate the cancer cell type.

Instructions for Coding:

- ICD-O-3 identifies the morphology codes with an “M” preceding the code number. Do NOT record the “M”.
- Review all pathology reports related to the case.
- Code the final pathologic diagnosis for solid tumors.
- The codes for cancer, NOS (8000) and carcinoma, NOS (8010) are not interchangeable. If the physician says that the patient has carcinoma, then code carcinoma, NOS (8010).

Malignant Solid Tumors

Diagnosed January 1, 2007 and after	#1 <i>Multiple Primaries and Histology Coding Manual</i> #2 ICD-O-3
Diagnosed January 1, 2001 – December 31, 2006	ICD-O-3
Diagnosed prior to 2001	ICD-O-2 (enter into historic ICD-O-2 field) AND ICD-O-3 (enter into ICD-O-3 histologic type field)

Benign/Borderline Intracranial and Other CNS Tumor

Diagnosed January 1, 2007 and after	#1 <i>Multiple Primaries and Histology Coding Manual</i> #2 ICD-O-3
Diagnosed January 1, 2004 – December 31, 2006	ICD-O-3
Diagnosed prior to 2004	Not Reportable

Lymphomas, Leukemias and other Hematopoietic Malignancies

Diagnosed January 1, 2010 and after	<i>Hematopoietic and Lymphoid Neoplasms Case Reportability and Coding Manual and the Hematopoietic Database</i>
Diagnosed January 1, 2001 – December 31, 2009	ICD-O-3
Diagnosed prior to 2001	ICD-O-2 (enter into historic ICD-O-2 field) AND ICD-O-3 (enter into ICD-O-3 histologic type field)

Ambiguous Terms Used to Code Histology

When any of the ambiguous terms below are used to describe a more specific histology code the more specific histology

- Apparent(ly)
- Appears
- Compatible with
- Comparable with
- Consistent with
- Favor(s)
- Most likely
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Typical (of)

EXCEPTION: If the final diagnosis is “Not Otherwise Specified” (carcinomas, NOS, melanoma, NOS, then code the histology from the microscopic description or comment if it identifies a more specific histology type.

Further instructions and rules that clarify histology coding are found in the *Multiple Primary and Histology Coding Rules* manual.

BEHAVIOR CODE

The behavior code occupies the 5th digit of the morphology code. This component of the histologic code indicates the way in which the neoplasm will act or behave – malignant (3) or non-malignant (2). Only neoplasms with the behavior code of 0 (benign), 1 (borderline), 2 (in situ) or 3 (invasive) are to be reported to the Arkansas Central Cancer Registry. ACCR only requires primary sites to be collected and submitted. If the pathology report describes the cancer as metastatic, the registrar should be alerted that the primary site is not described on this report and must take steps to identify the primary site with a behavior code of 3. The hospital registry does **not** utilize behavior codes of 6 or 9.

Colon and rectal sites with high grade or severe dysplasia are reportable as behavior code 2 cases only if the pathologist states they are equivalent to carcinoma in situ **and** the reporting facility’s registry has a documented policy to this effect. Abstract text **MUST** document pathology as in situ carcinoma. **Delete paragraph**

The following terms are synonymous with behavior code 2 (in-situ) cancers:

- Adenocarcinoma in an adenomatous polyp with no invasion of stalk
- Clark’s level 1 for melanoma (limited to epithelium)
- Comedocarcinoma, non-infiltrating (C50. *)

- Confined to epithelium
- Hutchinson's melanotic freckle, NOS (C44. *)
- Intracystic, non-infiltrating
- Intraductal
- Intraepidermal, NOS
- Intraepithelial, NOS
- Involvement up to but not including the basement membrane
- Lentigo maligna (C44. *)
- Lobular neoplasia
- Lobular, noninfiltrating (C50. *)
- Noninfiltrating
- Noninvasive
- No stromal involvement
- Papillary, noninfiltrating or intraductal
- Pre-cancerous melanosis (C44. *)
- Queyrat's erythroplasia (C60. *)

Behavior code is coded as malignant (3) if there is documentation of any invasion present.

Juvenile astrocytoma (9421/1) should be coded as 3 by agreement of North American registry standard-setters.

Grade of Differentiation

These are coding instructions for cases **diagnosed 1/1/2014 and forward**.

A. Hematopoietic and Lymphoid Neoplasms

Cell Indicators (Codes 5, 6, 7, 8, 9)

Cell indicator describes the lineage or phenotype of the cell. Codes 5, 6, 7, and 8 are used ONLY for hematopoietic and lymphoid neoplasms. Code 9 indicates cell type not determined, not stated, or not applicable.

Coding Grade for Hematopoietic and Lymphoid Neoplasms

1. Determine the histology based on the current Hematopoietic and Lymphoid Neoplasm Manual
2. Determine the cell indicator by applying the "Grade of Tumor Rules" within the current Hematopoietic and Lymphoid Neoplasm Manual to code the grade.

B. Solid Tumors

Grade, Differentiation (Codes 1, 2, 3, 4, 9)

Pathologic examination determines the grade, or degree of differentiation, of the tumor. For these cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). These similarities/differences may be based on pattern (architecture), cytology nuclear features, or a combination of these elements, depending upon the grading system that is used. Some grading systems use only pattern, for example Gleason grading in prostate. Others use only a nuclear grade such as Fuhrman's

grade for kidneys. Most systems use a combination of pattern and cytologic and nuclear features.

Coding for Solid Tumors:

1. Systemic treatment and radiation can alter a tumor’s grade. Therefore, it is important to code grade based on information prior to neoadjuvant therapy even if grade is unknown.
2. Code the grade from the primary tumor only.
 - a. Do NOT code grade based on metastatic tumor or recurrence. In the rare instance that tumor tissue extends contiguously to an adjacent site and tissue from the primary site is not available, code grade from the contiguous site.
 - b. If primary site is unknown, code grade to 9.
3. Code the grade for specific histologic terms that imply a grade.

Carcinoma, undifferentiated (8020/34)

Follicular adenocarcinoma, well differentiated (8331/31)

4. In situ and/or combination in situ/invasive components:
 - a. If a grade is given for an in situ tumor, code it. Do NOT code grade for dysplasia such as high grade dysplasia.
 - b. If there are both in situ and invasive components, code only the grade for the invasive portion even if its grade is unknown.
5. If there is more than one grade, code the highest grade within the applicable system. Code the highest grade even if it is only a focus. Code grade in the following priority order using the first applicable system:
 - a. Special grade systems for the sites listed in Coding for Solid Tumors #6
 - b. Differentiation: use Coding for Solid Tumors #7: 2, 3, or 4 grade system
 - c. Nuclear Grade: use Coding for Solid Tumors #7: 2, 3, or 4 grade system
 - d. If it isn’t clear whether it is a differentiation or nuclear grade and a 2, 3, or 4 grade system was used, code it.
 - e. Terminology (use Coding for Solid Tumors #8)
6. Use the information from the special grade systems first. If no special grade can be coded, continue with Coding for Solid Tumors #7-9.

Special grade systems for solid tumors

Based on CS Site-Specific factors for breast, prostate, heart, mediastinum, peritoneum, retroperitoneum, soft tissue, and kidney parenchyma is used to code grade. Do NOT use for any other groups including WHO (CNS tumors), WHO/ISUP (bladder, renal pelvis) or FIGO (female gynecologic sites) grades.

7. Use the Two-, Three-, or Four-grade system information
 - a. Two-grade system

Term	Description	Grade Code
1/2, I/II	Low Grade	2
2/2, II/II	High Grade	4

In transitional cell carcinoma for bladder, the terminology high grade TCC and low grade TCC are coded in the two-grade system

b. Three-grade system

Term	Description	Grade Code
1/3	Low Grade	2
2/3	Intermediate Grade	3
3/3	High Grade	4

c. Four-grade system

Term	Description	Grade Code
1/4	Grade 1; Well Differentiated	1
2/4	Grade 2; Moderately Differentiated	2
3/4	Grade 3; Poorly Differentiated	3
4/4	Grade 4; Undifferentiated	4

8. Terminology: use the 'Description' column or 'Grade' column to code grade. Breast & Prostate use the same grade code with a few noted exceptions.

Description	Grade	Assign Grade Code	Exception Breast/Prostate code
Differentiated, NOS	I	1	
Well Differentiated	I	1	
Stated 'Grade 1'	I	1	
Intermediate differentiation	II	2	
Low grade	I-II	2	1
Moderately differentiation	II	2	
Moderately well differentiated	II	2	
Stated 'Grade II'	II	2	
Moderately Poorly differentiated	III	3	
Poorly differentiated	III	3	
Dedifferentiated	III	3	
Stated as 'Grade III'	III	3	
High grade	III-IV	4	3
Undifferentiated, anaplastic, not differentiated	IV	4	
Stated as 'Grade IV'	4	4	

9. If no description fits or grade is unknown prior to neoadjuvant therapy, code as a 9 (unknown)

C. Special Grade Systems Rules

Breast (exclude lymphomas)

- Use Bloom Richardson (BR) or Nottingham score/grade to code grade based on CSv2 site-specific factor 7 (SSF) as state below.
- Code the tumor grade using the following priority order:
 - a. BR Scores 3-9
 - b. BR Grade (low, intermediate, high)
- If only a grade of 1-4 is given with no information on the score and it is unclear if it is a Nottingham or BR Grade, do not use the table below. Continue with the next priority according to “Coding for Solid Tumors” #7 above.
- Code the highest score if multiple scores are reported.

Description	CS Code	Grade Code
Score of 3	030	1
Score of 4	040	1
Score of 5	050	1
Score of 6	060	2
Score of 7	070	2
Score of 8	080	3
Score of 9	090	3
Low Grade, BR grade 1, score not given	110	1
Medium (Intermediate) Grade, BR grade 2, score not given	120	2
High Grade, BR grade 3, score not given	130	3

Kidney Parenchyma (exclude lymphomas)

- The Fuhrman Nuclear Grade should be used to code grade for kidney parenchyma only based on CSv2 SSF 6 as stated below.
- Do NOT use for kidney renal pelvis.
- If your registry does not collect this SSF, use the description in the table to determine grade.

Description	CS Code	Grade Code
Grade 1	010	1
Grade 2	020	2
Grade 3	030	3
Grade 4	040	4

Soft Tissue: Grade for Sarcomas (excluding lymphomas)

- The grade for sarcomas should be used to code grade based on CSv2 SSF1 as stated below.
- If your registry does not collect this SSF, use the description in the table to determine grade.
- The grading system of the French Federation of Cancer Centers Sarcoma Group (FNCLCC) is the preferred system.
- Record the grade from any three-grade sarcoma grading system the pathologist uses. For terms such as “well differentiated” or “poorly differentiated”, go to Coding for Solid Tumors #8.
- In some cases, especially for needle biopsies, grade may be specified only as “low grade” or “high grade”. The numeric grade takes precedence over “low grade” or “high grade”.

Description	CS Code	Grade Code
Specified as Grade 1 (of 3)	010	2
Specified as Grade 2 (of 3)	020	3
Specified as Grade 3 (of 3)	030	4
Grade stated as low grade, NOS	100	2
Grade stated as high grade, NOS	200	4

Prostate (excluding lymphomas)

- Use the highest Gleason score from the biopsy/TURP or prostatectomy/autopsy.
- Exclude results from tests performed after neoadjuvant therapy began.
- This information is collected in CSv2 SSF 8 and SSF 10 as stated below.
- Usually prostatic cancers are graded using Gleason score or pattern. Prostatic cancer generally shows two main histologic patterns. The primary pattern, pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade. The secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10.
- If there are two numbers, assume that they refer to two patterns and sum them to obtain the score.
- If only one number is given and it is less than or equal to 5 and not specified as a score, do not use the information because it could refer to either a score or a grade.
- If only one number is given and it is greater than 5, assume that it is a score and use it.

- If the pathology report specifies a specific number out of a total of 10, the first number given is the score. Example: Pathology report says Gleason 3/10. The Gleason score would be 3.

Gleason Score	CS Code	Grade Code	AJCC 7 th	SEER 2003-2013	AJCC 6 th	SEER prior 2003
2	002	1	G1	G1	G1	G1
3	003	1	G1	G1	G1	G1
4	004	1	G1	G1	G1	G1
5*	005	1	G1	G2	G2	G2
6*	006	1	G1	G2	G2	G2
7*	007	2	G2	G3	G3	G3
8	008	3	G3	G3	G3	G3
9	009	3	G3	G3	G3	G3
10	010	3	G3	G3	G3	G3

*The relationship in Gleason score to grade changes for 1/1/2014 and forward diagnoses in order to have the grade field in sync with AJCC 7th edition. Analysis of prostate grade before 2014 based solely on grade is not recommended.

**Please refer to *FORDS 2015*-Section One: Case Eligibility and Coding Principles, Cancer Identification, Coding Grade for full instructions on coding grade.

Date of Diagnosis

Record the month, day, and year this cancer was originally diagnosed by a medical practitioner. This date should reflect the first clinical onset of disease and may not be histologically confirmed. This date should not be changed, even if the disease is histologically confirmed later.

Example: Patient has a diagnostic ultrasound on June 6, 2010 that is highly suspicious for malignancy. On June 30, 2010 a biopsy is performed and results show invasive ductal carcinoma. Date of diagnosis is 06/06/2010 (CCYY=2010, MM=06, DD=06)

- Backdating- If a non-diagnostic workup was performed on a patient but at a later date malignancy is confirmed and the physician specifically states that in retrospect the patient had cancer earlier backdate the date of diagnosis to reflect the earlier date. **This also includes pathology that may have been diagnostic but upon further review of the specimen it is now thought to have been malignant. However, the abstractor must carefully review the additional information before making the change.** Refer to the list of “Ambiguous Terms” in Chapter 2 for terminology that constitutes a diagnosis of cancer.
- Record the date as completely as possible. Leave any unknown portions of the date blank. **Example:** The patient was admitted to your facility in June of 2010 for seed implant radiation for prostate cancer diagnosed elsewhere approximately 4 months earlier, exact date unknown. Date of Diagnosis: 02/__/2010 (CCYY= 2010, MM= 02, DD= blank)
- If the cancer was first diagnosed at autopsy, the date of diagnosis is the date of death.

- If only the time of year (spring, middle, fall, or winter) is documented use April, July, October, and either December (if end of year) or January (if beginning of year) respectively.
- Year of diagnosis cannot be blank for analytic cases. If year of diagnosis is not known, it should be approximated for all cases as follows (and noted in a text field as estimated):
 1. If you know there was treatment before the patient arrived at the hospital, try to determine whether that was “this year” or “last year”, based on the current time of year and whether the treatment was likely days, weeks, or months ago.
Example: The patient was admitted for initial chemotherapy on January 2 after recovering from surgery. Enter the preceding year as the diagnosis date.
 2. Code a “couple of years” to two years earlier
 3. Code a “few years: to three years earlier
 4. Code “several” to four years earlier
 5. Use whatever information is available to calculate the year of diagnosis.
 6. If no information about the date of diagnosis is available:
 - a) Analytic Cases:
 - Use the date of admission as the date of diagnosis
 - In the absence of an admission date, code the date of first treatment as the date of diagnosis
 - Please note in a text field that no information was available
 - b) Non-Analytic Cases:
 - When no information is available to approximate a year of diagnosis for non-analytic cases, the field may be left blank.

Date of Diagnosis Flag

This flag explains why no appropriate value is in the field, Date of Diagnosis.

Code	Description
12	A proper value is applicable but not known (e.g. date of diagnosis is unknown)
Blank	A valid date is provided in item Date of Diagnosis

Diagnostic Confirmation

Information for this field records the best method of how the reported cancer was diagnosed at any time in the patient’s history.

The data item represents a hierarchical coding scheme with code 1 taking precedence.

If any time during the patient’s cancer experience, a more definitive diagnostic method is performed and confirms a malignancy; this data item should be changed to reflect that confirmation.

Example: Patient is diagnosed on 2/10/10, by CT scan with probable lung cancer with no further workup. Diagnostic confirmation is coded to radiology (7). Later in March of 2010, the patient

undergoes a bronchoscopy in which biopsies confirm squamous cell carcinoma. The diagnostic confirmation code is changed to reflect the positive histology (1).

Instruction for Coding Solid Tumors:

- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy, or dilation and curettage. Bone marrow biopsy and bone marrow aspiration.
- Assign code 2 when the microscopic diagnosis is based on cytologic examination of *cells* such as fine-needle aspiration (FNA), sputum smears, cervical smears, vaginal smears, bronchial brushings and washings, tracheal washings, Prostatic secretions, breast secretions, gastric fluids, spinal fluid, peritoneal fluid, pleural fluid and urinary sediment – includes paraffin-block specimens from concentrate spinal, pleural, or peritoneal fluid
- Assign code 4 when the case is reported as microscopically confirmed, but no information is available about the method (histology or cytology)
- Assign code 5 when the diagnosis of cancer is based on certain laboratory tests or marker studies clinically diagnostic (abnormal electrophoretic spike for multiple myeloma or Waldenstrom’s macroglobulemia, alpha -fetoprotein for liver cancer) for that specific cancer.
- Assign code 6 when the diagnosis is based on the surgeon’s operative report from a surgical exploration or by endoscopy in the absence of tissue or cytologic findings. Autopsy only case (information from gross autopsy report)
- Assign code 7 when the diagnosis is based on the report by the physician from an imaging technique only, includes ultrasound, computerized (axial) tomography (CT or CAT) and magnetic resonance imaging (MRI) – no positive histology or cytology
- Assign code 8 when the case was diagnosed by any clinical method not mentioned above – no positive histology or cytology. Reported by the physician in the medical record.
- Assign code 9 when there is a statement of malignancy reported in the medical record– method of confirmation is unknown

Microscopic Confirmation for Solid Tumors

Code	Label	Definition
1	Positive histology	Histologic confirmation
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; cells microscopically examined)
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory test/marker studies which are clinically diagnostic for cancer. Elevated PSA is NOT diagnostic of cancer. If the physician used the PSA as the basis of diagnosing prostate cancer with NO other work up, record code 5.

6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from imaging technique only
8	Clinical diagnosis only, other than 5, 6, or 7	The malignancy was reported by the physician in the medical record
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed

Instructions for Coding Hematopoietic or Lymphoid Tumors (9590-9992)

There is no priority hierarchy for coding Diagnostic Confirmation for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the *Hematopoietic Database* for information on the definitive diagnostic confirmation for specific types of tumors.

- Use code 1 when **ONLY** the tissue, bone marrow, or blood was used to diagnose the specific histology. Do not use code 1 if the provisional diagnosis was based on tissue, bone marrow, or blood and the immunophenotyping or genetic testing on that same tissue, bone marrow, or blood identified the specific disease (see code 3).
- For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC) or peripheral blood smear. Do not use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow or blood.
- Use code 2 when the microscopic diagnosis is based on cytologic examination of *cells* (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal pleural or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.
- Assign code 3 when there is a histology positive for cancer **AND** positive immunophenotyping and/or genetic testing results. Do not use code 3 for neoplasms diagnosed prior to January 1, 2010. **Example:** bone marrow exam is positive for acute myeloid leukemia (9861/3) Genetic testing shows AML with **invasion** (16) (p13.1q22) (9871/3).
- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.
- Assign code 8 when the case was diagnosed by any clinical method not mentioned in a preceding code. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a

clinical diagnosis based on the information from the equivocal tests and the patient's clinical presentation.

Codes for Hematopoietic and Lymphoid Neoplasms

Code	Label	Definition
1	Positive histology	Histologic confirmation
2	Positive cytology	Cytologic confirmation (no tissue microscopically examined; cells microscopically examined)
3	Positive histology PLUS positive immunophenotyping AND/OR positive genetic studies	Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results.
4	Positive microscopic confirmation, method not specified	Microscopic confirmation is all that is known. It is unknown if the cells were from histology or cytology
5	Positive laboratory test/marker study	A clinical diagnosis of cancer is based on laboratory test/marker studies which are clinically diagnostic for cancer. Elevated PSA is NOT diagnostic of cancer. If the physician used the PSA as the basis of diagnosing prostate cancer with NO other work up, record code 5.
6	Direct visualization without microscopic confirmation	The tumor was visualized during a surgical or endoscopic procedure only with no tissue resected for microscopic examination.
7	Radiography and other imaging techniques without microscopic confirmation	The malignancy was reported by the physician from imaging technique only
8	Clinical diagnosis only, other than 5, 6, or 7	The malignancy was reported by the physician in the medical record
9	Unknown whether or not microscopically confirmed	A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed

Laterality

Laterality identifies the side of a paired organ or the side of the body on which the reportable tumor originated. This applies to the primary site only. Laterality supplements staging and extent of disease information and defines the number of primaries involved.

Instructions for Coding

- Code laterality for all paired sites
- Do not code metastatic sites as bilateral involvement
- Where the right and left sides of a paired sites are contiguous (come into contact) and the lesion is at the point of contact of the right and left sides, use code 5, midline. Most paired sites cannot develop midline tumors (such as breast) because the right and left

organs do not touch. Skin of the trunk is an example of a site where midline coding is possible.

- Non-paired sites may be coded right or left, if appropriate. Otherwise, code non-paired sites to 0.
- If both lungs have nodules or tumors and lung of origin is not known, assign code 4

Laterality Codes:

Code	Definition
0	Organ is not a paired site
1	Origin of primary is right
2	Origin of primary is left
3	Only one side involved, right or left origin not specified
4	Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumor
5	Paired site: midline tumor
9	Paired site, but no information concerning laterality

Paired Organ Sites Why highlighted sites duplicated?

ICD-O-3	Site	ICD-O-3	Site
C07.9	Parotid	C44.2	Skin of External Ear
C08.0	Submandibular gland	C44.3	Skin- other unspecified parts of the face
C08.1	Sublingual gland	C44.5	Skin of trunk
C09.0	Tonsillar fossa	C44.6	Skin of upper limb & shoulder
C09.1	Tonsillar pillar	C44.7	Skin of lower limb & hip
C09.8	Overlapping lesion of tonsil	C47.1	Peripheral nerves & autonomic nervous system, upper limb & shoulder
C09.9	Tonsil, NOS	C47.2	Peripheral nerves & autonomic nervous system of lower limb & hip
C30.0	Nasal cavity – excludes nasal cartilage & nasal septum	C49.1	Connective, subcutaneous, & other soft tissues-upper limb & shoulder
C30.1	Middle ear	C49.2	Connective, subcutaneous, & other soft tissues, lower limb & hip

C31.0	Maxillary sinus	C50.0 – C50.9	Breast
C31.2	Frontal sinus	C56.9	Ovary
C34.0	Main bronchus – excluding carina	C57.0	Fallopian tube
C34.1- C34.9	Lung	C62.0 –C62.9	Testis, undescended, descended, nos
C38.4	Pleura, Nos	C63.0	Epididymis
C40.0	Long bone-upper limb & scapula	C63.1	Spermatic cord
C40.1	Short bone, upper limb	C64.9	Kidney, nos
C40.2	Long bone, lower limb	C65.9	Renal pelvis
C40.3	Short bone, lower limb	C66.9	Ureter
C41.3	Rib & clavicle-excludes sternum	C69.0-C69.9	Eye & lacrimal gland
C41.4	Pelvic bones-excludes sacrum, coccyx, & symphysis pubis	C74.0-C74.9	Adrenal gland
C44.1	Skin of eyelid	C75.4	Carotid body
C44.2	Skin of external ear	C70.0	Cerebral meninges, NOS
C44.3	Skin of other & unspecified parts of face	C71.0	Cerebrum
C44.5	Skin of trunk	C71.1	Frontal lobe
C44.6	Skin of upper limb & shoulder	C71.2	Temporal lobe
C44.7	Skin of lower limb & hip	C71.3	Parietal lobe
C72.2	Olfactory nerve	C71.4	Occipital lobe
C72.3	Optic nerve	C72.4	Acoustic nerve
C72.5	Cranial nerve		

Codes C70.0 – C72.5 exclude cases diagnosed prior to 2004, should only be coded as paired organ site for cases diagnosed 1/1/04 and after

Chapter 7

STAGING SCHEMES

SEER Summary Stage

SEER Summary Stage was previously required for cases diagnosed in 2001-2003. SEER Summary Stage 2000 is required again for cases diagnosed in 2015 and forward. For all other years, vendors have been instructed to transmit this field as blank. For instructions see the SEER Summary Staging Manual 2000 at <http://seer.cancer.gov/tools/ssm/>. Pages 1-15 provide important introductory material and are followed by site-specific chapters.

AJCC Stage

AJCC staging **is required** for all facilities in 2015. Fields include clinical and pathologic T, N and M elements as well as Group, Descriptor and TNM Edition Number. Please refer to FORDS 2015

<https://www.facs.org/~media/files/quality%20programs/cancer/coc/fords/fords%202015.ashx> and the AJCC Cancer Staging Manual, 7th Edition. AJCC training materials can be accessed at <https://cancerstaging.org/CSE/Registrar/Pages/default.aspx>.

Please refer to the appropriate staging manual for cases diagnosed prior to January 1, 2004

NOTE: *AJCC Manual for Staging Cancer*, Third Edition used with cases diagnosed 1989-1992
AJCC Manual for Staging Cancer, Fourth Edition used with cases diagnosed 1993-1997
AJCC Manual for Staging Cancer, Fifth Edition used with cases diagnosed 1998-2002
AJCC Manual for Staging Cancer, Sixth Edition used with cases diagnosed 2003-2009
AJCC Manual for Staging Cancer, Seventh Edition used with cases diagnosed 2010 forward

Collaborative Staging

Collaborative Staging will be used for cases diagnosed on or after January 1, 2004.

Collaborative Staging Version 2 (CSv2) will be used for cases diagnosed on or after January 1, 2010

The Collaborative Staging System schemas consist of the data fields necessary to derive T, N, M, and Stage Group according to the sixth and seventh editions of the AJCC Staging Manual; Summary Stage 1977, and SEER Summary Stage 2000.

- Collaborative Staging is collected on all cases diagnosed on or after January 1, 2004 regardless of whether they are microscopically confirmed.
- Collaborative Staging is collected on all sites/histologies.
- All schemas apply to all histologies unless otherwise noted.

REFER TO THE APPROPRIATE MANUAL WHEN STAGING. NEVER RELY ON YOUR MEMORY.

Regional Nodes Positive

Record the exact number of regional lymph nodes examined by the pathologist and found to contain metastasis. Note: distant lymph nodes are coded in the “CS Mets at DX” field

Code	Description
00	All nodes examined are negative
01-89	1-89 nodes are positive (Code exact number of positive nodes)
90	90 or more nodes are positive
95	Positive aspiration or core biopsy of lymph node(s) was performed
97	Positive nodes are documented, but the number is unspecified
98	No nodes were examined
99	It is unknown whether nodes are positive; not applicable; not stated in patient record

Regional Nodes Examined

Record the total number of regional lymph nodes that were removed and examined by the pathologist. Refer to *CSv2 Coding Instructions Part I, Section 1: General Instructions* for complete directions.

Code	Description
00	No nodes were examined
01-89	1-89 nodes were examined
90	90 or more nodes were examined
95	No regional nodes were removed, but aspiration or core biopsy of regional nodes was performed
96	Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated
97	Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated
98	Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown
99	It is unknown whether nodes were examined; not applicable or negative; not stated in patient record

Surgical Diagnostic and Staging Procedure (RX Summ-DX/Stg Proc)

Identifies the positive surgical procedure(s) performed in an effort to diagnose and/or stage disease. This data item is used to track the use of surgical procedure resources that are not considered treatment.

Instructions for Coding:

- Record the type of procedure performed as part of the initial diagnosis and workup, whether this is done at your institution or another facility
- Only record positive procedures. For benign and borderline reportable tumors, report biopsies positive for those conditions. For malignant tumors, report procedures if they were positive for malignancy.
- If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy or primary site)
- If a lymph node is biopsied or removed to diagnose or stage **lymphoma** and that node is NOT the only node involved with lymphoma, use code 2. If there is only a single lymph node involved with lymphoma use the data item *Surgical Procedure of Primary Site* to code these procedures.
- Do **not** code surgical procedures which aspirate, biopsy, or remove *regional lymph nodes* in an effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery* to code these procedures.
- Code brushings, washing and cell aspiration, as positive cytologic diagnostic confirmation in the data item *Diagnostic Confirmation*. These are not considered surgical procedures and should **not** be coded in this data item.
- Do **not** code excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical Procedure of Primary Site* to code these procedures.
- **If a needle biopsy preceded an excisional biopsy or more extensive surgery, even if no tumor remained at the time of surgery, both the needle biopsy (*Surgical Diagnostic and Staging Procedure*) and the *Surgical Procedure of the Primary Site* are to be reported. Surgical margins must be examined to determine whether a biopsy intended as incisional is excisional instead, and margins cannot be evaluated for a needle biopsy.**
- Do not code palliative surgical procedures in this data item. Use the data item *Palliative Procedure* to code these procedures.

Date of Surgical, Diagnostic and Staging Procedure (RX Date-DX/Stg/Proc)

This data item records the date on which the surgical diagnostic and/or staging procedure was performed and is used to track the use of surgical procedure resources that are not considered treatment.

Coding Instructions:

- Record the date on which the surgical diagnostic and/or staging procedure described in *Surgical Diagnostic and Staging Procedure* was performed at this or any facility
- Record the date as completely as possible. Leave any unknown portions of the date blank.
- If information for this item is entirely unknown or not applicable, leave the field blank and complete the *RX Date-DX/Stg/Proc Flag* field

Rx Date-DX/Stg/Proc Flag

This flag explains why there is not appropriate value in the corresponding date field, *Date of Surgical Diagnostic and Staging Procedure*.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any diagnostic or staging procedure performed)
11	No proper value is applicable in this context (for example, no diagnostic or staging procedure performed; autopsy only)
12	A proper value is applicable but not known
Blank	A valid date is provided

Chapter 8

TUMOR-DIRECTED TREATMENT

Record all cancer-directed therapy information available whether administered at the reporting hospital or at another facility. If the patient receives part of the first course of therapy at the reporting hospital and is transferred to another facility to continue treatment, also record the treatment given at the other hospital, if it is known. Documenting all treatments in the given RX Summ fields provides a complete “picture” of the patient’s cancer experience and is meaningful in calculating survival statistics and assessing treatment success. Subsequent courses of treatment should only be mentioned in text fields.

Date of First Course Treatment (Date of 1st Crs RX-CoC)

Record the earliest date on which treatment (surgery, radiation, systemic or other therapy) for the reported cancer began, including active surveillance only, whether administered at the reporting hospital or at another facility.

Instructions for Coding:

- Record the date as completely as possible. Leave any unknown portions of the date blank. **Example:** Patient came to your facility for chemotherapy in March of 2010 after having had surgery in February of 2010, exact day unknown. 02/__/2010 (CCYY=2010, MM=02, DD=blank)
- If active surveillance or watchful waiting is selected as the first course of treatment, record the date this decision is made.
- In case of non-treatment in which a physician decides not to treat a patient or a patient’s family or guardian declines all treatment, record the date this decision was made as first course of treatment
- Leave this item blank if the cancer was diagnosed at autopsy and not suspected prior to that
- If the patient expired before planned treatment could begin, enter the date of death

Date of First Course Treatment Flag

This flag explains why there is no appropriate value in the corresponding date field, Date of First Course of Treatment. Refer to *FORDS Section two, Coding Instructions* for instructions to code this item.

Rx Summ – Treatment Status

This data item summarizes whether the patient received any treatment, including watchful waiting. This item was added to document active surveillance and eliminate searching each treatment modality in order to determine whether any treatment was given. It is used in

conjunction with *Date of First Course of Treatment* to document whether treatment was or was not given, whether it is unknown if treatment was given, or whether treatment was given on an unknown date.

Instructions for Coding:

- This item may be left blank for cases diagnosed prior to 2010
- Treatment given after a period of active surveillance is considered subsequent treatment and if not coded in this item
- Use code 0 when treatment is refused or the physician decides not to treat for any reason, including co-morbidities

Code	Description
0	No treatment given
1	Treatment given
2	Active surveillance (watchful waiting)
9	Unknown if treatment was given

Date of First Surgical Procedure: Formerly called *Date of Cancer-directed Surgery*.

This data item records the earliest date on which any first course surgical procedure was performed and can be used to sequence multiple treatment modalities and to evaluate the time intervals between treatments.

Instructions for Coding:

- Record the date of the first surgical procedure of the types coded as *Surgical Procedure of Primary Site, Scope of Regional Lymph Node Surgery or Surgical Procedure/Other Site* performed for this cancer.
- **A needle biopsy is not considered to be an excision and therefore not a primary breast surgery. The date it was performed is not entered as the Date of First Surgical Procedure. It is now only entered in Date of Surgical, Diagnostic and Staging Procedure.**
- If a biopsy of the primary site (excluding needle biopsy) is the initial surgical procedure and leaves only microscopic residual tumor, code the date of the biopsy in this field.
Example: An excisional biopsy of a right forearm lesion done on 4/15/10 showed a Clark level II melanoma extending to the deep margin. Re-excision on 4/22/10 did not show any residual tumor. Code the *Date of First Surgical Procedure* as 4/15/10.

RX Date – Surgery Flag

This flag explains why there is no appropriate value in the corresponding date field, *Date of First Surgical procedure*. Registries should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Refer to *FORDS Manual, Section Two: Coding Instructions* for further instructions

Date of Most Definitive Surgery

This field records the date of the most definitive surgical procedure of the primary site performed as part of the first course of treatment. Record the date on which the surgery described by *Surgical Procedure of Primary Site* was performed at this or any facility.

RX Date – Most Definitive Surgery Flag

This flag explains why there is no appropriate value in the corresponding date field, *Date of Most Definitive Surgical Resection of the Primary Site*.

Code	Description
10	No information whatsoever can be inferred from this exceptional value (that is, unknown if any surgery performed)
11	No proper value is applicable in this context (example: no surgery performed)
12	A proper value is applicable but not known.
Blank	A valid date is provided in item

Surgical Procedure of Primary Site

This data item records the surgical procedure(s) performed to the primary site.

Instructions for Coding:

- Site-specific codes for this data item are found in *Appendix B* of FORDS manual.
- If registry software allows only one procedure to be collected, document the most invasive surgical procedure for the primary site.
- If registry software allows for multiple procedures to be recorded, this item refers to the most invasive surgical procedure of the primary site.
- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- [If a needle biopsy preceded an excisional biopsy or more extensive surgery even if no tumor remained at the time of surgery both the needle biopsy \(*Surgical Diagnostic and Staging Procedure*\) and the *Surgical Procedure of the Primary Site* are to be reported. Surgical margins must be examined to determine whether a biopsy intended as incisional is excisional instead, and margins cannot be evaluated for a needle biopsy.](#)
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix B.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results. Do not rely on registry software to perform this task for you.

- If the procedure coded in this item was provided to prolong a patient’s life by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item Palliative Care

Surgical Procedure of Primary Site – General Codes

Code	Label	Definition
00	None	No surgical procedure or primary site, Diagnosed at autopsy.
10-19	Site-specific codes; tumor destruction	Tumor destruction, no pathologic specimen produced. Refer to <i>Appendix B</i> for the correct site-specific code for the procedure
20-80	Site-specific codes; resection	Refer to <i>Appendix B</i> for the correct site-specific code for the procedure
90	Surgery, NOS	A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided
98	Site-specific codes; special	Special code. Refer to <i>Appendix B</i> for the correct site-specific code for the procedure
99	Unknown	Patient record does not state whether a surgical procedure of the primary site was performed and no information is available. Death certificate only.

Reason for No Surgery of Primary Site

This field records the reason that no surgery was performed on the primary site. This data item provides information related to the quality of care and describes why primary site surgery was not performed.

Instructions for Coding:

- If *Surgical Procedure of Primary Site* is coded 00, then record the reason based on documentation in the patient record
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient
- Code 1 if *Surgical Procedure of Primary Site* is coded 98
- Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended
- Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed
- Cases coded 8 can be followed and updated to a more definitive code as appropriate
- Code 9 if the treatment plan offered multiple choices, but is unknown which treatment, if any was provided

Surgical Margins of the Primary Site

This data item records the final status of the surgical margins after resection of the primary tumor.

Instructions for Coding:

- Code the margin status as it appears in the pathology report after the resection of the primary tumor.
- Microscopic involvement is not visible to the eye and is usually documented in the final diagnosis or microscopic portion of the pathology report.
- Macroscopic is visible to the eye and is documented in the operative report or the gross portion of the pathology report.
- Codes 0-3 are hierarchical; if two codes describe the margin status, use the numerically higher code.
- If no surgery of the primary site was performed, code 8
- If the pathology report makes no mention of margins, code 9
- For lymphomas (M-9590-9726, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0-C77.9), code 9.

Example: Patient has Excisional biopsy with involved margins. Later has a modified radical mastectomy with clear margins. Code the margin status after the mastectomy, 0-All margins grossly and microscopically negative.

Surgical Margin Definitions

Code	Label	Definition
0	No residual tumor	All margins grossly & microscopically negative
1	Residual tumor, NOS	Involvement indicated but not otherwise specified
2	Microscopic residual	Residual tumor identified microscopically, is not visible to the naked eye
3	Macroscopic residual tumor	Gross tumor of the primary site which is visible to the naked eye
7	Margins not evaluable	Cannot be assessed (indeterminate)
8	No primary site surgery	No surgical procedure of the primary site. Diagnosed at autopsy
9	Unknown or not applicable	Unknown whether a surgical procedure to the primary site was performed; death certificate only; for lymphomas with a lymph node primary site; unknown or ill-defined primary; or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.

Scope of Regional Lymph Node Surgery

This field identifies the removal, biopsy or aspiration of regional lymph node(s) at the time of the surgery of primary site or during a separate surgical event.

There is no minimum number of lymph nodes removed in order to record this field. If only one lymph node was removed, code using the range of 1-5.

Instructions for Coding:

- The scope of regional lymph node surgery is collected for each surgical event even if the surgery of the primary site was not performed.
- Codes 0-7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.
- Code 9 for primaries of the meninges, brain, spinal cord, cranial nerves, and other parts of the central nervous system (C70.0-C70.9, C71.0-C71.9, C72.0-C72.9); for lymphomas (M-9590-9596, 9650-9719, 9727-9729) for a lymph node site (C77.0-C77.9); for unknown and ill-defined primaries (C76.0-C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)
- Do not record distant lymph node removal in this field. Code in Surgical Procedure/Other Site.
- Refer to current AJCC Cancer Staging Manual for site-specific identification of regional lymph nodes.
- If the procedure coded in this item was provided to prolong patient's life for by controlling symptoms, to alleviate pain, or to make the patient more comfortable, then also record this surgery in the item Palliative Care

Regional Lymph Node Coding Definitions

Code	Label	Definition
0	None	No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy
1	Biopsy or aspiration of regional lymph node, NOS	Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
2	Sentinel lymph node biopsy	Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary
3	Number of regional nodes removed, unknown or not stated; regional lymph nodes removed, NOS	Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not stated. The procedure is not specified as sentinel node biopsy.

4	1-3 regional lymph nodes removed	Sampling or dissection of regional lymph node(s) fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy
5	4 or more regional lymph nodes removed	Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen as sentinel node biopsy.
6	Sentinel node biopsy and code 3,4, or 5 at same time, or timing not stated	Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 was performed, but timing was not stated in patient record.
7	Sentinel node biopsy and code 3, 4, or 5 at different times	Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.
9	Unknown or not applicable	It is unknown whether regional lymph node surgery was performed; death certificate only; for lymphomas with a lymph node primary site; unknown or ill-defined primary; or for hematopoietic reticuloendothelial, immunoproliferative, or myeloproliferative disease.

See general instructions applying to all sites and additional notes specific to breast, *FORDS Section Two, Coding Instructions*

Surgical Procedure/Other Site

Record the surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site.

- If other tissues or organs are removed during primary site surgery that are not specifically defined by the site-specific Surgical Procedure of the Primary Site code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.
- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”
- Surgical Procedure/Other Site is collected for each surgical even if surgery of the primary site was not performed **Please review wording??**

Surgical Procedure/Other Site Definitions

Code	Label	Definition
0	None	No surgical procedure or non-primary site was performed. Diagnosed at autopsy.
1	Non-Primary site surgical procedure was performed	Non-primary surgical resection of other site(s), unknown if regional or distant
2	Non-primary surgical procedure to other regional sites	Resection of regional site
3	Non-primary surgical procedure to <i>distant lymph nodes</i>	Resection of distant lymph node(s)

4	Non-primary surgical procedure to distant site	Resection of distant site
5	Combination of codes	Any combination of surgical procedures 2, 3 or 4
9	Unknown	Unknown whether any surgical procedure of non-primary site is performed. Death certificate only.

Date Radiation Started

This field records the date on which radiation therapy began at any facility that is part of the first course of treatment. It is important to be able to sequence the use of multiple treatment modalities and to evaluate the time intervals between the treatments. For some disease, the sequence of radiation and surgical therapy is important when determining the analytic utility of pathologic stage information.

Instructions for Coding:

- If radiation therapy is the first or only treatment administered to the patient, then the date radiation started should be the same as the date entered into the item Date of First Course Treatment.
- The date when treatment started will typically be found in the radiation oncologist's summary letter for the first course of treatment
- Record the date as completely as possible. Leave any unknown portions of the date blank.

RX date – Radiation Flag

This flag explains why there is no appropriate value in the corresponding date field, *Date Radiation Started*. Registrars should enter this data item directly (when appropriate) even if the traditional form of date entry is used in the software.

Regional Treatment Modality

Records the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the area of interest during the first course of therapy. Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Instructions for Coding:

- Radiation treatment modality will typically be found in the radiation oncologist's summary letters for the first course of treatment.
- In the event multiple radiation therapy modalities were employed in the treatment of the patient, record only the dominant modality.
- Note that in some circumstances the boost treatment may precede the regional treatment

- For purposes of this data item, photons and x-rays are equivalent
- Code IMRT or conformal 3D whenever either is explicitly mentioned
- Code radioembolization as brachytherapy

Note: Do not confuse a diagnostic **radioiodine scan** with treatment. Only treatment is recorded in this item.

Regional Dose

Records the dominant or most clinically significant total dose of regional radiation therapy delivered to the patient during the first course of treatment. The unit of measure is CentiGray (cGy).

Boost Treatment Modality

Records the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment.

Date Radiation Ended

Records the date on which the patient completes or receives the last radiation treatment at any facility. **Radiation Date Ended Flag**, This flag explains why there is no appropriate value in the corresponding date field, Date Radiation Ended.

Radiation/Surgery Sequence

This data item records the sequencing of radiation and surgical procedures given as part of the first course of treatment

Instructions for Coding:

- Surgical procedures include *Surgical Procedure of Primary Site*, *Scope of Regional Lymph Node Surgery*, *Surgical Procedure/Other Site*. If all of these procedures are coded 0, or it is not known whether the patient received both surgery and radiation, then this item should be coded 0.
- If the patient received both radiation therapy and any one or a combination of the following surgical procedures: *Surgical Procedure of Primary Site*, *Regional Lymph Node Surgery*, or *Surgical Procedure of Other Site*, then code this item 2-9, as appropriate.
- If multiple first course treatment episodes were given such that both codes 4 and 7 seem to apply, use the code that defines the first sequence that applies.

Code	Label	Definition
0	No radiation therapy and/or surgical procedures	No radiation therapy given and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional sites, distant site or distant lymph node(s); or no reconstructive surgery. Diagnosed at autopsy.

2	Radiation therapy before surgery	Radiation given before surgery to primary site...
3	Radiation therapy after surgery	Radiation therapy given after surgery to primary site...
4	Radiation therapy both before and after surgery	At least two courses of radiation therapy are given, at least one before and after any surgery to primary site...
5	Intraoperative radiation therapy	Intraoperative therapy given during surgery to primary site...
6	Intraoperative radiation therapy with other therapy administered before or after surgery	Intraoperative radiation therapy given during surgery to primary site...
7	Surgery both before and after radiation	Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s) or distant lymph node(s).
9	Sequence unknown	Administration of radiation therapy and surgery to primary site...and the sequence of the treatment is not stated in the patient record.

Refer to *FORDS Section Two, Coding Instructions* for complete instructions/*First course of treatment*.

Date Chemotherapy Started

Record the date initiation of chemotherapy that is part of the first course of treatment. **RX Date-Chemo Flag**, This flag explains why there is no appropriate value in the corresponding date field, Date Chemotherapy Started.

Chemotherapy

Code	Definition
00	If chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.
00	If the treatment plan offered multiple options and the patient selected treatment that did not include chemotherapy.
01	Chemotherapy administered as first course therapy, but the type and number of agents is not documented in patient record
02	Single-agent chemotherapy administered as first course therapy
03	Multi-agent chemotherapy administered as first course therapy
82	Chemotherapy was not recommended/administered because it was contra-indicated due to patient risk factor
85	Chemotherapy was not administered because patient died prior to planned or recommended therapy
86	Chemo was not administered. It was recommended by patient's physician but was not administered as part of first course therapy. No reason stated in patient record

87	Chemo not administered. Recommended by physician. Patient refused
88	Chemo was recommended, unknown if administered
99	Unknown if chemo recommended or administered, because it is not in patient record. Death certificate only

Refer to the *SEER Rx Interactive Drug Database* (<http://www.seer.cancer.gov/>) for a list of chemotherapeutic agents.

Refer to *FORDS Section Two, Coding Instructions* for complete instructions/*First Course of Treatment*

Hormone Therapy (Hormone/Steroid)

This data item records the type of hormone therapy administered as first course treatment at this and all other facilities. This therapy is defined as any agent (drug) and/or procedure that affect cancer tissue by changing the hormonal balance of the patient. Included are hormones, anti-hormones and steroids. It is not usually used as a curative measure.

Instructions for Coding:

- Record prednisone as hormonal therapy when administered in combination with chemotherapy such as MOPP or COPP
- Do not code prednisone as hormonal therapy when it is administered for reasons other than chemotherapeutic treatment
- Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. Do not code hormone replacement therapy as part of first course therapy.

Code	Definition
00	None, hormone therapy was not part of the planned first course therapy. Diagnosed at autopsy.
01	Hormone therapy administered as first course therapy
82	Hormone therapy not recommended/administered, contraindicated due to patient risk factors
85	Hormone therapy not administered, patient died prior to planned
86	Hormone therapy not administered, recommended by patient's physician, not administered as part of first course. No reason in patient record
87	Hormone therapy not administered, recommended, patient refused
88	Hormone therapy recommended, unknown if administered
99	Unknown if hormonal agent recommended or administered. Death certificate only

Refer to the *SEER Rx Interactive Drug Database* (<http://www.seer.cancer.gov/>) for a list of hormonal agents.

Date Hormone Therapy Started

This field records the date the hormonal therapy that is part of the first course of treatment. **RX Date-Hormone Flag**, this flag explains why there is no appropriate value in the corresponding date field, Date Hormone Therapy Started.

Refer to *FORDS Section Two, Coding Instructions* for complete instructions

Immunotherapy (BRM)

Records the type of immunotherapy administered as first course treatment in this or any other facilities. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to the tumor cells.

Code	Definition
00	None, immunotherapy was not part of first course therapy. Diagnosed at autopsy
01	Immunotherapy administered at first course therapy
82	Immunotherapy not recommend/administered because contraindicated due to patient risk factors
85	Immunotherapy not administered, patient died prior
86	Immunotherapy not administered, recommended by patient's physician but not administered as part of first course, no reason in patient record
87	Immunotherapy not administered, recommended, patient refused
88	Immunotherapy recommended, unknown if administered
99	Unknown whether an immunotherapeutic agent(s) was recommended or administered, not in patient record. Death certificate only

Refer to the *SEER Rx Interactive Drug Database* (<http://www.seer.cancer.gov/>) for a list of hormonal agents.

Date Immunotherapy Started

Record the date of initiation of immunotherapy or a biologic response modifier (BRM) that is part of the first course of treatment. **RX Date-BRM Flag**, this flag explains why there is no appropriate value in the corresponding date field, Date Immunotherapy Started.

Refer to *FORDS Section Two, Coding Instructions* for complete instructions

Hematologic Transplant and Endocrine Procedures

Identifies systemic therapeutic *procedures* administered as part of the first course of treatment at this and all other facilities. This field allows for the coding of treatment that involve the alteration of the immune system or change the patient's response to tumor cells but does not involve the administration of antineoplastic agents. Procedures coded in this field include bone marrow transplants, stem cell harvests, and endocrine surgery and/or radiation.

Instructions for Coding:

- Bone marrow transplants should be coded as autologous (bone marrow from patient) or allogeneic (bone marrow donated from family member). Syngeneic transplants (marrow from identical twin) are coded as allogeneic.
- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.
- Endocrine irradiation and/or endocrine surgery as procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long term control of the cancer's growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.

Code	Definition
00	No transplant procedure or endocrine therapy was administered as part of first course therapy
10	A bone marrow transplant procedure was administered, but the type was not specified
11	Bone marrow transplant-autologous (stem cell transplant or boost)
12	Bone marrow transplant-allogeneic
20	Stem cell harvest and infusion. Umbilical cord stem cell transplant
30	Endocrine surgery and/or endocrine radiation therapy
40	Combination of codes 30 and 10, 11, 12 or 20
82	Hematologic transplant and/or endocrine surgery/radiation was not recommended, contraindicated due to patient risk factors
85	Hematologic transplant and/or endocrine surgery/radiation not administered patient died prior to recommended therapy
86	Hematologic transplant and/or endocrine surgery/radiation not administered, recommend by physician, not administered as part of first course therapy
87	Hematologic transplant and/or endocrine surgery/radiation was not administered, recommended, treatment refused by patient
88	Hematologic transplant and/or endocrine surgery/radiation was recommended, but unknown if administered
99	Unknown whether hematologic transplant and/or endocrine surgery/radiation was recommend, not in patient record. Death certificate only

Refer to *FORDS Section Two, Coding Instructions* for complete instructions

Other Treatment

This field identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual. Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Instructions for Coding:

- The principal treatment for certain reportable hematopoietic disease could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain **hematopoietic disease ONLY**. Consult the most recent version of the *Hematopoietic Manual and Database* for instructions to code other treatments for a specific disease.
- Code 1 for embolization using alcohol as an embolizing agent and for embolization to a site other than the liver where the embolizing agent is unknown. Do not code presurgical embolization that is given only to shrink the tumor.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation)
- Code 8 if it is known that a physician recommended treatment as Other Treatment, and no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a specialist for Other Treatment the registry can follow. If follow up with the specialist or facility determines the patient was never there, code 0.

Code	Label	Definition
0	None	All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment.
1	Other	Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy)
2	Other-Experimental	This code is not defined. It may be used to record participation in institution-based clinical trials.
3	Other-Double Blind	A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.
6	Other-Unproven	Cancer treatment administered by nonmedical personnel
7	Refusal	Other treatment was not administered. It was recommended by the patient’s physician, but this treatment was refused by the patient, patient’s family member, or patient’s guardian.
8	Recommended; Unknown if administered	Other treatment was recommended but it is unknown if it was administered.
9	Unknown	It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration.

Date Other Treatment Started

Records the start date for other treatments which cannot be coded as surgery, radiation, or systemic therapy according to the defined data items in this manual.

Instructions for Coding:

- Record the date on which the care coded as *Other Treatment* was initiated.
- If other treatment is the first or only treatment administered to the patient, then the *Date Other Treatment Started* should be the same as the *Date of First Course of Treatment*.
- Record the date as completely as possible. Leave any unknown positions of the date blank.
- **RX Date – Other Flag** explains why there is no appropriate value in the corresponding date field, *Date Other Treatment Started*.

Palliative Procedure

Identifies any care provided in an effort to palliate or alleviate symptoms. Palliative care is performed to relieve symptoms and may include surgery, radiation therapy, systemic therapy and/or other pain management therapy. This data item allows reporting facilities to track care that is considered palliative rather than diagnostic or curative in intent.

Instructions for Coding:

- Record the type of palliative care provided
- Surgical procedures, radiation therapy, or systemic therapy provided to prolong the patient's life by controlling symptoms, to alleviate pain, or to make the patient comfortable should be coded palliative care and as first course therapy if that procedure removes or modifies either primary or metastatic malignant tissue
- Palliative care is not used to diagnose or stage the primary tumor
- Do not code routine pain management following surgery or other treatment, do not code first course pain management for persistent pain

Code	Definition
0	No palliative care provided. Diagnosed at autopsy.
1	Surgery to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made
2	Radiation therapy to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor is made
3	Chemotherapy, hormone therapy or other systemic drugs to alleviate symptoms, but no attempt to diagnose, stage, or treat the primary tumor
4	Patient received or was referred to pain management therapy
5	Any combination of codes 1, 2, and/or 3 without code 4
6	Any combination of codes 1, 2, and/or 3 with code 4
7	Palliative care was performed or referred, but no information on type available
9	Unknown if palliative care was performed

Recurrence

Recurrence indicates the return of the cancer after a period of remission or after the patient has experienced a period of documented disease-free intermission. Underline highlighted Use this field for **first recurrence only**.

Instructions for Coding:

- Codes 00-70 are hierarchical. Record the highest-numbered applicable response.
- Use codes “06, 16, 17, 26, 27, 36, or 46” for tumors that are originally diagnosed as in situ. Do not use these codes for any other tumors.
- Codes 00, 88, or 99 may apply to any tumor.
- Codes 51-59 apply only if all first occurrences were in a single category. There may be multiple metastases within the distant location.
- Code **00** for lymphoma or leukemias that are in remission. If the patient relapses, then code recurrence status as **59**.
- If the patient has more than one primary and the physician does not state which cancer has recurred, code the recurrent disease to each tumor and at later date if the recurrent primary is identified, revise the codes appropriately.

Date of First Recurrence

Record the date the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period. Recurrence date flag explains why there is no appropriate value in the corresponding date field, *Date of First Recurrence*.

Refer to *FORDS Section Two, Coding Instructions* for complete instructions

Chapter 9

OUTCOME INFORMATION

Date of Last Contact or Death

This field records the date of last contact with the patient or the date of death. This information is used for patient follow-up and outcome studies.

Instructions for Coding:

- Record the date which the patient was known to be alive or date of death
- If a patient has multiple primaries, all records should have the same date of last contact
- As of January 1, 2006, CoC does not require class 00 cases to be followed
- Record the date as completely as possible. Leave any unknown portions of the date blank.

Date of Last Contact Flag

This data item explains why there no appropriate value in the corresponding date field, *Date of Last Contact or Death*.

Instructions for Coding:

- Leave this item blank if *Date of Last Contact or Death* has a full or partial date recorded
- Code 12 if the *Date of Last Contact or Death* cannot be determined

Vital Status

Record the patient's vital status at the date of the last contact. If a patient has multiple primaries, all records should have the same vital status code.

0-Dead
1-Alive

Cancer Status

Records the presence or absence of clinical evidence of the reported primary at the date the patient was last known to be alive, or at the date of death.

Instructions for Coding:

- Cancer status is based on information from the patient's physician or other official source such as death certificate
- The patient's cancer status should only be changed if new information is received from the patient's physician or other official source. If information is obtained from the patient's family member, or other non-physician, then cancer status is not updated.
- Cancer status changes if the patient has a recurrence or relapse.

- If a patient has multiple primaries, each primary could have a different cancer status.

Code	Label
1	No evidence of this cancer
2	Evidence of this cancer
9	Unknown, indeterminate whether this cancer is present; not stated in patient record

Underlying Cause of Death

This information may be found on the death certificate or in the medical record. If the Date of Last Contact or Death is on or after 1/1/2000, the cause of death must be coded in the abstract using ICD-10-CM. If the death certificate/death information is not available or the field is not applicable use the following codes:

0000 – Patient alive at last contact

7777 – State death certificate or listing not available

7797 – State death certificate or listing available, underlying cause of death not coded

Note: Death certificate from the Arkansas Bureau of Vital Statistics are coded using ICD-10-CM.

ICD Revision Number

Enter the ICD-Edition that applies for the date of death

0 – Patient alive at last contact

1 – ICD-10 (date of death on or after 1/1/2000)

9 – ICD-9 (date of death before 1/1/2000)

Chapter 10

TEXT FIELDS

ACCR frequently receives abstracts from multiple facilities that must be consolidated into one case. Thus, abstracts must contain coordinating text in order for ACCR to assure that what is entered into the ACCR database is the most accurate information for each case reported. The operative concept here is “corroborating”. That is, text must provide the rationale for selecting the codes assigned to primary site, histology, extent of disease, and treatment fields. Brief, meaningful comments are all it takes to tell us what we need to know.

Text is also evaluated in some data quality audits to ensure coding accuracy and completeness. Missing or inadequate text to support the coded fields results in unnecessary errors affecting final statistical results of an audit.

One way to improve your text is to fill in the text fields first as you abstract, then code fields from that information. While it may feel awkward at first, it will show you how important accurate text is to ACCR. These required text fields are considered in our QA and auditing process, so good text entries may save you questions later.

Tips:

- Enter relevant information only
- Include only information that the registry is authorized to collect (think HIPAA)
- If information is unavailable, state so in the text

Please refer to Minimum Text Requirements, General and by Site on ACCR website for specifics.

Appendix A

ACCR STAFF RESOURCES

Theressia Mitchell, CTR, RHIT
Program Director
Arkansas Central Cancer Registry
800-462-0599 or (501) 661-2463
Theressia.mitchell@arkansas.gov

John Guire, CTR
Quality Assurance Coordinator/Education Trainer
800-462-0599 or 501-661-2089
John.guire@arkansas.gov

QA Specialists:

Sue Ann Caudell, CTR
Cancer Information Management Specialist
800-462-0599 or (501) 280-4129
Sue.caudell@arkansas.gov

Cheryl Washington
Cancer Information Management Specialist
800-462-0599 or (501) 661-2069
cheryl.washington@arkansas.gov

Karyn Cramer, CTR
Cancer Information Management Specialist
870-736-3892
karyn.cramer@arkansas.gov

Sharon Deramus, LPN, CTR
Cancer Information Management Specialist - WebPlus Facilities Abstract Support
479-981-3118
Sharon.deramus@arkansas.gov

Tammy Henderson
Cancer Information Management Specialist
800-462-0599 or 501-661-2841
Tamara.henderson@arkansas.gov

LaShonda Wert, RHIT, CTR
State Regional Contact
501-661-2141
Lashonda.wert@arkansas.gov

Technical Support Personnel

Alicia Jones

Administrative Analyst

800-462-0599 or (501) 661-2960

Alicia.m.jones@arkansas.gov

Arkansas Central Cancer Registry

Mailing Address:

4815 West Markham Street, Slot 7

Little Rock, AR 72205

Website:

<http://www.healthy.arkansas.gov/programsServices/healthStatistics/CancerRegistry/Pages/default.aspx>

Appendix B

STATE LAW

Subchapter 2 – Cancer

20-15-201. Reporting requirements.

The Arkansas Department of Health shall accumulate such data concerning cancer in Arkansas and its residents as is deemed appropriate for the purpose of describing the frequency of cancer, furnishing reports to health professionals and the public, and for planning and evaluating cancer prevention and control programs. Such data shall be collected under the authority of regulations promulgated by the Arkansas State Board of Health.

20-15-202. State Cancer Plan.

A task force consisting of public and private entities will be established by the Director of the Department of Health to assist the department to develop a strategic plan for a coordinated, comprehensive, statewide network of cancer resources, services, and programs.

20-15-203. Confidentiality.

Information accumulated and maintained in the Cancer Registry of Arkansas shall not be divulged except as statistical information which does not identify individuals and for purposes of such research as approved by the Arkansas State Board of Health.

20-15-204. Agreements with other states.

The Arkansas Department of Health is hereby authorized to enter into agreement with other states and federal organizations authorized to exchange registry data. Such agreements shall prohibit divulging information to entities without prior approval of the Arkansas State Department of Health.

20-15-205. Gifts, grants, and donations.

The Department of Health is authorized to receive gifts, grants, and donations for the purpose of this subchapter.

ACCR Rules and Regulations
RULES PERTAINING TO THE ARKANSAS CANCER REGISTRY

Table of Contents

SECTION I. AUTHORITY	1
SECTION II. PURPOSE	1
SECTION III. DEFINITIONS	1
SECTION IV. PARTICIPATION IN THE PROGRAM.....	2
SECTION V. CANCER CASE REPORTING	3
SECTION VI. CONFIDENTIALITY.....	4
SECTION VII. RELEASE OF DATA	4
SECTION VIII. VIOLATIONS AND PENALTIES	5
SECTION IX. EFFECTIVE DATE	5
SECTION X. SEVERABILITY	5
SECTION XI. REPEAL.....	5

SECTION I. AUTHORITY

The following Rules Pertaining to the Arkansas Cancer Registry are duly adopted and promulgated by the Arkansas State Board of Health pursuant to the authority expressly conferred by the laws of the State of Arkansas, specifically Ark. Code Ann. §§ 20-15-201 - 205.

SECTION II. PURPOSE

The purpose of these rules and regulations is to clarify the cancer-reporting responsibilities of medical care professionals, hospitals, laboratories and institutions, pursuant to Arkansas law. In addition, it contains intervention for noncompliance, reinforces the confidentiality requirements, and authorizes the exchange of cancer incidence data with other states and for the data to be made available to the public. In carrying out this mandate, The Arkansas Central Cancer Registry (“ACCR”) collaborates with the National Cancer Institute, the Centers for Disease Control and Prevention, medical research institutions, and national and international cancer surveillance programs designated by the ACCR, and public health agencies. The importance of cancer registration was reinforced by the passage of federal legislation in 1992 (Public Law 102-515) establishing the National Program of Cancer Registries, in which Arkansas participates.

SECTION III. DEFINITIONS

A. “Benign neoplasms” means a benign tumor that does not grow in an unlimited, aggressive manner and does not invade surrounding tissues and does not metastasize.

B. “Borderline tumor” means a neoplasm with many histologic criteria of malignancy, but future behavior is uncertain.

C. “Cancer” means cellular abnormalities with widely variable courses, some grow rapidly, others grow slowly, others stop growing completely and some regress.

D. “Casefinding” means a systematic process of locating cases eligible for inclusion in the cancer registry to include but not limited to pathology reports and disease indices.

E. “Casefinding Audit” means a systematic process of reviewing facility based documents and information to ensure that all eligible/reportable cancer cases were identified, abstracted and reported by facilities to the ACCR.

F. “Hospital Reporting Manual” means the manual containing guidelines and requirements to assist hospital registries in reporting cancer cases to the Arkansas Central Cancer Registry. The Hospital Reporting Manual is attached hereto as Appendix A.

G. “In Situ (in place) cancer” means a cancer that involves only the place in which it began and that has not spread, or invaded and may regress.

H. “Invasive cancer” means a tumor that grows in an uncontrolled manner and invades surrounding tissues and is capable of metastasizing.

I. “New Primary” means a very basic definition is a first time diagnosed cancer. Multiple Primary and Histology Coding Rules must be applied to determine a new primary.

J. “Non-Hospital Reporting Manual” means the manual containing requirements and guidelines to assist non-hospital facilities in reporting cancer cases to the Arkansas Central Cancer Registry. The Non-Hospital Reporting Manual is attached hereto as Appendix B.

K. “Re-Abstracting (Quality Assurance) Audit” means a systematic process of reviewing specific data items and codes, to help ensure quality and accurate coding is being submitted by facilities to the ACCR.

L. “Registry” means the system for the reporting, collection, and analysis of cancer cases by the Arkansas Department of Health.

M. "Reporting" means the notification furnished to the Arkansas Department of Health of cases of in situ or invasive neoplasms of the human body, not including squamous cell and basal cell carcinoma of the skin.

SECTION IV. PARTICIPATION IN THE PROGRAM

A. All licensed health care facilities and providers including, but not limited to: hospitals, pathology laboratories, health care practitioners, radiation treatment facilities, specialty clinics (ex. dermatology, oncology, urology clinics, etc.), surgery centers/clinics, and dental offices shall participate in the program.

B. All participants shall designate specific staff member(s) to be responsible for reporting required cancer data and shall notify the ACCR of the name(s), title, work telephone number and e-mail address of the designated staff member(s).

SECTION V. CANCER CASE REPORTING

A. Reportable Cancer Cases

1. Any newly diagnosed in-situ or invasive cancer or reportable benign and borderline conditions as defined by the ACCR Hospital Manual (page 12) and Non-Hospital Reporting Manual (appendix F of the manual) is considered a reportable diagnosis. If a patient subsequently develops a new primary cancer, it shall be reported separately.

B. Format for reporting

1. The format for reporting, the required codes, and the standards for completeness and quality are defined in the ACCR Hospital and Non-Hospital Reporting Manuals. Text is required for specified variables and shall be adequate to permit quality assurance evaluation of coding decisions.

C. Data Items to be reported

1. The standardized report of cancer shall include as a minimum those data items required by the ACCR, a list of which is maintained in the ACCR Hospital and Non-Hospital reporting manuals. The report of cancer shall include the listed demographic, diagnostic, and treatment data as defined by the department.

D. Deadline for Reporting

1. Reporting shall occur no later than six months after the date of diagnosis of cancer.

E. Failure to Report

1. If a hospital, laboratory, facility or health care practitioner fails to provide the required information in the format or time specified by the ACCR or if the data are of unacceptable quality, personnel from the ACCR staff may enter the facility to abstract the information.

F. Quality Assurance

1. Staff members from the ACCR shall perform periodic quality assurance activities on all reporting facilities. These activities shall include:

- a. Casefinding to ensure that all reportable cancer cases have been accessioned; and
- b. Reabstracting the records of cancer patients to ensure accurate and complete coding of all data.

2. Reporting facilities shall assist the ACCR staff by providing the necessary casefinding documents, medical records and office space for conducting quality assurance activities.
3. In order to improve the quality of the data, the ACCR or their appointees shall offer training to reporting facility personnel if deemed necessary.

SECTION VI. CONFIDENTIALITY

A. All information reported to the ACCR shall be confidential and shall not be disclosed under any circumstances except:

- 1 To other state cancer registries or federal organizations with which the department has data sharing agreements that ensure confidentiality;
- 2 To department of health officials and its agents who are obligated to keep such information confidential; and
- 3 For approved cancer research under specific conditions where names and identities of the individuals are appropriately protected, and when such research is conducted for the purpose of cancer prevention, control and treatment.

B. Protection of Patient Identifying Information Obtained by Special Studies and Other Research Studies.

1. All identifying information such as records of interviews, questionnaires, reports, statements, notes and memoranda that are procured or prepared by employees or agents of the Arkansas Central Cancer Registry shall be used solely for statistical, scientific and medical research purposes and shall be held strictly confidential by the ACCR. This applies also to identifying information procured by any other person, agency, or organization, including public or private colleges and universities acting jointly with the ACCR in connection with special cancer studies and health research investigations.

SECTION VII. RELEASE OF DATA

A. Release of non-identifying information

1. To Federal Agencies: The ACCR is authorized to collaborate with the National Program of Cancer Registries (NPCR), the Centers for Disease Control and Prevention (CDC), and the National Cancer Institute (NCI) to provide cancer incidence statistics and participate in cancer studies.
2. To the Arkansas Department of Health: The ACCR shall work closely with the Arkansas Department of Health in investigating cancer-related issues and in evaluating programs. Because the ACCR data are an integral part of the Arkansas Department of Health cancer prevention and control programs, the use of registry data by public health officials shall be considered an in-house activity. Data required by the Arkansas Department of Health for responding to concerns expressed about threats to the public shall receive priority in determining the order of processing requests.

3. To the general public: Public reports published by the ACCR shall include aggregate, not patient identifying information or facility identifying information. Information that would potentially identify a cancer patient shall not be published.

4. To Others: The ACCR is authorized to collaborate with the North American Association of Central Cancer Registries (NAACCR) to provide cancer incidence statistics and participate in cancer studies.

B. Release of identifying information

1. Identifying information collected from any hospital, laboratory, facility or health care practitioner may be released to qualified persons for the purposes of cancer prevention, control and research, provided that each request for identifying information follows the established procedure outlined in the ACCR Policies and Procedures Manual and receives prior approval by the department and the Board of Health.

2. Data linkages with ACCR files shall be performed only by the ACCR staff, and the Registry may require the removal of identifiers to protect the identity of cases. The actual costs of the data linkage shall be borne by the researcher.

C. Interstate Exchange of Data

1. Because cancer patients may be diagnosed or receive treatment in another state, the ACCR is authorized to sign agreements with other states to acquire cancer data concerning Arkansas residents and, in return, to provide those states with data relating to their residents. Each signatory state shall agree in writing to keep all patient data confidential and privileged as defined in the contract for data exchange, a copy of which is included in the ACCR Policies and Procedures Manual.

SECTION VIII. VIOLATIONS AND PENALTIES

Every firm, person, or corporation who violates this rule may be assessed a civil penalty by the board. The penalty shall not exceed one thousand dollars (\$1,000) for each violation. Each day of a continuing violation may be deemed a separate violation for purposes of penalty assessments. However, no single fine levied by the Board shall exceed ten thousand dollars (\$10,000).

SECTION IX. EFFECTIVE DATE

The effective date of these Rules and Regulations shall be March 1, 2012.

SECTION X. SEVERABILITY

If any provision of these Rules and Regulations, or the application thereof to any person or circumstances is held invalid, such invalidity shall not affect other provisions or applications of these Rules and Regulations which can give effect without the invalid provisions or applications, and to this end the provisions hereto are declared to be severable.

SECTION XI. REPEAL

All Regulations and parts of Regulations in conflict herewith are hereby repealed.

CERTIFICATION

This is to certify that the foregoing Rules Pertaining to the Arkansas Cancer Registry adopted by the Arkansas State Board of Health at a regular session of said Board held in Little Rock, Arkansas on the 3rd day of November, 2011.

Appendix C

Cancer Registries Amendment Act

Public Law 102-515
102d Congress

An Act

Entitled the "Cancer Registries Amendment Act".

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled.

SECTION 1. SHORT TITLE.

This act may be cited as the "Cancer Registries Amendment Act".

SEC. 2. FINDINGS AND PURPOSE.

a. Findings.-Congress finds that-

1. cancer control efforts, including prevention and early detection, are best addressed locally by State health departments that can identify unique needs;
2. cancer control programs and existing statewide population-based cancer registries have identified cancer incidence and cancer mortality rates that indicate the burden of cancer for Americans is substantial and varies widely by geographic location and by ethnicity;
3. statewide cancer incidence and cancer mortality data, can be used to identify cancer trends, patterns, and variation for directing cancer control intervention;
4. the American Association of Central Cancer Registries (AACCR) cites that of the 50 States, approximately 38 have established cancer registries, many are not statewide and 10 have no cancer registry; and
5. AACCR also cites that of the 50 States, 39 collect data on less than 100 percent of their population, and less than half have adequate resources for insuring minimum standards for quality and for completeness of case information.

b. Purpose.-It is the purpose of this Act to establish a national program of cancer registries.

SEC. 3. NATIONAL PROGRAM OF CANCER REGISTRIES.

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the following new part: "Part M-National Program of Cancer Registries"

SEC. 399H. NATIONAL PROGRAM OF CANCER REGISTRIES.

a. "In general.-The Secretary, acting through the Director of the Centers for Disease Control, may make grants to States, or may make grants or enter into contracts with academic or nonprofit organizations designated by the State to operate the State's cancer registry in lieu of making a grant directly to the State, to support the operation of population-based, statewide cancer registries in order to collect, for each form of in-situ and invasive cancer (with the exception of basal cell and squamous cell carcinoma of the skin), data concerning-

1. "demographic information about each case of cancer;
2. "information on the industrial or occupational history of the individuals with the cancers, to the extent such information is available from the same record;

3. "administrative information, including date of diagnosis and source of information;
4. "pathological data characterizing the cancer, including the cancer site, stage of disease (pursuant to Staging Guide), incidence, and type of treatment; and
5. "other elements determined appropriate by the Secretary.

b. "Matching Funds.-

1. "In General.-The Secretary may make a grant under subsection (a) only if the State, or the academic or nonprofit private organization designated by the State to operate the cancer registry of the State, involving agrees, with respect to the costs of the program, to make available (directly or through donations from public or private entities) non-Federal contributions toward such costs in an amount that is not less than 25 percent of such costs or \$1 for every \$3 of Federal funds provided in the grant.

2. "Determination Of Amount of Non-Federal Contribution; Maintenance of Effort.-

A. "Non-Federal contributions required in paragraph (1) may be in cash or in kind, fairly evaluated, including plant, equipment, or services. Amounts provided by the Federal Government, may not be included in determining the amount of such non-Federal contributions.

B. "With respect to a State in which the purpose described in subsection (a) is to be carried out, the Secretary, in making a determination of the amount of non-Federal contributions provided under paragraph (1), may include only such contributions as are in excess of the amount of such contributions made by the State toward the collection of data on cancer for the fiscal year preceding the first year for which a grant under subsection (a) is made with respect to the State. The Secretary may decrease the amount of non-Federal contributions that otherwise would have been required by this subsection in those cases in which the State can demonstrate that decreasing such amount is appropriate because of financial hardship.

c. "Eligibility for Grants.-

1. "In General.-No grant shall be made by the Secretary under subsection (a) unless an application has been submitted to, and approved by, the Secretary. Such application shall be in such form, submitted in such a manner, and be accompanied by such information, as the Secretary may specify. No such application may be approved unless it contains assurances that the applicant will use the funds provided only for the purposes specified in the approved application and in accordance with the requirements of this section, that the application will establish such fiscal control and fund accounting procedures as may be necessary to assure proper disbursement and accounting of Federal funds paid to the applicant under subsection (a) of this section, and that the applicant will comply with the peer review requirements under sections 491 and 492.

2. "Assurances.-Each applicant, prior to receiving Federal funds under subsection (a), shall provide assurances satisfactory to the Secretary that the applicant will-

A. "provide for the establishment of a registry in accordance with subsection (a);

B. "comply with appropriate standards of completeness, timeliness, and quality of population-based cancer registry data;

C. "provide for the annual publication of reports of cancer data under subsection (a); and

D. "provide for the authorization under State law of the statewide cancer registry, including promulgation of regulations providing-

- i. "a means to assure the complete reporting of cancer cases (as defined in subsection (a)) to the statewide cancer registry by hospitals or other facilities or other facilities providing screening, diagnostic or therapeutic services to patients with respect to cancer;
- ii. "a means to assure the complete reporting of cancer cases (as defined in subsection (a)) to the statewide cancer registry by physicians, surgeons, and all other health care practitioners diagnosing or providing treatment for cancer patients, except for cases directly referred to or previously admitted to a hospital or other facility providing screening, diagnostic or therapeutic services to patients in that State and reported by those facilities;
- iii. "a means for the statewide cancer registry to access all records of physicians and surgeons, hospitals, individuals, or agencies providing such services to patients which would identify cases of cancer or would establish characteristics of the cancer, treatment of the cancer, or medical status of any identified patient;
- iv. "for the reporting of cancer case data to the statewide cancer registry in such a format, with such data elements, and in accordance with such standards of quality timeliness and completeness, as may be established by the Secretary;
- v. "for the protection of the confidentiality of all cancer case data reported to the statewide cancer registry, including a prohibition on disclosure to any person of information reported to the statewide cancer registry that identifies, or could lead to the identification of, an individual cancer patient, except for disclosure to other State cancer registries and local and State health officers;
- vi. "for a means by which confidential case data may in accordance with State law be disclosed to cancer researchers for the purposes of cancer prevention, control and research;
- vii. "for the authorization or the conduct, by the statewide cancer registry or other persons and organizations, of studies utilizing statewide cancer registry data, including studies of the sources and causes of cancer, evaluations of the cost, quality, efficacy, and appropriateness of diagnostic, therapeutic, rehabilitative, and preventative services and programs relating to cancer, and any other clinical, epidemiological, or other cancer research; and
- viii. "for protection for individuals complying with the law, including provisions specifying that no person shall be held liable in any civil action with respect to a cancer case report provided to the statewide cancer registry, or with respect to access to cancer case information provided to the statewide cancer registry.

d. "Relationship to Certain Programs.-

1. "In General.-This section may not be construed to act as a replacement for or diminishment of the program carried out by the Director of the National Cancer Institute and designated by such Director as the Surveillance, Epidemiology, and End Results Program (SEER).

2. "Supplanting of Activities.-In area where both such programs exist, the Secretary shall ensure that SEER support is not supplanted and that any additional activities are consistent with the guidelines provided for in subsection (c)(2) (C) and (D) and are appropriately coordinated with the existing SEER program.
3. "Transfer of Responsibility.-The Secretary may not transfer administration responsibility for such SEER program from such Director.
4. "Coordination.-To encourage the greatest possible efficiency and effectiveness of Federally supported efforts with respect to the activities described in this subsection, the Secretary shall take steps to assure the appropriate coordination of programs supported under this part with existing Federally supported cancer registry programs.
- e. "Requirement Regarding Certain Study on Breast Cancer.-In the case of a grant under subsection (a) to any State specified in section 399K(b), the Secretary may establish such conditions regarding the receipt of the grant as the Secretary determines are necessary to facilitate the collection of data for the study carried out under section 399C.

"SEC. 399I. PLANNING GRANTS REGARDING REGISTRIES.

a. In General.-

1. "States.-The Secretary, acting through the Director of the Centers for Disease Control, may make grants to States for the purpose of developing plans that meet the assurances required by the Secretary under section 399B(c)(2).
 2. "Other Entities.-For the purpose described in paragraph (1), the Secretary may make grants to public entities other than States and to nonprofit private entities. Such a grant may be made to an entity only if the State in which the purpose is to be carried out has certified that the State approves the entity as qualified to carry out the purpose.
- b. "Application.-The Secretary may make a grant under subsection (a) only if an application for the grant is submitted to the Secretary, the application contains the certification required in subsection (a)(2) (if the application is for a grant under such subsection), and the application is in such form, is made in such a manner, and contains such agreements, assurances, and information as the Secretary determines to be necessary to carry out this section."

SEC. 399J. TECHNICAL ASSISTANCE IN OPERATIONS OF STATEWIDE CANCER REGISTRIES.

"The Secretary, acting through the Director of the Centers for Disease Control, may, directly or through grants and contracts, or both, provide technical assistance to the States in the establishment and operation of statewide registries, including assistance in the development of model legislation for statewide cancer registries and assistance in establishing a computerized reporting and data processing system."

SEC. 399K. STUDY IN CERTAIN STATES TO DETERMINE THE FACTORS CONTRIBUTING TO THE ELEVATED BREAST CANCER MORTALITY RATES.

- a. "In General.-Subject to subsections (c) and (d), the Secretary, acting through the Director of the National Cancer Institute, shall conduct a study for the purpose of determining the factors contributing to the fact that the breast cancer mortality rates in other States.

b. "Relevant States.-The States referred to in subsection (a) are Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Vermont, and the District of Columbia.

c. "Cooperation of State.-The Secretary may conduct the study required in subsection (a) in a State only if the State agrees to cooperate with the Secretary in the conduct of the study, including providing information from any registry operated by the State pursuant to section 399H(a).

d. "Planning, Commencement, and Duration.-The Secretary shall, during each of the fiscal years 1993 and 1994, develop a plan for conducting the study required in subsection (a). The study shall be initiated by the Secretary not later than fiscal year 1994, and the collection of data under the study may continue through fiscal year 1998.

e. "Report.-Not later than September 30, 1999, the Secretary shall complete the study required in subsection (a) and submit to the Committee on Energy and Commerce of the House of Representatives, and to the Committee on Labor and Human Resources of the Senate, a report describing the findings and recommendations made as a result of the study."

SEC. 399L. AUTHORIZATION OF APPROPRIATIONS.

a. "Registries.-For the purpose of carrying out this part, the Secretary may use \$30,000,000 for each of the fiscal years 1993 through 1997. Out of any amounts used for any such fiscal year, the Secretary may obligate not more than 25 percent for carrying out section 399I, and not more than 10 percent may be expended for assessing the accuracy, completeness and quality of data collected, and not more than 10 percent of which is to be expended under subsection 399J.

b. "Breast Cancer Study.-Of the amounts appropriated for the National Cancer Institute under subpart 1 of part C of title IV for any fiscal year in which the study required in section 399K is being carried out, the Secretary shall expend not less than \$1,000,000 for the study."

Approved October 24, 1992.

Authorization extended through 19

Appendix D

HIPAA ACT

§ 164.512 Uses and disclosures for which consent, an authorization, or opportunity to agree or object is not required.

A covered entity may use or disclose protected health information without the written consent or authorization of the individual as described in §§ 164.506 and 164.508, respectively, or the opportunity for the individual to agree or object as described in § 164.510, in the situations covered by this section, subject to the applicable requirements of this section. When the covered entity is required by this section to inform the individual of, or when the individual may agree to, a use or disclosure permitted by this section, the covered entity's information and the individual's agreement may be given orally.

(a) Standard: uses and disclosures required by law.

(1) A covered entity may use or disclose protected health information to the extent that such use or disclosure is required by law and the use or disclosure complies with and is limited to the relevant requirements of such law.

(2) A covered entity must meet the requirements described in paragraph (c), (e), or (f) of this section for uses or disclosures required by law.

(b) Standard: uses and disclosures for public health activities.

(1) Permitted disclosures. A covered entity may disclose protected health information for the public health activities and purposes described in this paragraph to:

(i) A public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions; or, at the direction of a public health authority, to an official of a foreign government agency that is acting in collaboration with a public health authority

Appendix E

ACCR REPORTABLE LIST

The following ICD-10-CM list is intended to assist in reportable neoplasm casefinding activities. It should be used to identify potentially reportable tumors. Any reportable neoplasm diagnosed on or after January 1, 1996 should be reported to the Arkansas Central Cancer Registry. Effective dates **October 1, 2015 – September 30, 2016**

Reportable Neoplasms:

- Malignant neoplasms (exclusions noted below)
- Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
- Carcinoma in situ (exclusions noted below)
- Carcinoid, NOS (excluding appendix, unless stated to be malignant)
- Pilocytic/juvenile astrocytoma is listed as 9421/1 in ICD-0-3, is reportable and should be coded to 9421/3
- Squamous intraepithelial neoplasia grade III of vulva (VIN), vagina (VAIN), and anus (AIN) beginning with 2001 cases
- Primary tumors that originate in a mucous membrane are reportable and include the following: Lip, Anus, Labia, Clitoris, Scrotum, Vulva, Vagina, Prepuce and Penis

Code	Definition
C00._ - C96._	Malignancies (primary and secondary)
D00._ - D09._	In Situ neoplasms; CIS cervix/CIN3- 8077/2 and Prostatic Intraepithelial Carcinoma/PIN- 8148/2 are NOT reportable
D18.02	Hemangioma of intracranial structures and any site
D18.1	Lymphomangioma Note: includes only lymphomangioma of brain, other parts of nervous system and endocrine gland
D32._	Benign neoplasm of meninges (cerebral, spinal, and unspecified)
D33._	Benign neoplasm of brain and other parts CNS
D35.2 – D35.4	Benign pituitary gland and craniopharyngeal duct, pineal gland
D42._, D43._	Neoplasms of uncertain behavior meninges, brain, CNS
D44.3 – D44.5	Neoplasm of uncertain or unknown behavior Pituitary gland and craniopharyngeal duct (pouch), pineal gland
D45	Polycythemia Vera (9950/3)
D46._	Myelodysplastic Syndromes
D47.1	Chronic Myeloproliferative disease
D47.3	Essential thrombocythemia
D47.4	Osteomyelofibrosis
D47.7	Other specified neoplasms of uncertain/unknown behavior of lymphoid, hematopoietic
D47.Z_	Other neoplasms of uncertain behavior of lymphoid, hematopoietic tissue
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue
D49.6, D49.7	Neoplasms of uncertain behavior of brain, endocrine glands, and other CNS
D72.1	Eosinophilia, reportable diagnosis: Hypereosinophilic syndrome

E34.0	Carcinoid Syndrome
R18.0	Malignant Ascites
Z51.0	Encounter or admission for radiotherapy
Z51.1	Encounter or admission for chemotherapy and immunotherapy

Neoplasms not required by ACCR:

Morphology Codes	Diagnosis/Terminology
8000-8004	Neoplasms, malignant, NOS of skin
8010/2	Carcinoma in situ of cervix
8010-8045	Epithelial carcinomas of skin
8050-8084	Papillary and Squamous cell carcinoma of skin
8077/2	Squamous Intraepithelial Neoplasia, grade 3 of cervix (CINIII)
8090-8110	Basal cell carcinoma of skin
8148/2	Prostatic Intraepithelial Neoplasia (PIN)

Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries which moved from /3 to /1 are **NOT** collected as of 1/1/2001

The following terms are synonymous with in situ disease (Behavior code 2):

Adenocarcinoma in an adenomatous polyp with no invasion of stalk

Clark's level I melanoma or limited to epithelium

Noninfiltrating comedocarcinoma, confined to epithelium

Hutchison's melanotic freckle NOS, intracystic-noninfiltrating, intraductal, intraepithelium NOS, intraepidermal NOS (involvement up to but not Including basement membrane.)

Lentigo maligna, lobular neoplasia, lobular-noninfiltrating, noninvasive, no stromal involvement, papillary noninfiltrating or intraductal

Vaginal intraepithelial neoplasia Grade III or VAIN III

Vulvar intraepithelial neoplasia Grade III or VIN III

Anal intraepithelial neoplasia Grade III or AIN III

- **If any invasion is present, no matter how limited cases must be coded to invasive behavior**
- **If other benign or borderline diseases are required to be collected by your hospital cancer committee or other appointed officials, they are not required to be reported to ACCR.**

For cases diagnosed **before October 1, 2015** use the ICD-9-CM Reportable List found at:

<http://www.healthy.arkansas.gov/programsServices/healthStatistics/CancerRegistry/Pages/Registrars.aspx>

Appendix F

MEDICAL ABBREVIATION LIST

Abbreviations which are acceptable to use when abstracting cases are listed below. For abbreviated names of Antineoplastic Drugs see *SEER Program Self-Instructional Manual for Tumor Registrars, Book 8, Third Edition* or *SEER RX website*.

Abdomen	ABD	Cervical Intraepithelial Neoplasia	CIN
Abdominal Perineal Acid Phosphatase	AP	Cervix	CX
Acquired Immunodeficiency Syndrome	ACID PHOS	Cesium	CS
Acute Granulocytic Leukemia	AIDS	Chemotherapy	CHEMO
Acute Lymphocytic Leukemia	AGL	Chest X-ray	CXR
Acute Myelogenous Leukemia	ALL	Chief Complaint	CC
Adenocarcinoma	AML	Chronic Granulocytic Leukemia	CGL
Adjacent	ADENOCA	Chronic Lymphocytic Leukemia	CLL
Admission, Admit	ADJ	Chronic Myeloid Leukemia	CML
Alcohol	ADM	Clear	CLR
Alkaline Phosphatase	ETOH	Common Bile Duct	CBD
Alpha-fetoprotein	ALK PHOS	Complete Blood Count	CBC
Also known as	AFP	Computerized Axila Tomography Scan	CT, CAT
Ambulatory	AKA	Consistent With	C/W
Anaplastic	AMB	Continue	CONT
Anterior	ANAP	Cystoscopy	CYSTO
Anteroposterior	ANT	Cytology	CYTO
Approximately	AP	Date of Birth	DOB
Arteriovenous	APPROX	Death Clearance Only	DCO
Aspiration	AV	Decreased	DECR (<)
Auscultation & Percussion	ASP	Dermatology	DERM
Autopsy	A & P	Diagnosis	DX
Axillary	AUT	Diameter	DIA
Bacillus Calmette-Guerin	AX	Differentiated	DIFF
Barium	BCG	Dilation & Curettage	D & C
Barium Enema	BA	Discharge	DIS, DISC
Benign Prostatic Hypertrophy/hyperplasia	BE	Discontinued	DC
Bilateral	BPH	Disease	DZ, DIS
Bilateral Salpingo-oophorectomy	BIL	Doctor	DR, MD
Biological Response Modifier	BSO	Ears, Nose, & Throat	ENT
Biopsy	BRM	Emergency Room	ER
Blood Urea Nitrogen	BX	Enlarged	ENL
	BUN	Esophagogastroduodenosc	EGD

opy **CAN PAGE BE
ADJUSTED???**

Bone Marrow	BM	Estrogen Receptor	ER
Bone Scan	BSC	Evaluation	EVAL
Calcium	CA	Examination	EXAM
Carcinoembryonic Antigen	CEA	Examination under anesthesia	EUA
Carcinoma	CA	Excision	EXC
Carcinoma In Situ	CIS	Exploratory Laparotomy	EXP LAP
CAT Scan	CT	Extend, Extension	EXT
Centimeter	CM	External	EXT
Central Nervous System	CNS	Extremity	EXT
Cerebrospinal Fluid	CSF	Eyes, ears, nose, & throat	EENT
Family History	FH	Midclavicular line	MCL
Floor of mouth	FOM	Middle lobe	ML
Follow-up	FU	Millimeter	MM
Frozen Section	FS	Minimum	MIN
Gastroenterostomy	GE	Moderate	MOD
Gastrointestinal	GI	Moderately Differentiated	MD, MOD DIFF
Grade	GR	Modified Radical	MRM
		Mastectomy	
Gynecology	GYN	Nausea & Vomiting	N & V
Head, Eyes, Ears, Nose, & Throat	HEENT	Negative	NEG (or -)
Hematocrit	HCT	Neurology	NEURO
Hemoglobin	HGB	No evidence of disease	NED
History	HX	Normal	NL
History & Physical	H & P	No significant findings	NSF
History of	HO	Not applicable	NA
History of Present Illness	HPI	Not otherwise specified	NOS
Hormone	HORM	Not recorded	NR
Hospital	HOSP	Obstructed (ing, ion)	OBST
Human Chorionic Gonadotropin	HCG	Operating Room	OR
Human Immunodeficiency Virus	HIV	Operative report	OP report
Hysterectomy	HYST	Outpatient	OP
Immunoglobulin	IG	Packs per day	PPD
Includes, including	INCL	Palpated	PALP
Increase	INCR (or>)	Papanicolaou Smear	PAP
Infiltrating	INFILT	Papillary	PAP
Inpatient	IP	Past Medical History	PMH
Intravenous	IV	Pathology	PATH
Intravenous Pyelogram	IVP	Patient	PT
Kidneys, Ureter, Bladder	KUB	Percutaneous	PERC
Laparotomy	LAP	Physical Examination	PE
Lateral	LAT	Platelets	PLT
Left	L, LT	Poorly differentiated	PD, POOR DIFF
Left Costal Margin	LCM	Positive	POS (or +)
Left lower extremity	LLE	Positron Emission Tomography	PET
Left lower lobe	LLL	Possible	POSS
Left lower quadrant	LLQ	Posterior	POST
Left upper extremity	LUE	Posteroanterior	PA
Left upper lobe	LUL	Postoperative	PO, POSTOP

Left upper quadrant	LUQ	Preoperative	PREOP
Liver, kidney, spleen, (bladder)	LKS(B)	Present Illness	PI
Lower extremity	LE	Prior to admission	PTA
Lower inner quadrant	LIQ	Probable	PROB
Lower outer quadrant	LOQ	Progesterone receptor	PR
Lumbar puncture	LP	Pulmonary	PULM
Lumbosacral	LS	Radiation	RAD
Lymph Node(s)	LN, LNs, LNS	Radiation absorbed dose	RAD
Macroscopic	MACRO	Radiation therapy	RT
Magnetic Resonance Imaging	MRI	Radical	RAD
Malignant	MALIG, MAL	Radium	RA
Mastectomy	MAST	Red blood cells	RBC
Maxillary	MAX	Resection	RESEC
Medicine	MED	Respiratory	RESPIR
Metastatic, Metastases	MET, METS	Review of systems	ROS
Microscopic	MICRO	Right	R, RT
Right costal margin	RCM	Transurethral Resection	TUR
Right lower extremity	RLE	Transurethral Resection Bladder	TURB
Right lower lobe	RLL	Transurethral Resection Prostate	TURP
Right lower quadrant	RLQ	Treatment	RX, TX
Right middle lobe	RML	Undifferentiated	UNDIFF
Right upper extremity	RUE	Upper extremity	UE
Right upper lobe	RUL	Upper gastrointestinal	UGI
Right upper quadrant	RUQ	Upper inner quadrant	UIQ
Rule out	RO, R/O	Upper outer quadrant	UOQ
Salpingo-oophorectomy	SO	Vagina, Vaginal	VAG
Shortness of breath	SOB	Vaginal Hysterectomy	VAG HYST
Specimen	SPEC	Vaginal intraepithelial neoplasia	VAIN
Small	SM, SML	Vascular	VASC
Small bowel	SB, SML BWL	Vulvar intraepithelial neoplasia	VIN
Squamous	SQ, SQUAM	Well differentiated	WD, WELL DIFF
Squamous Cell Carcinoma	SCC	White blood cells	WBC
Status post	S/P	With	W/ or C
Surgery, Surgical	SURG	Within normal limits	WNL
Symptoms	SX	Without	W/O
Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy	TAH-BSO	Work-up	W/U
Total Vaginal Hysterectomy	TVH	X-ray	XR
Transitional Cell Carcinoma	TCC	Year	YR

Appendix G

OFFICIAL UNITED STATES POSTAL SERVICE ABBREVIATIONS

State/Possession	Abbreviation
ALABAMA	AL
ALASKA	AK
AMERICAN SAMOA	AS
ARIZONA	AZ
ARKANSAS	AR
CALIFORNIA	CA
COLORADO	CO
CONNECTICUT	CT
DELAWARE	DE
DISTRICT OF COLUMBIA	DC
FEDERATED STATES OF MICRONESIA	FM
FLORIDA	FL
GEORGIA	GA
GUAM	GU
HAWAII	HI
IDAHO	ID
ILLINOIS	IL
INDIANA	IN
IOWA	IA
KANSAS	KS
KENTUCKY	KY
LOUISIANA	LA
MAINE	ME
MARSHALL ISLANDS	MH
MARYLAND	MD
MASSACHUSETTS	MA
MICHIGAN	MI
MINNESOTA	MN
MISSISSIPPI	MS
MISSOURI	MO
MONTANA	MT
NEBRASKA	NE
NEVADA	NV
NEW HAMPSHIRE	NH
NEW JERSEY	NJ
NEW MEXICO	NM
NEW YORK	NY
NORTH CAROLINA	NC
NORTH DAKOTA	ND

NORTHERN MARIANA ISLANDS	MP
OHIO	OH
OKLAHOMA	OK
OREGON	OR
PALAU	PW
PENNSYLVANIA	PA
PUERTO RICO	PR
RHODE ISLAND	RI
SOUTH CAROLINA	SC
SOUTH DAKOTA	SD
TENNESSEE	TN
TEXAS	TX
UTAH	UT
VERMONT	VT
VIRGIN ISLANDS	VI
VIRGINIA	VA
WASHINGTON	WA
WEST VIRGINIA	WV
WISCONSIN	WI
WYOMING	WY

Appendix H

SURGERY – CANCER TREATMENT

Surgery is the oldest form of cancer treatment. It also has a key role in diagnosing cancer and finding out how far it has spread (staging). Advances in surgical techniques have allowed surgeons to successfully operate on a growing number of patients. Today, less invasive operations often can be done to remove tumors while saving as much normal tissue and function as possible.

Surgery offers the greatest chance for cure for many types of cancer, especially those that have not spread to other parts of the body. Most people with cancer will have some type of surgery.

Why is surgery used for cancer?

Surgery can be done for many reasons. Some types of surgery are very minor and may be called procedures, while others are much bigger operations. The more common types of cancer surgeries are reviewed here.

Preventive (prophylactic) surgery

Preventive surgery is done to remove body tissue that is likely to become cancerous (malignant), even though there are no signs of cancer at the time of the surgery. For example, pre-cancerous polyps may be removed from the colon.

Sometimes preventive surgery is used to remove an entire organ when a person has an inherited condition that puts them at a much higher risk for having cancer someday. For example, some women with a strong family history of breast cancer are found to have a change (mutation) in their DNA in a breast cancer gene (BRCA1 or BRCA2). Because their risk of getting breast cancer is high, these women may want to consider prophylactic mastectomy (the breasts are removed before cancer is found).

Diagnostic surgery

This type of surgery is used to get a tissue sample to tell whether or not cancer is present or to tell what type of cancer it is. The diagnosis of cancer is often made by looking at the cells under a microscope. Many methods are used to get a sample of cells from a suspicious-looking area. These are described in the section, "Surgery to diagnose and stage cancer."

Staging surgery

Staging surgery is done to find out how much cancer there is and how far it has spread. While the physical exam and the results of lab and imaging tests can help figure out the clinical stage of the cancer, the surgical stage (also called the pathologic stage) is usually a more exact measure of how far the cancer has spread.

Examples of surgical procedures commonly used to stage cancers, such as laparotomy and laparoscopy, are described in the section, "Surgery to diagnose and stage cancer."

Curative surgery

Curative surgery is done when a tumor appears to be confined to one area, and it is likely that all of the tumor can be removed. Curative surgery can be the main treatment for the cancer. It may be used alone or along with chemotherapy or radiation therapy, which can be given before or after the operation.

Sometimes radiation therapy is actually used during an operation. This is called intraoperative radiation therapy.

Debulking (cytoreductive) surgery

Debulking surgery is done to remove some, but not all, of the tumor. It is done when removing the entire tumor would cause too much damage to an organ or near-by tissues. In these cases, the doctor may remove as much of the tumor as possible and then try to treat what's left with radiation therapy or chemotherapy. Debulking surgery is commonly used for advanced cancer of the ovary.

Palliative surgery

This type of surgery is used to treat complications of advanced cancer. It is not intended to cure the cancer. Palliative surgery can also be used to correct a problem that is causing discomfort or disability. For example, some cancers in the abdomen may grow large enough to block off (obstruct) the intestine. If this happens, surgery can be used to remove the blockage. Palliative surgery may also be used to treat pain when the pain is hard to control by other means.

Supportive surgery

Supportive surgery is used to help with other types of treatment. For example, a vascular access device such as a port-a-cath can be surgically placed into a large vein. The port can then be used to give treatments or draw blood for testing, instead of having needles put in the arms.

Restorative (reconstructive) surgery

This type of surgery is used to change the way a person looks after major cancer surgery or to restore the function of an organ or body part after surgery. Examples include breast reconstruction after mastectomy or the use of tissue flaps, bone grafts, or prosthetic (metal or plastic) materials after surgery for oral cavity cancers. For more information on these types of reconstructive surgery, please see the American Cancer Society documents [Breast Reconstruction after Mastectomy](#) and [Oral Cavity and Oropharyngeal Cancer](#).

Surgery to diagnose and stage cancer

A biopsy is a procedure done to remove a tissue sample so that it can be looked at under a microscope. Some biopsies may need to be done in surgery, but many types of biopsies involve removing tumor samples through a thin needle or an endoscope (a flexible lighted tube). Biopsies are often done by surgeons, but they can be done by other doctors, too. Some of the more common ways to do a biopsy are reviewed here.

Fine needle aspiration biopsy

Fine needle aspiration (FNA) uses a very thin needle attached to a syringe to pull out a small amount of tissue from a tumor. If the tumor can't be felt near the surface of the body, the needle can be guided into the tumor by looking at it with an imaging method such as an ultrasound (US) or CT (computed tomography) scan.

The main advantage of FNA is that no surgical incision (cutting through the skin) is needed. A drawback is that in some cases the needle can't take out enough tissue for a definite diagnosis. A more invasive type of biopsy may then be needed.

Core needle biopsy

This type of biopsy uses a slightly larger needle to take out some of the tissue. A core biopsy can be aspirated (removed) with a needle if the tumor can be felt at the surface. Core biopsies can also be guided by imaging methods if the tumor is too deep to be felt.

The advantage of core biopsy is that it usually collects enough tissue to find out whether or not the tumor is cancer.

Excisional or incisional biopsy

For these biopsies a surgeon cuts through the skin to remove the entire tumor (excisional biopsy) or a small part of the tumor (incisional biopsy). They can often be done with local or regional anesthesia. This means numbing medicine is used just in the area where the biopsy will be done. If the tumor is inside the chest or abdomen, general anesthesia (drugs that put you into a deep sleep) may be needed.

Endoscopy

This procedure uses a thin, flexible tube with a viewing lens or a video camera and a fiber optic light on the end. If a video camera is used, it is connected to a television screen. This allows the doctor to clearly see any tumors in the area. Endoscopes can be passed through natural body openings to look at areas of concern in places such as the following:

- throat (pharyngoscopy)
- voice box (laryngoscopy)
- esophagus (esophagoscopy)
- stomach (gastroscopy)
- small intestine (duodenoscopy)
- colon (colonoscopy or sigmoidoscopy)
- bladder (cystoscopy)
- respiratory tract -- windpipe, bronchi, and lungs (bronchoscopy)

Some of the advantages of endoscopy are:

- The doctor can look right at the tumor and get a good idea of where it is and how big it is.
- A biopsy can be taken through the scope to find out if the tumor is cancer.
- An open surgical incision or general anesthesia is usually not needed.

Local numbing medicines are needed before some types of endoscopy. Medicines may also be given to make you sleepy.

Ultrasonography

Ultrasound devices can be attached to the end of some endoscopes. This allows doctors to look at the layers of the esophagus (swallowing tube), bronchus (main breathing tube), and parts of the large intestine (bowel). Nearby lymph nodes can be seen, too. Using the ultrasound pictures to guide it, a needle can be placed through the endoscope and cells can be collected from lymph nodes that do not look normal.

Laparoscopy, thoracoscopy, or mediastinoscopy

Laparoscopy is much like endoscopy, but a small incision is made in the skin of the abdomen (belly). A thin tube called a laparoscope is then put through the incision and into the abdomen to look for possible areas of cancer that can be biopsied. When this type of procedure is done to look inside the chest it is called a thoracoscopy or mediastinoscopy.

Open surgical exploration (laparotomy, thoracotomy, or mediastinotomy)

When less invasive tests do not give enough information about a suspicious area in the abdomen, a laparotomy may be needed. In this procedure, a surgeon makes an incision, usually from the bottom of the sternum (breastbone) down to the lower part of the abdomen (belly), which allows him to look directly at the area in question. The location and size of the tumor and the surrounding areas can be seen and biopsies can be taken, if needed. Because this is a major surgical procedure, general anesthesia (medicines that put you in a deep sleep) is needed. An operation much like this can be done to open and look inside the chest. It is called a thoracotomy.

If lymph nodes near the trachea are swollen, a mediastinotomy is done. General anesthesia (medicines that put you in a deep sleep) is used for this procedure. A special scope (mediastinoscope) is put in the body through a small incision above the top of the sternum (breastbone) and biopsies are collected from the areas of concern.

Special surgery techniques

When most people think of surgery, they picture a doctor using a scalpel and other surgical instruments to remove, repair, or replace parts of the body affected by disease. But newer techniques, using different types of instruments, have expanded the concept of what surgery is. Some of these newer techniques are described below.

Laser surgery

A laser is a highly focused and powerful beam of light energy which can be used for very precise surgical work, such as repairing a damaged retina in the eye. It can also be used to cut through tissue (instead of using a scalpel) or to vaporize (burn and destroy) cancers of the cervix, larynx (voice box), liver, rectum, or skin.

Some surgeries can be made less invasive by using laser light. For example, with fiber optics the light can be directed inside the body without having to make a large incision.

Lasers are also used in a type of surgery called photoablation or photocoagulation. This means lasers are used to destroy tissue or to seal tissues or vessels. This type of surgery is often used to relieve symptoms, such as when large tumors block the windpipe or esophagus, causing problems with breathing or eating.

Cryosurgery

Cryosurgery involves the use of a liquid nitrogen spray or a very cold probe to freeze and kill abnormal cells. This technique is sometimes used to treat pre-cancerous conditions, such as those affecting the cervix. Cryosurgery is also being studied as a treatment for some cancers, such as those of the prostate.

Electrosurgery

High-frequency electrical current can be used to destroy cells. It is used for some cancers of the skin and mouth.

Mohs surgery

Mohs micrographic surgery, also called microscopically controlled surgery, is a technique to remove certain skin cancers by shaving off one thin layer at a time. After each layer is removed, a specially trained dermatologist (skin doctor) or a pathologist (doctor who specializes in diagnosing and classifying diseases by lab tests) looks at the tissue layer under a microscope. When all the cells look normal under the microscope, the surgeon stops removing layers of tissue.

This technique is used when the extent of the cancer is not known or when as much healthy tissue as possible needs to be preserved (as in cancers around the eye). It is done under local anesthesia by a specially trained surgeon.

Chemosurgery is an older name for this surgery and refers to certain chemicals put on the tissue before it is removed. Mohs surgery does not involve use of cancer chemotherapy drugs.

Laparoscopic surgery

A laparoscope is a long, narrow, flexible tube placed through a small incision (cut) to look inside the body. It is sometimes used to take biopsy samples. In recent years, doctors have found that by creating some small holes and using special instruments, the laparoscope can be used to perform surgery without making a large incision. This can help reduce blood loss during surgery and pain afterwards. It can also shorten hospital stays. Laparoscopic surgery is commonly used today to remove gallbladders and to repair hernias.

The role of laparoscopic surgery in cancer treatment is not yet clear. Doctors are now studying whether it is safe and effective to use laparoscopic surgeries for many cancers of the bladder, colon, prostate, and kidney, among others. It may prove to be as safe and effective as standard surgery while being less invasive. Some studies have hinted at this being the case. But larger, long-term studies still need to be completed.

Thorascopic surgery

A thoracoscope is a narrow, rigid tube with a camera connected at one end that can be placed through a small incision (cut) into the chest after the lung is collapsed. This allows the doctor to see inside the entire chest. Any areas of concern on the lining of the chest wall can be biopsied, fluid can be drained, and small tumors on the surface of the lung can be removed with small stapling devices. This less-invasive approach has also been used to remove parts (lobes) of the lung that contain cancer. Studies have shown that for early stage lung cancer, results are much like removing part of the lung by doing an open thoracotomy (incision in the side of the chest).

Other forms of surgery

Newer ways to remove or destroy cancer tumors are always being explored. Some methods are beginning to blur the lines between what we commonly think of as "surgery" and other forms of treatment. Researchers are testing many new techniques, using things such as high intensity focused ultrasound (HIFU); microwaves or radio waves (radiofrequency ablation, or RFA); or even magnets in an attempt to get rid of unwanted tissue. While promising, these techniques are still largely experimental.

As doctors learn how to better control the energy waves used in radiation therapy, some newer radiation techniques that are almost as effective as surgery have been found. By using radiation sources from different angles, stereotactic radiation therapy delivers a large precise radiation dose to a small tumor area. The doses are so exact that the term stereotactic surgery is sometimes used, even though no incision (cut) is actually made. In fact, the machines used to deliver this treatment have names like Gamma Knife and Cyber Knife, although no actual knife is involved. The most common site being treated with this technique is the brain, but it is also being used in head, neck, lung, and spine tumors. Researchers are looking for ways to use it to treat other types of cancer, too.

Appendix I

GLOSSARY OF TREATMENT TERMS

GLOSSARY OF TREATMENT TERMS (referenced from the training manual prepared by the American College of Surgeons Commission on Cancer)

Abdominal-perineal resection: Surgical procedure used in the treatment of colorectal Cancer that requires a combined approach through the abdomen and the perineum. Complications include ureteral injury, urinary dysfunction, urinary tract infections, sexual dysfunction, perineal and abdominal wound infections, and stomal complications.

Adjuvant therapy: A therapy that aids another, such as chemotherapy, after surgery.

Allogeneic bone marrow transplantation: Transplanting bone marrow from one person to another person who is of the same tissue type.

Amputation: The removal of a limb or another appendage or outgrowth of the body.

Antioncogenes: Genes having the ability to regulate growth and inhibit carcinogenesis.

Antrectomy: Excision of the antrum.

Autologous bone marrow transplantation: Transplanting the patient's own bone marrow after ablative treatment.

BCG: Bacille Calmette Guerin vaccine, a tuberculosis vaccine, containing living, avirulent, bone-strain tubercle bacilli. It is administered by a special technique using a multiple puncture disk and is used immunotherapy for the treatment of cancer, particularly malignant melanoma and bladder cancer.

Bilobectomy: Removal of two lobes.

Billroth I: Pylorectomy with end-to-end anastomosis of the upper portion of the stomach to the duodenum.

Billroth II: Partial gastric resection with closure of duodenal stump and gastrojejunostomy.

Biopsy: Removal and examination, usually microscopic, of tissue from the living body. Biopsies are done to determine whether a tumor is malignant benign.

Excisional: The entire lesion is removed by surgical cutting

Incisional: Biopsy of a selected portion of a lesion

Needle aspiration: Biopsy in which tissue is obtained by application by suction through a needle attached to a syringe

Punch: A type of incisional biopsy

Shave: A type of incisional biopsy since the tumor is rarely totally removed

Brachytherapy: Radiation from a source placed within the body or a body cavity.

Cecetomy: Excision of the cecum.

Cecocolostomy: Surgical anastomosis of the ileum to the cecum.

Cervicectomy: Excision of the cervix utero.

Cholecystectomy: Excision of the gallbladder.

Cholecystojejunostomy: Surgical anastomosis of the gallbladder and jejunum.

Colectomy: Excision of the colon or a portion of it.

Colony-stimulating factor (CSF): Soluble protein factors that stimulate division and maturation of bone marrow stem cells. All CSFs are named a function of the cell most responsive to the factor (e.g., granulocyte colony-stimulating factor or GCSF).

Coloproctectomy: Surgical removal of the colon and rectum.

Colposcopy: The process of examining the vagina and cervix by means of a speculum and a magnifying lens; procedure used for the early detection of malignant changes on the cervix/vagina cuff.

Conization: The removal of a “cone” of tissue, as a partial excision of the cervix. This can be done with a scalpel or electrocautery; the scapel technique preserves the histologic elements of the tissue better.

Continent urinary reservoir (Continent ileal reservoir): Also called the “kock pouch”; a surgical procedure which provides an intra-abdominal pouch that stores urine and has two nipples valves that maintain continence and prevent ureteral reflux.

Craniotomy: Any surgical operation on the cranium.

Cryoprostectomy: Destruction of the prostate by the application of extreme cold.

Cryosurgery: The destruction of tissue by application of extreme cold.

Cystectomy: Excision of the urinary bladder or a part of it.

Debulking: Surgery to reduce tumor to aggregates of 2 cm. Or less; improves the response to postoperative chemotherapy.

Duodenostomy: Surgical formation of a permanent opening into the duodenum.

Endoscopic retrograde cholangiopancreatogram (ERCP): A procedure consisting of a combination of retrograde cholangiography and transhepatic cholangiography used to visualize all portions of the biliary tree.

Enterectomy: An excision of a portion of the intestine.

Esophagectomy: An excision of a portion of the esophagus.

Esophagocoloplasty: An excision of a portion of the esophagus and its replacement by a segment of the colon.

Esophageoenterostomy: An excision of the esophagus and the stomach.

Esophagoscopy: Direct visual examination of the esophagus with an esophagoscope.

Fulguration: Destruction of living tissue by electric sparks generated by a high frequency current.

Gastrectomy: Excision of all (total) or a portion (partial or subtotal) of the stomach.

Glossectomy: Excision of all or a portion of the tongue.

Gray: The S1 (Système International d'Unités) unit of absorbed radiation dose, defined as the transfer of 1 joule of energy per Kg of absorbing material. 1 Gray = 100 rads.

Hartmann's operation: Resection of a portion of the colon, with the proximal end of the colon brought out as a colostomy and the distal stump or rectum being closed.

Hemicolectomy: Excision of approximately half of the colon.

Hepatectomy: Excision of all or a portion of the liver.

Hysterectomy: Surgical removal of the uterus.

Abdominal: performed through the abdominal wall

Modified radical (type2): removal of the uterus a portion of the parametrium

Radical or Wertheim procedure (type3): removal of the uterus and excision of the pelvic lymph nodes with wide lateral excision of the parametrical and paravaginal supporting structure

Simple (type 1): removal of the uterus

Subtotal: the cervix is left in place

Total (pan): the uterus and cervix are completely excised

Vaginal: performed through the vagina

Ileal conduit: A surgical procedure that uses a segment of the ileum for the diversion of urinary flow from the ureters.

Ileocollectomy: Excision of the ileum and part of the colon.

Ileocolostomy: Surgical anastomosis of the ileum to the colon.

Immunotherapy: Passive immunization of an individual by administration of performed antibodies actively produced in another individual (serum or gamma globulins). The term has also come to include the use of immunopotentiators, replacement of immunocompetent tissue (bone marrow), and infusion of specially-treated white blood cells.

Intensification therapy (also called reintensification therapy): This therapy has been proposed to prevent the return of the leukemic cell population. After one year of sustained, complete remission, the person undergoes the same intensive induction therapy as in the initial treatment period. The objective is bone marrow depression. After recovery of the bone marrow depression, the person continues on maintenance therapy for another year.

Interferon: Natural glycoprotein released by cells invaded by viruses or certain infectious agents; acts as a stimulant to noninfected cells, causing them to synthesize another protein with antiviral capabilities. Interferons are divided into these subsets, with each originating from a different cell and having distinctive chemical and biologic properties:

Alpha: produced by leukocytes in response to a viral infection

Beta: produced by fibroblasts in response to a viral infection

Gamma: produced by lymphoid cells in culture that is stimulated by a mitogen

Interleukin-2: Glycoprotein produced by helper T-cells that is an essential factor in the growth of T-cells and seems to induce the production of interferon. It is used as an anti-cancer drug in the treatment of a wide variety of solid tumors.

Intrathecal chemotherapy: Cytotoxic drugs injected into the cerebrospinal fluid (CSF), thus bypassing the blood-brain barrier.

Intravesical chemotherapy: Chemotherapy administered via a Foley catheter for the treatment of bladder cancer. The Foley is then usually clamped for a period of time and then emptied. This procedure delivers a high local concentration to the tumor area. Patients receiving this therapy require life-long cystoscopic surveillance for recurrent disease.

Jejunostomy: Surgical creation of a permanent opening between the jejunum and the surface of the abdominal wall.

Laminectomy: Excision of the lamina.

Laryngectomy: Partial or total removal of the larynx.

Laryngopharyngectomy: Excision of the larynx and pharynx.

LEEP: Loop Electrosurgical Excision Procedure uses an electrical current passed through a thin wire to loop to act as a knife to excise tissue.

Limp perfusion: Used in the treatment of malignant melanoma, where certain chemotherapeutic drugs (usually L-phenylalanine and DTIC) are instilled into the affected extremity by arterial perfusion. A pump system counteracts the normal arterial pressure, permitting a steady state of infusion, allowing the drugs to have the greatest effect at the disease site, usually performed after surgical removal of the bulk of the tumor mass.

Lingulectomy: Excision of the lingual of the left lung.

Lumpectomy: (tylectomy) Excision of only the local lesion in carcinoma of the breast.

Lymphadenectomy: Excision of one or more lymph nodes.

Lymphangiography: The film produced by lymphangiography, which is an x-ray of the lymphatic channels after introduction of a contrast medium.

Mandibulectomy: Excision of the mandible.

Mastectomy: Surgical removal of breast tissue.

Extended radical: Supraradical mastectomy; surgical removal of the internal mammary chain of lymph nodes, the entire involved breast, the underlying chest muscle, and the lymph nodes in the axilla.

Halstead radical: surgical en bloc removal of the entire involved breast, the underlying chest muscles, and the lymph nodes in the axilla.

Modified radical: surgical removal of the entire involved breast and many lymph nodes in the axilla. The underlying chest muscles are removed in part or are left in after removal of axillary lymph nodes.

Partial: removal of the tumor along with varying amounts of surrounding normal tissue (also called segmental, tylectomy, or quadrantectomy).

Simple (total): surgical removal of the entire involved breast with or without the underlying chest muscles, and axillary lymph node dissection is not done.

Subcutaneous: excision of the breast tissue with preservation of overlying skin, nipple, and areola.

Neck dissection: Excision of lymph nodes in neck area.

Modified radical neck: the same lymph nodes are removed as in a radical neck dissection; however one or more non-lymphatic structures are preserved

Radical neck dissection: includes the removal of all ipsilateral cervical lymph node groups (i.e., lymph nodes from levels I through V or submental, submandibular, cranial jugular, medical jugular, caudal jugular, dorsal cervical nodes along the accessory nerve and supraclavicular) and removal of the spinal accessory nerve, internal jugular vein and sternocleidomastoid muscle.

Selective neck dissection: preserves one or more lymph node groups routinely removed in a radical neck dissection

Nephrectomy: Surgical removal of a kidney and usually Gerota's fascia, perinephric fat; renal vein, and appropriate lymph nodes.

Nephroureterectomy: Removal of the kidney and ureter.

Omentectomy: Excision of all or part of the omentum.

Ommaya Reservoir: This device is a subcutaneous cerebrospinal fluid (CSF) reservoir that is implanted surgically under the scalp and provides access to the CSF through a burr hole in the scalp. Drugs are injected into the reservoir with a syringe, and the domed reservoir is then depressed manually to mix the drug within the CSF. This device eliminates the need for multiple lumbar punctures in the repeated administration of intrathecal chemotherapy.

Oophorectomy: Excision of one or both ovaries; also called ovariectomy.

Orchiectomy: Surgical removal of one or both testis.

Pancreatectomy: Excision of the pancreas.

Pancreaticoduodenostomy: Anastomosis of the pancreatic duct to a different site on the duodenum.

Pancreaticogastrostomy: Anastomosis of the pancreatic duct to the stomach.

Pancreaticojejunostomy: Anastomosis of the pancreatic duct to the jejunum.

Pancreaticoduodenectomy: Excision of the head of the pancreas and the adjacent portion of the duodenum.

Parotidectomy: Excision of a parotid gland.

Pelvic exenteration: Surgical removal of all reproductive organs and adjacent tissue.

Anterior: includes the bladder, distal ureters and genital organs with their ligamentous attachments and pelvic lymph nodes

Extended: includes pelvic blood vessels or bony pelvis

Posterior: includes the rectum and rectosigmoid with ligamentous attachments and pelvic lymph nodes

Total: includes removal of all pelvic contents and pelvic lymph nodes. A radical hysterectomy, pelvic lymph node dissection, removal of the bladder, distal ureters and genital organs with their ligamentous attachments.

Pharyngectomy: Excision of part of the pharynx.

Pharyngolaryngectomy: Excision of the pharynx and larynx.

Photodynamic therapy: A photosensitizing drug is exposed to specific wavelengths of light in the presence of oxygen.

Pneumonectomy: Excision of lung tissue.

Lobectomy: excision of a single lobe

Partial: excision of less than the entire lung

Total: excision of the entire lung

Proctectomy: Excision of the rectum.

Proctectomy: Excision of the rectum and lower colon.

Prostatectomy: Excision of the prostate.

Quadrantectomy: Removal of one-fourth of the tissue.

Rectosigmoidectomy: Excision of the rectosigmoid colon; also called a proctosigmoidectomy.

Salpingo-oophorectomy: Excision of the fallopian tube and ovary.

Sigmoidectomy: Excision of the sigmoid colon.

Sigmoidoscopy: Direct examination of the interior of the sigmoid colon.

Splenectomy: Excision of the spleen.

Stereotactic surgery: A surgical technique used in neurology in which precise localization of the target tissue is possible through use of three-dimensional coordinates, also known as stereotaxis surgery.

Thermal ablation: Destruction of tissue with heat.

Thyroidectomy: Excision of the thyroid gland.

Subtotal: more than two-thirds of the gland is removed

Total: the entire gland is removed

Total abdominal hysterectomy with bilateral salpingectomy and oophorectomy

(TAHBSO): Total removal of the uterus and the cervix performed through the abdominal wall rather than the vagina route, in addition, the fallopian tubes and the ovaries are removed bilaterally.

Trachelectomy: Excision of the uterine cervix.

Transurethral resection of prostate (TURP): Removal of a portion of the prostate gland by means of an instrument passed through the urethra. This procedure removes only enlarged prostatic tissue, as in benign prostatic hypertrophy. Normal prostatic tissue and the outer capsule are left intact.

Tylectomy: Lumpectomy.

Ureterosigmoidostomy: A surgically-created anastomosis of one or both ureters to the sigmoid colon. In this form of diversion of urinary flow, there is no need for an appliance because the urine flows into the colon which acts as a kind of reservoir.

Vulvectomy: Excision of the vulva.

Appendix J

CANCER ABSTRACTING TIPS

Start by reading the H & P to find the signs and symptoms associated with the illness, details of any workup that has already been performed for this malignancy, past history of other malignancies and smoking history. Review all scopes, surgeries, histology & cytology reports, pertinent labs, x-rays, scans, ultrasounds, MRIs etc. to aid in determining the primary site as well as to identify the extent of disease for staging. Review the discharge summary and use as a guide but follow coding rules and principles to ensure proper primary site, histology, behavior & grade codes are assigned. Some cases will be a clinical diagnosis made by the physician based on lab, x-ray etc. findings and may never be confirmed by biopsy.

1. PRIMARY SITE

Use the ICD-0 code manual to assign the correct code. Follow all general rules as well as site-specific rules in Multiple Primary and Histology Coding Manual to determine how many primaries/abstracts. Use all information available in the medical record to determine the site-try to be specific and code to the subsite if documentation is available.

2. HISTOLOGY/BEHAVIOR/GRADE

Use the correct ICD-0 code manual to assign the codes. All pathology and cytology reports for the case should be reviewed to determine the most accurate histology term. **Make this second paragraph**

Refer to and follow all general as well as site-specific rules in Multiple Primary and Histology Coding Manual to determine correct histology. **Make this first paragraph**

Be certain of the behavior code-in situ (2) or invasive (3). Review the in situ terms often and become familiar with them. If even a **tiny focus** of invasion is documented on the path report the case is no longer considered in situ but invasive.

Always code the highest grade/differentiation when two are given.

3. DIAGNOSTIC CONFIRMATION

Determine if the case was confirmed microscopically or **not** microscopically.

Positive **histology** specimen (tissue from biopsy, surgery, autopsy, D&C and bone marrow biopsy/aspiration, peripheral blood smear) always takes precedence over positive **cytology**.

4. DATE OF DIAGNOSIS

Use the first date of diagnosis whether clinically or histologically confirmed. If the physician states that in retrospect the patient had cancer at an earlier date, use the earlier date as the date of diagnosis. Use the date treatment was started as the date of diagnosis if the patient receives a first course of treatment before a diagnosis is documented. Use the actual date of diagnosis for an in

utero diagnosis, for cases diagnosed on January 1, 2009 or later. If the year of diagnosis cannot be identified, it must be approximated. In that instance, the month and day are unknown.

5. TREATMENT

First course of therapy is all treatment planned at initial diagnosis- sometimes this may take up to a year or more; treatment means cancer directed therapy that modifies, controls, removes or destroys primary or metastatic cancer tissue. Treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence “Active surveillance” is a form of planned treatment for some patients; its use is coded in the new RX Summ-Treatment Status item. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts or the physician recommends no treatment be given. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities. If the cancer progresses during treatment and the treatment plan is changed it is no longer first course of therapy- it becomes subsequent therapy; if the patient becomes disease free and then has a recurrence the treatment is always considered subsequent therapy.

Appendix K

GEOCODES

Alphabetical List

- 585 Abyssinia
- 629 Aden
- 583 Afars and Issas
- 638 Afghanistan
- 500 Africa
- 570 Africa, East
- 510 Africa, North
- 540 Africa, South
- 545 Africa, Southwest
- 530 Africa, West
- 580 African Coastal Islands (previously included in 540)
- 037 Alabama
- 091 Alaska
- 481 Albania
- 224 Alberta
- 513 Algeria
- 250 America, Central
- 265 America, Latin
- 260 America, North (use a more specific term; see also North America)
- 300 America, South
- 121 American Samoa
- 611 Anatolia
- 641 Andaman Islands
- 443 Andorra
- 520 Anglo-Egyptian Sudan
- 543 Angola

245 Anguilla
665 Annam
245 Antigua
245 Antilles, NOS
245 Antilles, Netherlands
625 Arab Palestine (former)
629 Arabia, Saudi
629 Arabian Peninsula
365 Argentina
087 Arizona
071 Arkansas
611 Armenia (Turkey)
633 Armenia (U.S.S.R.)
245 Aruba
600 Asia, NOS
680 Asia, East
640 Asia, Mid-East
611 Asia Minor, NOS
610 Asia, Near-East
650 Asia, Southeast
620 Asian-Arab countries
634 Asian Republics of the former U.S.S.R.
109 Atlantic/Caribbean area, other U.S. possessions
100 Atlantic/Caribbean area, U.S. possessions
711 Australia
711 Australia New Guinea
436 Austria
633 Azerbaijan
633 Azerbaidzhan S.S.R.
445 Azores

B

247 Bahamas, The
629 Bahrain
443 Balearic Islands
463 Baltic Republic(s), NOS
463 Baltic States, NOS
645 Bangladesh
245 Barbados
245 Barbuda
545 Basutoland
431 Bavaria
545 Bechuanaland
457 Belarus
541 Belgian Congo
433 Belgium
252 Belize
539 Benin
246 Bermuda
456 Bessarabia
643 Bhutan
539 Bioko (Fernando Poo)
452 Bohemia
355 Bolivia
545 Bophuthatswana
673 Borneo
453 Bosnia-Herzegovina
545 Botswana
341 Brazil
226 British Columbia
331 British Honduras

245 British Virgin Islands
245 British West Indies, NOS
671 Brunei
454 Bulgaria
520 Burkina Faso (Upper Volta)
649 Burma (see Myanmar)

C

543 Cabinda
245 Caicos Islands
097 California
663 Cambodia
539 Cameroon
220 Canada
110 Canal Zone
443 Canary Islands
122 Canton Islands
545 Cape Colony
445 Cape Verde Islands
245 Caribbean, NOS
245 Caribbean Islands, other
123 Caroline Islands
711 Cartier Islands
633 Caucasian Republics of the former U.S.S.R.
245 Cayman Islands
500 Central Africa, NOS
539 Central African Republic
250 Central America
499 Central Europe, NOS
060 Central Midwest States
647 Ceylon (see Sri Lanka)

520 Chad
401 Channel Islands (British)
361 Chile
681 China, NOS
665 China, Cochin
682 China, People's Republic of
684 China, Republic of
723 Christmas Island
545 Ciskel
711 Cocos (Keeling) Islands
311 Colombia
083 Colorado
540 Comoros
226 Columbia, British
022 Columbia, District of
539 Congo, NOS
539 Congo-Brazzaville
541 Congo, Leopoldville
541 Congo, Belgian
539 Congo, French
541 Congo Kinshasa
007 Connecticut
124 Cook Islands
441 Corsica
256 Costa Rica
539 Cote d'Ivoire (Ivory Coast)
471 Crete
453 Croatia
241 Cuba
245 Curacao

495 Cyprus

517 Cyrenaica

452 Czechoslovakia

452 Czech Republic

D

539 Dahomey

453 Dalmatia

017 Delaware

425 Denmark

022 District of Columbia

583 Djibouti

449 Dobruja

245 Dominica

243 Dominican Republic

673 Dutch East Indies

332 Dutch Guiana

E

570 East Africa

680 East Asia

431 East Germany

673 East Indies, Dutch

645 East Pakistan

499 Eastern Europe, NOS

345 Ecuador

519 Egypt

410 Eire

254 El Salvador

125 Ellice Islands

122 Enderbury Islands

401 England

500 Equatorial Africa, NOS
539 Equatorial Guinea (Spanish Guinea)
585 Eritrea
458 Estonian S.S.R. (Estonia)
585 Ethiopia
499 Europe, NOS
470 Europe, other mainland

F

425 Faroe (Faeroe) Islands
300 Falkland Islands
431 Federal Republic of Germany
123 Federal States of Micronesia
539 Fernando Poo
721 Fiji
429 Finland
035 Florida
684 Formosa
721 Fortuna
441 France
545 Free State (Orange Free State)
539 French Congo
333 French Guiana
725 French Polynesia
583 French Somaliland
530 French West Africa, NOS
245 French West Indies
721 Futuna

G

539 Gabon
345 Galapagos Islands

539 Gambia, The
631 Gaza Strip
033 Georgia
633 Georgia (U.S.S.R.)
431 German Democratic Republic
430 Germanic countries
431 Germany
431 Germany, East
431 Germany, Federal Republic of
431 Germany, West
539 Ghana
485 Gibraltar
125 Gilbert Islands
471 Greece
210 Greenland
245 Grenada
245 Grenadines, The
245 Guadeloupe
126 Guam
251 Guatemala
401 Guernsey
331 Guiana, British
332 Guiana, Dutch
333 Guiana, French
539 Guinea
539 Guinea-Bissau (Portuguese Guinea)
539 Guinea, Equatorial Guinea, New (see New Guinea)
539 Guinea, Portuguese
331 Guyana

H

242 Haiti
099 Hawaii
432 Holland
253 Honduras
252 Honduras, British
683 Hong Kong
475 Hungary

I

421 Iceland
081 Idaho
061 Illinois
641 India
045 Indiana
673 Indies, Dutch East
660 Indochina
673 Indonesia
053 Iowa
637 Iran
627 Iraq
620 Iraq-Saudi Arabian, Neutral Zone
410 Ireland (Eire)
410 Ireland, NOS
404 Ireland, Northern
410 Ireland, Republic of
400 Isle of Man
631 Israel
583 Issas
447 Italy
539 Ivory Coast

J

244 Jamaica
423 Jan Mayen
693 Japan
673 Java
401 Jersey
631 Jewish Palestine
127 Johnston Atoll
625 Jordan
453 Jugoslavia

K

539 Kameroon
663 Kampuchea
065 Kansas
634 Kazakh S.S.R.
634 Kazakhstan
047 Kentucky
575 Kenya
634 Kirghiz S.S.R.
122 Kiribati
695 Korea
695 Korea, North
695 Korea, South
629 Kuwait
634 Kyrgystan
634 Kyrgyz

L

221 Labrador
661 Laos
420 Lapland, NOS

265 Latin America, NOS
459 Latvia
459 Latvian S.S.R.
623 Lebanon
245 Leeward Island, NOS
545 Lesotho
539 Liberia
517 Libya
437 Liechtenstein
128 Line Islands, Southern
461 Lithuanian S.S.R.
461 Lithuania
073 Louisiana
434 Luxembourg

M

686 Macao
686 Macau
453 Macedonia
555 Madagascar
445 Madeira Islands
002 Maine
555 Malagasy Republic
551 Malawi
671 Malay Peninsula
671 Malaysia
640 Maldives
520 Mali
491 Malta
224 Manitoba
129 Mariana Islands

221 Maritime Provinces, Canada
131 Marshall Islands
245 Martinique
021 Maryland
005 Massachusetts
520 Mauritania
540 Mauritius
540 Mayotte
490 Mediterranean Islands, Other
721 Melanesian Islands
610 Mesopotamia, NOS
230 Mexico
041 Michigan
723 Micronesian Islands
640 Mid-East Asia
132 Midway Islands
052 Minnesota
240 Miquelon
039 Mississippi
063 Missouri
456 Moldavia
456 Moldavia S.S.R. (U.S.S.R.)
456 Moldova
441 Monaco
691 Mongolia
056 Montana
453 Montenegro
245 Montserrat
452 Moravia
511 Morocco

080 Mountain States
553 Mozambique
629 Muscat
649 Myanmar (see Burma)
N
545 Namibia
133 Nampo-shoto, Southern
545 Natal
723 Nauru
610 Near-East Asia
067 Nebraska
643 Nepal
432 Netherlands
245 Netherlands Antilles
332 Netherlands Guiana
085 Nevada
245 Nevis
221 New Brunswick
725 New Caledonia
001 New England
673 New Guinea, not Australian and Northeast
711 New Guinea, Australian
711 New Guinea, Northeast
003 New Hampshire
721 New Hebrides
008 New Jersey
086 New Mexico
011 New York
715 New Zealand
221 Newfoundland

255 Nicaragua
520 Niger
531 Nigeria
715 Niue
711 Norfolk Island
510 North Africa, NOS
___ North America (use more specific term)
240 North American islands
671 North Borneo (Malaysia)
025 North Carolina
040 North Central States
054 North Dakota
711 North East New Guinea
695 North Korea
010 North Mid-Atlantic States
499 Northern Europe, NOS
404 Northern Ireland
129 Northern Mariana Islands
050 Northern Midwest States
549 Northern Rhodesia
225 Northwest Territories (Canada)
423 Norway
998 Not United States, NOS
221 Nova Scotia
227 Nunavut
551 Nyasaland
O
720 Oceania
043 Ohio
075 Oklahoma

629 Oman
223 Ontario
545 Orange Free State
095 Oregon
403 Orkney Islands

P

120 Pacific area, U.S. possessions
090 Pacific Coast States
720 Pacific Islands
___ Pacific Islands, Trust Territory of the (use more specific term)
639 Pakistan
645 Pakistan, East
639 Pakistan, West
139 Palau (Trust Territory of the Pacific Islands)
625 Palestine, Arab
631 Palestine, Jewish
631 Palestine, NOS
631 Palestinian National Authority-- PNA
257 Panama
711 Papua New Guinea
371 Paraguay
014 Pennsylvania
629 People's Democratic Republic of Yemen
682 People's Republic of China
637 Persia
629 Persian Gulf States, NOS
351 Peru
675 Philippine Islands
675 Philippines
122 Phoenix Islands

725 Pitcairn

725 Pitcairn Islands

451 Poland

725 Polynesian Islands

445 Portugal

539 Portuguese Guinea

224 Prairie Provinces, Canada

221 Prince Edward Island

543 Principe

101 Puerto Rico

Q

629 Qatar

222 Quebec

R

684 Republic of China

545 Republic of South Africa

540 Reunion

006 Rhode Island

547 Rhodesia

549 Rhodesia, Northern

547 Rhodesia, Southern

539 Rio Muni

440 Romance-language countries

449 Romania

449 Roumania

577 Ruanda

449 Rumania

455 Russia, NOS

457 Russia, White

455 Russian Federation (former U.S.S.R.)

455 Russian S.F.S.R.

577 Rwanda

134 Ryukyu Islands

S

520 Sahara, Western (Spanish)

121 Samoa, American

725 Samoa, Western

245 St. Christopher-Nevis

540 St. Helena

245 St. Kitts

245 St. Lucia

240 St. Pierre

245 St. Vincent

447 San Marino

543 Sao Tome

447 Sardinia

224 Saskatchewan

629 Saudi Arabia

420 Scandinavia

403 Scotland

539 Senegal

453 Serbia

540 Seychelles

403 Shetland Islands

651 Siam

447 Sicily

539 Sierra Leone

643 Sikkim

671 Singapore

450 Slavic countries

453 Slavonia
452 Slovak Republic
452 Slovakia
453 Slovenia
721 Solomon Islands
581 Somali Republic
581 Somalia
581 Somaliland, French
540 South Africa
545 South Africa, Republic of
545 South Africa, Union of
300 South America
380 South American Islands
026 South Carolina
055 South Dakota
695 South Korea
020 South Mid-Atlantic States
545 Southwest Africa
650 Southeast Asia
030 Southeastern States
499 Southern Europe, NOS
128 Southern Line Islands
070 Southern Midwest States
133 Southern Nampo-shoto
547 Southern Rhodesia
629 Southern Yemen
___ Soviet Union (see individual republics)
443 Spain
520 Spanish Sahara
647 Sri Lanka (see Ceylon)

520 Sudan, Anglo-Egyptian Sudan)

520 Sudanese countries

673 Sumatra

332 Surinam

423 Svalbard

135 Swan Islands

545 Swaziland

427 Sweden

435 Switzerland

621 Syria

T

634 Tadjik S.S.R.

684 Taiwan

634 Tajikistan

571 Tanzania

571 Tanzanyika

571 Tanganyika

031 Tennessee

077 Texas

651 Thailand (Siam)

685 Tibet

245 Tobago

539 Togo

136 Tokelau Islands

725 Tonga

665 Tonkin

625 Trans-Jordan

545 Transkei

545 Transvaal

449 Transylvania

245 Trinidad

517 Tripoli

517 Tripolitania

629 Trucial States

515 Tunisia

611 Turkey

634 Turkmen S.S.R.

634 Turkmenistan

245 Turks Islands

125 Tuvalu

U

573 Uganda

456 Ukraine

456 Ukrainian S.S.R.

404 Ulster

545 Union of South Africa

Union of Soviet, Socialist Republics (U.S.S.R.) (see individual republics)

629 United Arab Emirates

519 United Kingdom

400 United Kingdom

000 United States

102 U.S. Virgin Islands

999 Unknown

520 Upper Volta

375 Uruguay

579 Urundi

084 Utah

634 Uzbekistan

634 Uzbek S.S.R.

V

- 721 Vanuatu
- 440 Vatican City
- 545 Venda
- 321 Venezuela
- 004 Vermont
- 665 Vietnam
- 245 Virgin Islands (British)
- 102 Virgin Islands (U.S.)
- 023 Virginia

W

- 137 Wake Island
- 402 Wales
- 449 Wallachia
- 721 Wallis
- 093 Washington (state)
- 022 Washington, D.C.
- 530 West Africa, NOS
- 539 West African countries, other
- 631 West Bank
- 431 West Germany
- 245 West Indies, NOS (see individual islands)
- 639 West Pakistan
- 024 West Virginia
- 499 Western Europe, NOS
- 520 Western (Spanish) Sahara
- 725 Western Samoa
- 457 White Russia
- 245 Windward Islands
- 051 Wisconsin

082 Wyoming

Y

629 Yemen

629 Yemen, People's Democratic Republic of

453 Yugoslavia (former Yugoslavia region)

225 Yukon Territory

Z

541 Zaire

549 Zambia

571 Zanzibar

547 Zimbabwe

Appendix L

EFFECTIVE DATES FOR CANCER REGISTRIES

These are the official dates of implementation for various coding references; remember that your registry may have varied from these dates.

STAGING AND CODING

International Classification of Diseases for Oncology

First edition.....1976-1991
 Second edition.....1992-2000
 Third edition.....2001-

American Joint Committee of Cancer

TNM Staging System

Second edition.....1983 (breast only**) – 1988
 Third edition.....1989-1992 (all sites***)
 Fourth edition.....1993-1997
 Fifth editionU.....1998-2002
 Sixth edition.....2003-2009
 Seventh edition.....2010-

SEER Extent of Disease Manual

First edition.....1988-1991
 Second edition.....1992-1997
 Third editionU.....1998-

Summary Staging

Summary Staging Guide.....1977-2000

SEER Summary Staging

Manual 2000v.....2001-

Collaborative Staging System.....2004† -2009

Collaborative Staging Version 2.....2010-
 Multiple Primary and Histology Coding Rules...2007-

CANCER PROGRAM STANDARDS

Cancer Program Manual 1986.....1986-1990

Cancer Program Manual 1991.....1991-1995

Cancer Program Standards

(Volume I).....1996-2003 (June)‡

Revised Cancer Program Standards

(Volume I) July 2003‡ -

Data Collection

Data Acquisition Manual1988-1994

1st revision 10/89

2nd revision 10/90

Data Acquisition Manual, revised1994-1995

Registry Operations and Data Standards

(ROADS Manual).....1996-2002

2-digit surgery codes.....1988-1997

“New” surgery codesU.....1998-2002

Facility Oncology Registry

Data Standards (FORDS)U2003-

SEER Program Manual

First edition.....1988-1991

Second edition.....1992-1997

Third editionU.....1998-2003†

Third edition revision 1

(Treatment codes only)U.....2003-

SEER Self-instructional Manuals for Cancer Registrars,

Book 8: Antineoplastic Agents,

Third editionU.....1993-

- * Effective with cases diagnosed on or after January 1 of the initial stated year and ending with cases diagnosed on December 31 of the closing year
- ** TNM staging of breast cancer was required as of 1982, prior to the second edition
- *** The commission of Cancer urged implementation of TNM staging of all sites as of 1989 but did not require it until 1991.
- † SEER permits treatment codes for cases diagnosed in 2003 to be submitted in either Third edition or Third Edition Revision 1 format. Contact SEER or your SEER central registry for further information.
- ‡ Proposed date as of 01/2003
- U Updated pages/errata were released after publication. Contact the publishing organization’s Web site for a copy.

Appendix M

HEALTH CARE FACILITIES

Cancer Registry Contacts

Arkansas Methodist Hospital

900 Kingshighway - Paragould, AR 72450 Fax: (870) 239-7110

Linda Northen, RHIT – Director HIM

(870) 239-7065

Linda.northen@arkansasmethodist.org

Arkansas Tech University

402 West O St. Dean 201 - Russellville, AR 72801 Fax: (501) 964-9504

Chris Merle

(501) 968-0364

cmerle@atu.edu

Ashley Co. Medical

P.O. Box 400 – 1015 Unity Road – Crossett, AR 71635 – Fax: (870) 364-1404

Kayla Hill-Supervisor

(870) 364-1242

Kayla.hill@acmconline.org

Baptist Health (LR, NLR, Arkadelphia, Heber Springs, Malvern, Stuttgart)

9601 Interstate 630, Exit 7 – Little Rock, AR 72205

Erin Propst

Doug Weeks

Kelly Savoy – Director Medical Rec

(501) 202-2084

Kelly.Savoy@baptist-health.org

Kathy Blundell

(903) 306-0864 (home) & (903) 490-4445 (cell)

Please call home # first.

Katherine.blundell@baptist-health.org

Susan Paxton

(903) 832-7137 (home) (903) 280-1024 (cell)

Please call home # first.

spaxton@windstream.net

susan.paxton@baptist-health.org

Baptist Health - Forrest City

1601 Newcastle – Forrest City, AR 72335 - Fax: (870) 261-0440

Penny Davis-Supervisor

(870) 261-0439

Penny_Davis@chs.net

Baxter Regional

624 Hospital Drive – Mountain Home, AR 72653- Fax: Fax (870) 425-2074

Cathey Hamel- Supervisor

(870) 508-1269

Bradley Medical

Warren, AR 71671 – Fax: (870) 226-4323

Jennifer Stroud-Supervisor

(870) 226-4322

jstroud@bcmed.org

CARTI

P.O. Box 55050 – Markham and University – Little Rock, AR 72215 – Fax: (501) 663-1746

CEO-Jan Berford

(501) 296-3403

Beth Coleman

(501) 296-3403

bcoleman@carti.com

Dana Ray

(501) 296-3404

dray@carti.com

Donna Laster

(501) 296-3408

(501) 663-0503 (Fax)

dlaster@carti.com

Melody Knight

(501) 296-3433

mknight@carti.com

Cora Whittemore

(501) 296-3402

whittemore@carti.com

Dan Summers-Supervisor

dsummers@carti.com

Chambers Medical Hospital

Hwy 10 E. Detroit Street – Danville, AR 72833

Nita Andrews

(479) 495-6273

(479) 495-6347 (Fax)

nitaandrews@chambers.com

Amber Bottoms-Supervisor

(479) 495-6258

(479) 495-6299 (Fax)

amberbottoms@chambershospital.com

Chicot Memorial

P.O. Box 512-2729 Hwy. 65 & 82 – Lake Village, AR 71653 – Fax: (870) 265-9309

Sharon Walker – HIM Director

(870) 265-5351 Ext 316

walkers@chicotmemorial.com

Bonnie Bush-Supervisor

(870) 265-5351 Ext: 325

bushb@chicotmemorial.com

Columbia Medical Park Hospital (Wadley Medical Center at Hope)

2001 S. Main – Hope, AR 71801 – Fax: (870) 722-7131

Lanelle Bell-Dir. Med. Records

(870) 722-2446

lbell@shiloh-corp.com

Community Medical Center Izard Co.

P.O. Box 438 – 103 Grasse Street – Calico Rock, AR 72519

Kim Skidmore-Supervisor

(870) 297-2404

kim.skidmore@cmcofic.org

Conway Regional

2302 College Avenue – Conway, AR 72032 – Fax: (501) 450-2103

Wendy Wiley (Director)

(501) 450-2132

(501) 513-5590

wwiley@conwayregional.org

Betty Belleton, CTR, BA

(501) 213-5988 – cell

(501) 961-1731 – home

belletonbettyej@uams.edu

Mary 'Cissy' Carrigan, CTR
(501) 213-5986 –cell
(501) 833-6023 –home
carriganmaryc@uams.edu

Crittenden Memorial Hospital

P.O. Box 2248 – 200 Tyler Street – West Memphis, AR 72303
Lisa Bailey-Supervisor
870-735-1500
[Lisa_bailey@cmhwm.org](mailto:lisa_bailey@cmhwm.org)

Cross Ridge Community Hospital

P.O. Box 590 – Wynne, AR 72396 – Fax: (870) 208-2104
Penny Chappell-Supervisor
(870) 238-3300 x 2146
pchappell@sbrmc.org

Dallas County Medical Center

201 Clifton Street – Fordyce, AR 71742 –Fax: (870) 352-7129
Frances Hartman-Director
(870) 352-3159
fhartman@dallascountymedicalcenter.com

Dardanelle Hospital (River Valley Med Ctr)

P.O. Box 578-200 N. 3rd – Dardanelle, AR 72834 – Fax: (479) 229-6166
Tonya Mays-Supervisor
(479) 229-6170
tonya.mays@dardanellehospital.com

Delta Memorial

300 E. Pickens Street – Dumas, AR 71639 – Fax: (870) 382-8153
Jenny Guthrie - Director
(870) 382-8245
Fax# (870) 382-8153
medrec@deltamem.org

DeQueen Regional Medical Center

1306 West Collin Raye Drive DeQueen, AR 71832 – Fax: (870) 642-7797
Shirley Clardy-Supervisor
(870) 642-7572 Ext: 308
No E-mail

Dewitt City Hospital

C/O Medical Records
P.O. Box 32 – 1641 Whitehead Drive – Dewitt, AR 72042 – Fax: (870) 946-4344

Ellen Dillion
(870) 946-3571 x 259
edillion@centurytel.net

Charlotte Hackney-Supervisor
(870) 233-2159
chackney@centurytel.net

Drew Memorial

778 Scogin Drive – Monticello, AR 71655 – Fax: (870) 460-3521
Rhonda Brown – Director Med.Rec.
(870) 460-3532
rbrown@drewmemorial.org

First Care Family Doctors, West

775 E. Douglas – Prairie Grove, AR 72753 – Fax: (479) 846-5056
Melinda Dobbs – Officer Manager
(479) 846-5005 Ext 2
Melinda.dobbs@mana.med

Five Rivers Medical Center

2801 Medical Center Drive – Pocahontas, AR 72455 – Fax: (870) 892-6286
Lona Dorman-Supervisor
(870) 892-6240
ldorman@FRMCAr.com

Fulton County Hospital

P.O. Box 517 – 679 N. Main – Salem, AR 72576 – Fax: 870-895-2717
Nancy Cole-Supervisor
(870) 895-2691
njcole@fultoncountyhospital.org

Garland County Community College

101 College Drive – Hot Springs, AR 71913 – Fax: (501) 760-4183
Susan Wallace
(501) 760-4293
swallace@admin.gccc.cc.ar.us

Valerie Bond
(501) 760-4294
vbond@admin.gccc.cc.ar.us

Great Rivers Medical Center

1520 N. Division – Blytheville, AR 72315 – Fax: (870) 838-7487
Michelle King – HIM Director

Michelle.king@greatrivermc.org

Debra Walker-Supervisor

(870) 838-7168

Dwalker2@allianceimaging.com

Harris Hospital

1205 McLain – Newport, AR 72112 – Fax: 870-512-3484

Shelia Drake-HIM Director

(870) 512-3052

Shelia_drake@chs.net

Healthpark Hospital

1636 Higdon Ferry Road – Hot Springs, AR 71973 – Fax: (501) 520-3706

Kathy Webber- Registrar

(501) 622-2129

kathy.webber@mercy.net

Helena Regional Medical

P.O. Box 788 – 1801 Martin Luther King Drive – Helena, AR 72342 – Fax: (870) 816-3690

Jackie Scott

Shirley Ingram – HIM Clerk

(870) 816-3681

(870) 816-3686

Jacqueline_scott@chs.net

Highland Oncology

22 West Colt Square – Fayetteville, AR 72703

Laurie Gibbs

(479) 361-5847

lgibbs@hogonc.com

Hope Cancer Resources (formerly NARTI)

5835 W. Sunset – Springdale, AR 72762 – Fax: (479) 361-9104

Bill Heburn-Interim CEO

Sherry Tuck

(479) 361-5847 Ext 19

sherry.tuc@hopecancerresources.org

Sandy Prince-Supervisor

(479) 361-5847 Ext 12

sprince@narti.org

Hospice Angels

3801 Camden Road, Chapel Village, Suite 12, Pine Bluff AR 71603 – Fax: (870) 534-4884

Susan Padgett
(870) 534-4847
padgetthospice@cablelynx.com

Vanessa Jensen
(870) 534-4847
Vanessa.hospice@cablelynx.com

Hot Springs Medical Group* Heritage Physicians Group**

#1 Mercy Lane #101 – Hot Springs, AR 71913

Christine
(501) 627-1800
501-609-2253

Howard County Memorial Hospital

8th & Leslie – P.O. Box 381 – Nashville, AR 71852

Carolyn Williams-Supervisor
870-845-4400 Ext 6992
carolynw@howardmemorial.com

Elekta

Charlette Bellefeuille
3208 Bugle Drive –
Pine Bluff, AR 71603
(870) 879-3651
(Fax) 870-879-3671
cbellefeuille@elekta.com

Kathy Dunaway
304 Wilburn Heights
Central City, AR 72914
1-479-434-4286
kathy_dunaway@yahoo.com
kdunaway@elekta.com

Jefferson Regional Medical Center

1515 W. 42nd Street – Pine Bluff, AR 71601 – Fax: (870) 541-7938

Loreene Hale, CTR
(870) 541-7306
Loreene.Hale@jrmc.org

Elijah Blackstone, HIM Mgr – Supervisor
(870) 541-8689
Elijah.blackstone@jrmc.org

John L. McClellan Memorial Hospital (LR VA)

4300 West 7th Street – Little Rock, AR 72205 - Fax: (501) 257-6915

Glynis White – Dir of CR

(501) 257-6914

glynis.white@va.gov

Jennifer Fielding

(501) 257-6912

Jennifer.fielding@va.gov

Debra Reed

(501)-257-6913

Debra.Reed2@va.gov

Michael P. Winn, Director

Marie Lisko-Supervisor

(501) 257-6816

marie.lisko@va.gov

Johnson County Regional Hospital

P.O. Box 738 – 1100 E. Poplar – Clarksville, AR 72830 – Fax: (479) 754-5349

Connie Young-Supervisor

(479) 754-5315

medrec2@arkansas.net

Lawrence Memorial

P.O. Box 839 – 1309 W. Main – Walnut Ridge, AR 72476 – Fax: (870) 886-5534

Darlene Johann, RHIT-Supervisor

(870) 886-1243

djohann@lawrencehealth.net

Little River Memorial Hospital

451 West Locke Street-Ashdown, AR 71822 - Fax: (870) 898-4172

Kayla Chandler -Supervisor

(870) 898-5011 Ex. 3147

Records.rlmh@sbcglobal.net

Little Rock Air Force Base

314th MDG/SGSAL

501-987-7464

Magnolia Hospital

P.O. Box 629 – Magnolia, AR 71754 Fax: 870-235-3223

Melissa Rogers

870-235-3420

McGehee – Desha County Hospital

P.O. Box 351 – 900 S. Third – McGehee, AR 71654 – Fax: (870) 222-5846

Kay Jones-Supervisor

(870) 222-2136

kjones@mcgeeehospital.org

Medical Center of South Arkansas

700 W. Grove Street – El Dorado, AR 71730 – Fax: (870) 863-2002

Barbara Murchison – CR Coord

(870) 863-2020

barbara.murchison@triadhospitals.com

Jeanette Worth

(870) 864-3575

Jeanette.worth@triadhospitals.com

Sandra Miller-Supervisor

(870) 864-2150

sandra.miller@triadhospitals.com

Mena Medical

311 N. Morrow – Mena, AR 71953 – Fax: (479) 394-4577

Connie Hernandez-Supervisor

(479) 394-6100 x 2356

Connie.mary@menaregional.com

Mercy Hospital – Turner Hospital

801 W. River – Ozark, AR 72949 – Fax: (501) 667-4791

Dianna Wilson – CR Coordinator

(479) 314-6621

diannawilson@mercy.net

Mercy Hospital of Scott County

P.O. Box 2230 – Hwy. 71 & 80 – Waldron, AR 72958 – Fax: (479) 637-3523

Dianna Wilson – CR Coordinator

(479) 314-6621

diannawilson@mercy.net

Mercy Medical Center

2710 Rife Medical Lane – Rogers, AR 72758 – Fax: 479-338-4838 – Ph 479-338-2847

Kim Leach-HIM Manager

479-338-3842

Kim.leach@mercy.net

Diane Cleveland, RHIT, CTR
(Contractor-K-Force)
800-397-9814 x 3486
K-Force fax: 817-788-0097
dcleveland@kforce.com

National Park Medical

1910 Malvern Avenue – Hot Springs, AR 71901 – Fax: (501) 321-9948
Beth Loveday
(501) 620-2721
Elizabeth.loveday@NPMCHS.com

Tonya Clark –Supervisor-HIM Dir.
Jerry Mabry-CEO
(501)-620-2527
tonya.clark@capellahealth.com

Northeast Arkansas Baptist Memorial Hospital

3024 Stadium Boulevard – Jonesboro, AR 72401 – Fax: (870) 972-7024
Pat Williams
(870) 972-7490
Pat.williams@bmhcc.org

Paul Betz – Administrator
Cynthia Teague-Supervisor
cynthia.teague@bmhcc.org

North Arkansas Regional Medical

620 N. Main – Harrison, AR 72601 – Fax: (870) 414-4949
Claudine Carrera, Director of HIM
870-414-4181
Claudine.carrera@narmc.com

Tim Hill
870-414-5155
Mercy Paris
500 E. Academy – Paris, AR 72855 – Fax: (479) 963-6155
Marilyn Frazier
(479) 963-6101
Marilyn.frasier@mercy.net

Shelly Caldwell
(479) 963-6101
Shelly.caldwell@mercy.net

Dianna Wilson – CR Coordinator

(479) 963-6101

diannawilson@mercy.net

North Metro Medical Center (Formerly Rebsamen)

1400 Braden Street – Box 159 – Jacksonville, AR 72076 – Fax: (501) 982-3055

Mike Schimming-CEO

(501) 985-7490

Northwest Medical Center of Benton & Washington County

POB 1405, 3000 Medical Center Parkway, Bentonville, AR – Fax: 479-2930

609 W. Maple Avenue, Springdale, AR – Fax: 479-2930

Diane Watters-Coding Manager

479-747-4505

Anne VanDussen-Davis, Cancer Registry

Ouachita County Medical

P.O. Box 797 – 638 California Street – Camden, AR 71701 – Fax: (870) 836-1460

Sharon Veith-Supervisor

(870) 836-1386

sveith@ouachitamedcenter.com

Ozark Health Medical Center

P.O. Box 206 – Clinton, AR 72031 – Fax: (501) 745-9479

Sheila Smith-Supervisor

(501) 745-9481

sheila.smith@myozarkhealth.com

Petit Jean Home Health

1401 East Broadway – Morrilton, AR 72110

Lydia Hoyt

(800) 337-2599

lhoyt@stvincenthealth.com

Piggott Community Hospital

1206 Gordon Duckworth Drive – Piggott, AR 72464 – Fax: (870) 598-3240

Janet Watson-Supervisor

(870) 598-3881 x 731

janwatson@centurytel.net

Pike County Memorial Hospital

315 East 13th Street – Murfreesboro, AR 71958- Fax: (870) 285-3305

Kay Wadley-Supervisor

903-293-0609

dwadley@paperlessimagingplus.com

Registry Partner's Inc.

706 Hillview Street – Texarkana, TX 75501 – Fax: (972) 692-6867
Crystal McDaniel, CTR
(903) 276-2532
cmcdaniel@cableone.net

Saline Memorial

#1 Medical Park Drive – Benton, AR 72015 – Fax: (501) 776-6078
Cindy Bullock-Supervisor
(501) 776-6079
cbullock@scmc.com

Debra Adams
(501) 776-6028
deb.adams@salinememorial.org

St. Vincent's - Morrilton

4 Hospital Drive – Morrilton, AR 72110 – Fax: (501) 977-2422
Molly Fisher
501-977-2300
mfisher@stvincenthealth.com

Tamika Savage – Cancer Registrar
(501) 552-3636
TamikaSavage@catholicealth.net

St. Bernard's Regional – Cancer Treatment Center

225 E. Jackson #45 – Jonesboro, AR 72401 – Fax: (870) 972-1610
Alicia Storey, RT
(870) 273-4487
astorey@sbrmc.org

Teresa Adams - abstractor
(870) 351-5769
aadams@sbrmc.org

Mercy Medical – Fort Smith

P.O. Box 17000 – 7301 Rogers – Fort Smith, AR 72917 Fax: (479) 452-0474
Diana Wilson. RHIA, CTR – CR Supv.
(479) 314-6621
Diana.wilson@.mercy.net

Marilyn Frazier HIM Dir.
(479) 314-6266

Mercy Medical Cancer Center – Hot Springs

1455 Higdon Ferry Road, Suite C – Hot Springs, AR 71913 – Fax: (501) 622-2363

Kathy Webber, CTR

(501) 622-2129

Kathy.Webber@mercy.net

Sandra Blanton

(501) 622-1965

Sandra.Blanton@mercy.net

Kay McHugh, Operation Mgr- Supv.

Kay.Mchughs@mercy.net

Tim Johnsen

Vicky Sanders, Executive Director

Philip Ruth-Director of Medical Imaging and Radiation Therapy

St. Mary's Regional Medical

C/O Medical Records – 1808 W. Main – Russellville, AR 72801 – Fax: (479) 964-9488

Anita Schwander-Supervisor

(479) 967-0719

Anitta.schwander@saintmarysregional.com

Paula Page

479-964-9110

Wendell Vanes, CFO

479-968-2841

St. Vincent's Medical Center

#2 St. Vincent Circle – Little Rock, AR 72205 – Fax: (501) 552-4308

Erin Holloway-Supervisor

501-552-3639

EHolloway@stvincenthealth.com

David Hall, MD

501-552-3000

Tamika Savage

(501) 552-3636

TamikaSavage@catholichealth.net

Senior Specialties Hospice

1310 West Main, Suite A – Russellville, AR 72801 – Fax: (501) 587-5969

Latricia James

(501) 967-9300

Dianna McGuire
(501) 967-9300 or (501) 443-4301 x 5739

South Mississippi County Regional Medical Center

P.O. Box 607 – Osceola, AR 72370 – Fax: (870) 563-7148
Faith Reeves, RHIT
(870) 563-7169
Faith.reeves@smcregional.com

Sparks Health System

P.O.Box 247 – Fort Smith, AR 72902-0247 – Fax: (479) 709-7423
Lori Lewis – Director
479-441-4054
llewis@sparks.org

Carol Dougherty
(479) 709-7474
cdougher@sparks.org

Kathleen Ridenour-Supervisor
479-709-1919
kridenou@sparks.org
D. Melody Trimble-CEO

Stone County Medical

P.O. Box 510 – Hwy. 14 E. – Mountain View, AR 72560 – Fax: (870) 269-8884
Jamie Smotherman
870-262-6206
jsmotherman@wrmc.com

Ron Wright
870-868-1945
rwright@wrmc.com

The Surgical Clinic of Central Arkansas

9500 Kanis Road #501 – Little Rock, AR 72031
Karen Smith-Supervisor
501-227-9080
ksmith@surgicalclinicofCA.com

UAMS/Cancer Registry

4301 West Markham, Slot 733 – Little Rock, AR 72205-7199 – Fax: (501) 686-8519
Bettye Belleton, CTR, BA
(501) 213-5988 – cell
(501) 961-1731 – home

belletonbettej@uams.edu

Dr. Peter Emanuel – Director

Lois J. Williams-Raynor, RHIA, CPC

Supervisor

(501) 213-5989 – cell

(501) 982-6143 – home

(501) 982-6143 – fax

williamsraynorloisj@uams.edu

Mary “Cissy” Carrigan, CTR

(501) 213-5986 – cell

(501) 833-6023 – home

carriganmaryc@uams.edu

UAMS/HIM Program

4301 West Markham, Slot 733 – Little Rock, AR 72205-7199 – Fax: (501) 686-8519

Kathy Trawick, Ed. D.

(501) 686-8613

TrawickKathyC@uams.edu

Karen K. Smith, RHIA, Instructor

(501) 686-7790

kksmith@uams.edu

VA Medical Center

Veterans Health Care System of the Ozarks

1100 North College – Fayetteville, AR 72703 – Fax: (479) 587-5829

(479) 443-4301 x 5424

Dr. Robert Levy

Dr. John Henley, Chief of Staff

robert.levy@va.gov

Washington Regional Medical Center

3215 N North Hills Blvd – Fayetteville, AR 72703 – Fax: 479-657-2533

Kayla Arnett

Pat Overton, CTR

479-657-2553 (work ph and fax)

poverton@wregional.org

White County Medical

3214 E. Race – Searcy, AR 72143 – Fax: 501-380-2342

Teresa Williams

501-380-3191

twilliams@wcmc.org

Renee Webb
501-380-2340
rwebb@wcmc.org

White River Medical Center

525 Virginia Drive – Batesville, AR 72501 – Fax: (870) 262-6216
Jamie Smotherman
870-262-6206
jsmotherman@wrmc.com

Ron Wright – Supervisor
870-262-1945
rwright@wrmc.com

Revised 01/20/2016